Protein	B-protein
kinase	I-protein
B	I-protein
(	O
c-Akt	B-protein
)	O
,	O
phosphatidylinositol	B-protein
3-kinase	I-protein
,	O
and	O
STAT5	B-protein
are	O
activated	O
by	O
erythropoietin	B-protein
(	O
EPO	B-protein
)	O
in	O
HCD57	B-cell_line
erythroid	I-cell_line
cells	I-cell_line
but	O
are	O
constitutively	O
active	O
in	O
an	O
EPO-independent	B-cell_line
,	I-cell_line
apoptosis-resistant	I-cell_line
subclone	I-cell_line
(	O
HCD57-SREI	B-cell_line
cells	I-cell_line
)	O
.	O

We	O
found	O
that	O
erythropoietin	B-protein
(	O
EPO	B-protein
)	O
and	O
stem	B-protein
cell	I-protein
factor	I-protein
(	O
SCF	B-protein
)	O
activated	B-protein
protein	I-protein
kinase	I-protein
B	I-protein
(	O
PKB/Akt	B-protein
)	O
in	O
EPO-dependent	B-cell_line
HCD57	I-cell_line
erythroid	I-cell_line
cells	I-cell_line
.	O

To	O
better	O
understand	O
signals	O
controlling	O
proliferation	O
and	O
viability	O
,	O
erythroid	O
cells	O
that	O
resist	O
apoptosis	O
in	O
the	O
absence	O
of	O
EPO	B-protein
were	O
subcloned	O
and	O
characterized	O
(	O
HCD57-SREI	B-cell_line
cells	I-cell_line
)	O
.	O

Constitutive	O
activations	O
of	O
PKB/Akt	B-protein
,	O
STAT5a	B-protein
,	O
and	O
STAT5b	B-protein
were	O
noted	O
in	O
these	O
EPO-independent	B-cell_line
cells	I-cell_line
.	O

PI3-kinase	B-protein
activity	O
was	O
an	O
upstream	O
activator	O
of	O
PKB/Akt	B-protein
because	O
the	O
PI3-kinase	B-protein
inhibitor	O
LY294002	O
blocked	O
both	O
constitutive	O
PKB/Akt	B-protein
and	O
factor-dependent	O
PKB/Akt	B-protein
activity	O
.	O

The	O
LY294002	O
study	O
showed	O
that	O
proliferation	O
and	O
viability	O
of	O
both	O
HCD57-SREI	B-cell_line
and	O
HCD57	B-cell_line
cells	I-cell_line
correlated	O
with	O
the	O
activity	O
of	O
PKB/Akt	B-protein
;	O
however	O
,	O
PKB/Akt	B-protein
activity	O
alone	O
did	O
not	O
protect	O
these	O
cells	O
from	O
apoptosis	O
.	O

Treatment	O
of	O
HCD57	B-cell_line
cells	I-cell_line
with	O
SCF	B-protein
also	O
activated	O
PKB/Akt	B-protein
,	O
but	O
did	O
not	O
protect	O
from	O
apoptosis	O
.	O

This	O
result	O
suggested	O
that	O
PKB/PI3-kinase	B-protein
activity	O
is	O
necessary	O
but	O
not	O
sufficient	O
to	O
promote	O
viability	O
and/or	O
proliferation	O
.	O

Constitutive	O
STAT5	B-protein
activity	O
,	O
activated	O
through	O
an	O
unknown	O
pathway	O
not	O
including	O
JAK2	B-protein
or	O
EPOR	B-protein
,	O
may	O
act	O
in	O
concert	O
with	O
the	O
constitutive	O
PI3-kinase	B-protein
/PKB/Akt	B-protein
pathway	O
to	O
protect	O
the	O
EPO-independent	B-cell_line
HCD57-SREI	I-cell_line
cells	I-cell_line
from	O
apoptosis	O
and	O
promote	O
limited	O
proliferation	O
.	O

From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

HEMATOPOIESIS	NULL
Protein	NULL
Kinase	NULL
B	NULL
(	NULL
c-Akt	NULL
)	NULL
,	NULL
Phosphatidylinositol	NULL
3-Kinase	NULL
,	NULL
and	NULL
STATS	NULL
Are	NULL
Activated	NULL
by	NULL
Erythropoietin	NULL
(	NULL
EPO	NULL
)	NULL
in	NULL
HCD57	NULL
Erythroid	NULL
Cells	NULL
But	NULL
Are	NULL
Constitutively	NULL
Active	NULL
in	NULL
an	NULL
EPO-Independent	NULL
,	NULL
Apoptosis-Resistant	NULL
Subclone	NULL
(	NULL
HCD57-SREI	NULL
Cells	NULL
)	NULL
By	NULL
Haifeng	NULL
Bao	NULL
,	NULL
Sarah	NULL
M.	NULL
Jacobs-Helber	NULL
,	NULL
Amy	NULL
E.	NULL
Lawson	NULL
,	NULL
Kalyani	NULL
Penta	NULL
,	NULL
Amittha	NULL
Wickrema	NULL
,	NULL
and	NULL
Stephen	NULL
T.	NULL
Sawyer	NULL
We	NULL
found	NULL
that	NULL
erythropoietin	NULL
(	NULL
EPO	NULL
)	NULL
and	NULL
stem	NULL
cell	NULL
factor	NULL
(	NULL
SCF	NULL
)	NULL
activated	NULL
protein	NULL
kinase	NULL
B	NULL
(	NULL
PKB/Akt	NULL
)	NULL
in	NULL
EPO-dependent	NULL
HCD57	NULL
erythroid	NULL
cells	NULL
.	NULL

To	NULL
better	NULL
understand	NULL
signals	NULL
controlling	NULL
proliferation	NULL
and	NULL
viability	NULL
,	NULL
erythroid	NULL
cells	NULL
that	NULL
resist	NULL
apoptosis	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
EPO	NULL
were	NULL
subcloned	NULL
and	NULL
characterized	NULL
(	NULL
HCD57-SREI	NULL
cells	NULL
)	NULL
.	NULL

Constitutive	NULL
activations	NULL
of	NULL
PKB/	NULL
Akt	NULL
,	NULL
STATS5a	NULL
,	NULL
and	NULL
STAT5b	NULL
were	NULL
noted	NULL
in	NULL
these	NULL
EPO-independent	NULL
cells	NULL
.	NULL

PI3-kinase	NULL
activity	NULL
was	NULL
an	NULL
upstream	NULL
acti-vator	NULL
of	NULL
PKB/	NULL
Akt	NULL
because	NULL
the	NULL
PI3-kinase	NULL
inhibitor	NULL
LY294002	NULL
blocked	NULL
both	NULL
constitutive	NULL
PKB/Akt	NULL
and	NULL
factor-dependent	NULL
PKB/	NULL
Akt	NULL
activity	NULL
.	NULL

The	NULL
LY294002	NULL
study	NULL
showed	NULL
that	NULL
proliferation	NULL
and	NULL
viability	NULL
of	NULL
both	NULL
HCD57-SREI	NULL
and	NULL
HCDS57	NULL
cells	NULL
RYTHROPOIETIN	NULL
(	NULL
EPO	NULL
)	NULL
is	NULL
the	NULL
primary	NULL
hormone	NULL
which	NULL
regulates	NULL
the	NULL
maturation	NULL
of	NULL
immature	NULL
erythroid	NULL
cells'*	NULL
into	NULL
erythrocytes	NULL
.	NULL

EPO	NULL
is	NULL
necessary	NULL
for	NULL
the	NULL
proliferation	NULL
,	NULL
erythroid	NULL
differentiation	NULL
,	NULL
and	NULL
prevention	NULL
of	NULL
apoptosis	NULL
of	NULL
erythroid	NULL
cells	NULL
;	NULL
it	NULL
is	NULL
not	NULL
yet	NULL
clear	NULL
whether	NULL
these	NULL
three	NULL
processes	NULL
are	NULL
regulated	NULL
by	NULL
distinct	NULL
signaling	NULL
pathways	NULL
.	NULL

!	NULL
``	NULL

Some	NULL
studies	NULL
suggest	NULL
that	NULL
EPO	NULL
might	NULL
act	NULL
primarily	NULL
to	NULL
maintain	NULL
viability	NULL
by	NULL
protecting	NULL
mature	NULL
erythroid	NULL
cells	NULL
from	NULL
programmed	NULL
cell	NULL
death	NULL
or	NULL
apoptosis	NULL
in	NULL
the	NULL
relatively	NULL
narrow	NULL
window	NULL
of	NULL
EPO-dependent	NULL
differentiation	NULL
.	NULL

!	NULL

The	NULL
``	NULL
knock	NULL
out	NULL
``	NULL
of	NULL
EPO	NULL
or	NULL
EPO	NULL
receptor	NULL
(	NULL
EPOR	NULL
)	NULL
results	NULL
in	NULL
EPO-/-	NULL
or	NULL
EPOR-/-	NULL
null	NULL
mice	NULL
that	NULL
allow	NULL
EPO-independent	NULL
proliferation	NULL
and	NULL
development	NULL
to	NULL
relatively	NULL
mature	NULL
erythroid	NULL
cells	NULL
(	NULL
CFU-E	NULL
)	NULL
that	NULL
then	NULL
undergo	NULL
apoptosis	NULL
.	NULL

This	NULL
is	NULL
consistent	NULL
with	NULL
the	NULL
requirement	NULL
of	NULL
EPO	NULL
only	NULL
in	NULL
the	NULL
later	NULL
(	NULL
CFU-e	NULL
)	NULL
differentiation	NULL
events	NULL
as	NULL
a	NULL
viability	NULL
factor	NULL
.	NULL

Whereas	NULL
the	NULL
anti-apoptotic	NULL
model	NULL
is	NULL
supported	NULL
in	NULL
EPO-responsive	NULL
erythroid	NULL
cells	NULL
(	NULL
proerythroblasts	NULL
and	NULL
erythroblasts	NULL
)	NULL
generated	NULL
from	NULL
mice	NULL
infected	NULL
with	NULL
the	NULL
anemia	NULL
strain	NULL
of	NULL
Friend	NULL
virus	NULL
'	NULL
(	NULL
where	NULL
the	NULL
Friend	NULL
virus	NULL
may	NULL
potentially	NULL
drive	NULL
proliferation	NULL
)	NULL
,	NULL
a	NULL
strictly	NULL
anti-apoptotic	NULL
signal	NULL
from	NULL
the	NULL
EPOR	NULL
may	NULL
be	NULL
unlikely	NULL
in	NULL
all	NULL
erythroid	NULL
cells	NULL
.	NULL

The	NULL
finding	NULL
that	NULL
many	NULL
cell	NULL
lines	NULL
require	NULL
EPO	NULL
for	NULL
proliferation	NULL
,	NULL
but	NULL
only	NULL
a	NULL
few	NULL
erythroid	NULL
cell	NULL
lines	NULL
partially	NULL
differentiate	NULL
in	NULL
response	NULL
to	NULL
EPO	NULL
and	NULL
do	NULL
not	NULL
require	NULL
EPO	NULL
for	NULL
proliferation	NULL
,	NULL
suggests	NULL
that	NULL
proliferation	NULL
,	NULL
differentiation	NULL
,	NULL
and	NULL
anti-apoptotic	NULL
pathways	NULL
may	NULL
be	NULL
controlled	NULL
separately	NULL
by	NULL
EPO	NULL
.	NULL

Cells	NULL
do	NULL
not	NULL
proliferate	NULL
without	NULL
cell	NULL
survival	NULL
;	NULL
therefore	NULL
,	NULL
establishing	NULL
the	NULL
existence	NULL
of	NULL
separate	NULL
control	NULL
of	NULL
proliferation	NULL
and	NULL
protection	NULL
from	NULL
apoptosis	NULL
is	NULL
difficult	NULL
.	NULL

EPO	NULL
acts	NULL
through	NULL
cell-surface	NULL
receptors	NULL
on	NULL
immature	NULL
erythroid	NULL
cells	NULL
.	NULL

>	NULL
``	NULL
The	NULL
EPOR	NULL
does	NULL
not	NULL
have	NULL
a	NULL
kinase	NULL
domain	NULL
and	NULL
transmits	NULL
an	NULL
intracellular	NULL
signal	NULL
by	NULL
interacting	NULL
with	NULL
cytoplasmic	NULL
nonreceptor	NULL
tyrosine	NULL
protein	NULL
kinases	NULL
.	NULL

Two	NULL
of	NULL
these	NULL
kinases	NULL
have	NULL
been	NULL
reported	NULL
to	NULL
become	NULL
phosphorylated	NULL
after	NULL
EPO	NULL
binding	NULL
to	NULL
cells	NULL
:	NULL
the	NULL
Janus	NULL
kinase	NULL
,	NULL
JAK2	NULL
,	NULL
and	NULL
the	NULL
c-fes	NULL
kinase	NULL
.	NULL

*	NULL
JAK2	NULL
can	NULL
physically	NULL
associate	NULL
with	NULL
the	NULL
This	NULL
interaction	NULL
is	NULL
constitutive	NULL
in	NULL
HCD57	NULL
erythroid	NULL
cells	NULL
,	NULL
but	NULL
JAK2	NULL
appears	NULL
to	NULL
be	NULL
selective	NULL
in	NULL
interacting	NULL
with	NULL
a	NULL
subset	NULL
of	NULL
highly	NULL
modified	NULL
EPOR	NULL
molecules	NULL
.	NULL

!	NULL
``	NULL

Known	NULL
substrates	NULL
of	NULL
tyrosine	NULL
protein	NULL
kinases	NULL
Blood	NULL
,	NULL
Vol	NULL
93	NULL
,	NULL
No	NULL
11	NULL
(	NULL
June	NULL
1	NULL
)	NULL
,	NULL
1999	NULL
;	NULL
pp	NULL
3757-3773	NULL
correlated	NULL
with	NULL
the	NULL
activity	NULL
of	NULL
PKB/Akt	NULL
;	NULL
however	NULL
,	NULL
PKB/	NULL
Akt	NULL
activity	NULL
alone	NULL
did	NULL
not	NULL
protect	NULL
these	NULL
cells	NULL
from	NULL
apoptosis	NULL
.	NULL

Treatment	NULL
of	NULL
HCD57	NULL
cells	NULL
with	NULL
SCF	NULL
also	NULL
activated	NULL
PKB/	NULL
Akt	NULL
,	NULL
but	NULL
did	NULL
not	NULL
protect	NULL
from	NULL
apoptosis	NULL
.	NULL

This	NULL
result	NULL
suggested	NULL
that	NULL
PKB/	NULL
PI3-kinase	NULL
activity	NULL
is	NULL
necessary	NULL
but	NULL
not	NULL
sufficient	NULL
to	NULL
promote	NULL
viability	NULL
and/or	NULL
proliferation	NULL
.	NULL

Constitutive	NULL
STATS	NULL
activity	NULL
,	NULL
activated	NULL
through	NULL
an	NULL
unknow	NULL
n	NULL
pathway	NULL
not	NULL
including	NULL
JAK2	NULL
or	NULL
EPOR	NULL
,	NULL
may	NULL
act	NULL
in	NULL
concert	NULL
with	NULL
the	NULL
constitutive	NULL
PI3-kinase/PKB/	NULL
Akt	NULL
pathway	NULL
to	NULL
protect	NULL
the	NULL
EPO-independent	NULL
HCDS57-SREI	NULL
cells	NULL
from	NULL
apoptosis	NULL
and	NULL
promote	NULL
limited	NULL
proliferation	NULL
.	NULL

©	NULL
1999	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
.	NULL

activated	NULL
by	NULL
EPO	NULL
binding	NULL
to	NULL
its	NULL
receptor	NULL
include	NULL
phosphatidyl-inositol-3	NULL
kinase	NULL
(	NULL
PI3-kinase	NULL
)	NULL
,	NULL
SHC	NULL
proteins	NULL
,	NULL
c-raf	NULL
,	NULL
STAT1	NULL
,	NULL
STAT3	NULL
,	NULL
STAT5SA	NULL
,	NULL
STAT5B	NULL
,	NULL
and	NULL
other	NULL
Recent	NULL
studies	NULL
have	NULL
suggested	NULL
that	NULL
c-Kit	NULL
,	NULL
the	NULL
receptor	NULL
for	NULL
stem	NULL
cell	NULL
factor	NULL
,	NULL
interacts	NULL
with	NULL
the	NULL
EPOR	NULL
and	NULL
transduces	NULL
an	NULL
intracellular	NULL
signal	NULL
through	NULL
the	NULL
EPOR	NULL
.	NULL
``	NULL

Our	NULL
laboratory	NULL
has	NULL
shown	NULL
that	NULL
stem	NULL
cell	NULL
factor	NULL
(	NULL
SCF	NULL
)	NULL
can	NULL
stimulate	NULL
proliferation	NULL
of	NULL
HCDS57	NULL
cells	NULL
but	NULL
can	NULL
not	NULL
protect	NULL
them	NULL
from	NULL
apoptosis	NULL
.	NULL
``	NULL

EPO	NULL
activates	NULL
JAK2/STAT	NULL
signaling	NULL
and	NULL
other	NULL
signaling	NULL
which	NULL
protects	NULL
the	NULL
cells	NULL
from	NULL
apoptosis	NULL
and	NULL
stimulates	NULL
proliferation	NULL
.	NULL

Because	NULL
SCF	NULL
does	NULL
not	NULL
activate	NULL
JAK2/STATS5	NULL
signaling	NULL
in	NULL
this	NULL
system	NULL
,	NULL
we	NULL
have	NULL
speculated	NULL
that	NULL
this	NULL
pathway	NULL
may	NULL
protect	NULL
erythroid	NULL
cells	NULL
from	NULL
apoptosis	NULL
.	NULL

Constitutive	NULL
STAT	NULL
activation	NULL
has	NULL
been	NULL
observed	NULL
in	NULL
transformed	NULL
cell	NULL
lines	NULL
and	NULL
cancerous	NULL
cells	NULL
.	NULL

``	NULL
3	NULL
>	NULL
In	NULL
most	NULL
cases	NULL
,	NULL
constitutively	NULL
activated	NULL
Janus	NULL
kinases	NULL
seem	NULL
to	NULL
be	NULL
responsible	NULL
for	NULL
activating	NULL
the	NULL
STAT	NULL
proteins	NULL
;	NULL
however	NULL
,	NULL
in	NULL
other	NULL
cells	NULL
and	NULL
cancers	NULL
,	NULL
other	NULL
kinases	NULL
may	NULL
phosphorylate	NULL
STAT	NULL
molecules	NULL
.	NULL

Oncogenes	NULL
such	NULL
as	NULL
v-abl	NULL
,	NULL
``	NULL
``	NULL
ber/abl	NULL
,	NULL
``	NULL
``	NULL
and	NULL
v-src	NULL
?	NULL

may	NULL
directly	NULL
phosphorylate	NULL
and	NULL
activate	NULL
STAT	NULL
proteins	NULL
.	NULL

These	NULL
studies	NULL
sug-	NULL
From	NULL
the	NULL
Department	NULL
of	NULL
Pharmacology	NULL
and	NULL
Toxicology	NULL
,	NULL
Medical	NULL
College	NULL
of	NULL
Virginia	NULL
campus	NULL
of	NULL
Virginia	NULL
Commonwealth	NULL
University	NULL
,	NULL
Richmond	NULL
,	NULL
VA	NULL
;	NULL
the	NULL
Department	NULL
of	NULL
Medicine	NULL
,	NULL
Stanford	NULL
University	NULL
,	NULL
San	NULL
Francisco	NULL
,	NULL
CA	NULL
;	NULL
and	NULL
Hematopoietic	NULL
Stem	NULL
Cell	NULL
Laboratory	NULL
,	NULL
University	NULL
of	NULL
Tilinois	NULL
,	NULL
Chicago	NULL
,	NULL
IL	NULL
.	NULL

Submitted	NULL
March	NULL
20	NULL
,	NULL
1998	NULL
;	NULL
accepted	NULL
February	NULL
1	NULL
,	NULL
1999	NULL
.	NULL

Supported	NULL
by	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
Grant	NULL
No	NULL
.	NULL

ROIDK39781	NULL
to	NULL
STS	NULL
.	NULL

and	NULL
an	NULL
American	NULL
Heart	NULL
Association	NULL
Fellowship	NULL
Grant	NULL
to	NULL
S.M.J.-H	NULL
.	NULL

Address	NULL
reprint	NULL
requests	NULL
to	NULL
Stephen	NULL
T.	NULL
Sawyer	NULL
,	NULL
PhD	NULL
,	NULL
Department	NULL
of	NULL
Pharmacology	NULL
&	NULL
Toxicology	NULL
,	NULL
Medical	NULL
College	NULL
of	NULL
Virginia	NULL
of	NULL
Virginia	NULL
Commonwealth	NULL
University	NULL
,	NULL
PO	NULL
Box	NULL
980613	NULL
,	NULL
Richmond	NULL
,	NULL
VA	NULL
23298-0613.	NULL
e-mail	NULL
:	NULL
ssawyer	NULL
@	NULL
hsc.vcu.edu	NULL
.	NULL

The	NULL
publication	NULL
costs	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
page	NULL
charge	NULL
payment	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
adver-tisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

©	NULL
1999	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
.	NULL

0006-4971/99/9311-0033	NULL
$	NULL
3.00/0	NULL
3757	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

3758	NULL
gest	NULL
a	NULL
possible	NULL
role	NULL
of	NULL
STAT	NULL
proteins	NULL
,	NULL
independent	NULL
of	NULL
Janus	NULL
kinases	NULL
,	NULL
in	NULL
signaling	NULL
the	NULL
proliferation	NULL
and	NULL
protecting	NULL
these	NULL
transformed	NULL
cells	NULL
from	NULL
apoptosis	NULL
.	NULL

However	NULL
,	NULL
the	NULL
role	NULL
of	NULL
STATS	NULL
signaling	NULL
in	NULL
erythroid	NULL
cells	NULL
is	NULL
controversial	NULL
.	NULL

STATS	NULL
activation	NULL
may	NULL
be	NULL
linked	NULL
to	NULL
enhanced	NULL
proliferation	NULL
'	NULL
``	NULL
``	NULL
``	NULL
;	NULL
in	NULL
contrast	NULL
,	NULL
a	NULL
mutant	NULL
EPOR	NULL
incapable	NULL
of	NULL
activating	NULL
STATS	NULL
still	NULL
promotes	NULL
proliferation	NULL
.	NULL
``	NULL

Wakao	NULL
et	NULL
al	NULL
``	NULL
``	NULL
and	NULL
Iwatsuki	NULL
et	NULL
al	NULL
``	NULL
``	NULL
have	NULL
separately	NULL
demonstrated	NULL
that	NULL
STAT5	NULL
is	NULL
required	NULL
for	NULL
erythroid	NULL
differentiation	NULL
;	NULL
in	NULL
contrast	NULL
,	NULL
deletion	NULL
of	NULL
STAT5A	NULL
and/or	NULL
STAT5B	NULL
results	NULL
in	NULL
STATS	NULL
null	NULL
mice	NULL
that	NULL
have	NULL
no	NULL
obvious	NULL
reduction	NULL
or	NULL
defects	NULL
in	NULL
erythroid	NULL
cells.4	NULL
``	NULL
42	NULL
The	NULL
involvement	NULL
of	NULL
PI3-kinase	NULL
in	NULL
cell	NULL
transformation	NULL
has	NULL
been	NULL
implicated	NULL
in	NULL
several	NULL
cell	NULL
lines	NULL
.	NULL

``	NULL
``	NULL
``	NULL
*	NULL
PI3-kinase	NULL
plays	NULL
an	NULL
important	NULL
role	NULL
in	NULL
regulation	NULL
of	NULL
cell	NULL
proliferation	NULL
and	NULL
apoptosis	NULL
;	NULL
in	NULL
addition	NULL
,	NULL
constitutive	NULL
PI3-kinase	NULL
activity	NULL
has	NULL
been	NULL
observed	NULL
in	NULL
cancerous	NULL
cells	NULL
and	NULL
,	NULL
therefore	NULL
,	NULL
may	NULL
contribute	NULL
to	NULL
the	NULL
malignant	NULL
transformation	NULL
of	NULL
cells	NULL
.	NULL

The	NULL
insulin	NULL
receptor	NULL
substrate	NULL
proteins	NULL
(	NULL
IRS	NULL
)	NULL
are	NULL
substrates	NULL
of	NULL
many	NULL
tyrosine	NULL
kinases	NULL
,	NULL
including	NULL
the	NULL
JAK2	NULL
kinase	NULL
bound	NULL
to	NULL
the	NULL
EPOR	NULL
.	NULL

***°	NULL
Activated	NULL
IRS-1	NULL
,	NULL
-2	NULL
,	NULL
-3	NULL
are	NULL
known	NULL
to	NULL
be	NULL
docking	NULL
sites	NULL
for	NULL
PI3-kinase	NULL
and	NULL
are	NULL
implicated	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
PI3-kinase	NULL
either	NULL
in	NULL
complexes	NULL
with	NULL
receptors	NULL
or	NULL
independently	NULL
of	NULL
receptors	NULL
.	NULL

An	NULL
important	NULL
downstream	NULL
effector	NULL
activated	NULL
by	NULL
the	NULL
PI3-kinase	NULL
signaling	NULL
pathway	NULL
is	NULL
protein	NULL
kinase	NULL
B	NULL
(	NULL
PKB/Akt	NULL
)	NULL
,	NULL
also	NULL
known	NULL
as	NULL
c-Akt	NULL
and	NULL
RAC-PK	NULL
.	NULL

PI3-kinase	NULL
activity	NULL
leads	NULL
to	NULL
accumulation	NULL
of	NULL
polyphosphatidylinositols	NULL
lipids	NULL
in	NULL
the	NULL
plasma	NULL
membrane	NULL
.	NULL

PKB/Akt	NULL
is	NULL
apparently	NULL
targeted	NULL
to	NULL
translocate	NULL
to	NULL
the	NULL
polyphosphatidyinositol	NULL
rich	NULL
membrane	NULL
via	NULL
a	NULL
pleckstrin	NULL
homology	NULL
domain	NULL
and	NULL
is	NULL
activated	NULL
at	NULL
the	NULL
membrane	NULL
by	NULL
phosphorylation	NULL
at	NULL
Thr®	NULL
``	NULL
``	NULL
and	NULL
Ser	NULL
``	NULL
from	NULL
two	NULL
distinct	NULL
phosphatidylinositol	NULL
dependent	NULL
kinases	NULL
.	NULL
``	NULL

PKB/Akt	NULL
activity	NULL
is	NULL
linked	NULL
to	NULL
the	NULL
control	NULL
of	NULL
many	NULL
diverse	NULL
cellular	NULL
functions	NULL
that	NULL
included	NULL
insulin-dependent	NULL
glucose	NULL
transport	NULL
,	NULL
glycolysis	NULL
,	NULL
glycogen	NULL
synthesis	NULL
and	NULL
protein	NULL
translation	NULL
,	NULL
and	NULL
viability	NULL
of	NULL
cells	NULL
.	NULL
``	NULL

''	NULL
Recent	NULL
work	NULL
has	NULL
shown	NULL
that	NULL
PKB/Akt	NULL
is	NULL
able	NULL
to	NULL
phosphorylate	NULL
the	NULL
pro-apoptotic	NULL
protein	NULL
BAD	NULL
.	NULL

Phosphorylation	NULL
of	NULL
BAD	NULL
correlates	NULL
with	NULL
the	NULL
cell	NULL
survival	NULL
and	NULL
it	NULL
is	NULL
suspected	NULL
that	NULL
phosphorylated	NULL
BAD	NULL
is	NULL
ineffective	NULL
in	NULL
disrupting	NULL
the	NULL
protective	NULL
action	NULL
of	NULL
Bel	NULL
anti-apoptotic	NULL
proteins	NULL
.	NULL

In	NULL
the	NULL
current	NULL
study	NULL
,	NULL
we	NULL
found	NULL
that	NULL
EPO	NULL
and	NULL
SCF	NULL
activated	NULL
PKB/Akt	NULL
in	NULL
the	NULL
EPO-dependent	NULL
erythroid	NULL
cells	NULL
but	NULL
the	NULL
PI3-kinase/PKB/Akt	NULL
pathway	NULL
was	NULL
constitutively	NULL
active	NULL
in	NULL
the	NULL
apop-tosis-resistant	NULL
,	NULL
EPO-independent	NULL
HCD57-SREI	NULL
cells	NULL
.	NULL

The	NULL
finding	NULL
of	NULL
constitutive	NULL
activity	NULL
of	NULL
STATS	NULL
in	NULL
this	NULL
apoptosis-resistant	NULL
subclone	NULL
of	NULL
HCD57	NULL
cells	NULL
suggests	NULL
that	NULL
STATS	NULL
activity	NULL
which	NULL
arises	NULL
through	NULL
a	NULL
signal	NULL
independent	NULL
of	NULL
Janus	NULL
kinase	NULL
activity	NULL
and	NULL
the	NULL
EPOR	NULL
may	NULL
also	NULL
act	NULL
in	NULL
concert	NULL
with	NULL
PKB/Akt	NULL
activity	NULL
to	NULL
prevent	NULL
cells	NULL
from	NULL
undergoing	NULL
apoptosis	NULL
induced	NULL
by	NULL
growth	NULL
factor	NULL
withdrawal	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Cell	NULL
culture	NULL
.	NULL

HCDS57	NULL
cells	NULL
,	NULL
obtained	NULL
from	NULL
Sandra	NULL
Ruscetti	NULL
(	NULL
Na-tional	NULL
Cancer	NULL
Institute	NULL
,	NULL
Frederick	NULL
,	NULL
MD	NULL
)	NULL
,	NULL
were	NULL
cultured	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
1.0	NULL
U	NULL
EPO/mL	NULL
in	NULL
Iscove	NULL
's	NULL
modified	NULL
Dulbecco	NULL
's	NULL
medium	NULL
and	NULL
25	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
.	NULL

In	NULL
experiments	NULL
to	NULL
test	NULL
the	NULL
action	NULL
of	NULL
signaling	NULL
by	NULL
EPO	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
further	NULL
cultured	NULL
overnight	NULL
in	NULL
the	NULL
same	NULL
medium	NULL
devoid	NULL
of	NULL
EPO	NULL
.	NULL

As	NULL
previously	NULL
reported	NULL
,	NULL
``	NULL
this	NULL
deprivation	NULL
of	NULL
EPO	NULL
increased	NULL
cell-surface	NULL
EPOR	NULL
but	NULL
was	NULL
an	NULL
insufficient	NULL
time	NULL
without	NULL
EPO	NULL
for	NULL
apoptosis	NULL
to	NULL
begin	NULL
.	NULL

HCD57-SREI	NULL
cells	NULL
were	NULL
subcloned	NULL
by	NULL
transferring	NULL
HCD57	NULL
cells	NULL
from	NULL
medium	NULL
containing	NULL
EPO	NULL
to	NULL
medium	NULL
free	NULL
of	NULL
EPO	NULL
but	NULL
containing	NULL
100	NULL
ng	NULL
SCF/mL	NULL
.	NULL

A	NULL
subclone	NULL
of	NULL
cells	NULL
that	NULL
survived	NULL
and	NULL
BAO	NULL
ET	NULL
AL	NULL
proliferated	NULL
was	NULL
then	NULL
cultured	NULL
in	NULL
the	NULL
same	NULL
medium	NULL
indicated	NULL
above	NULL
except	NULL
that	NULL
both	NULL
EPO	NULL
and	NULL
SCF	NULL
were	NULL
omitted	NULL
.	NULL

Apoptosis	NULL
studies	NULL
.	NULL

-	NULL
HCDS7	NULL
and	NULL
HCDS7-SREI	NULL
cells	NULL
were	NULL
cultured	NULL
either	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
cytokines	NULL
or	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
indicated	NULL
factors	NULL
for	NULL
72	NULL
hours	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
then	NULL
harvested	NULL
and	NULL
genomic	NULL
DNA	NULL
was	NULL
isolated	NULL
.	NULL
``	NULL

Ten	NULL
micrograms	NULL
of	NULL
genomic	NULL
DNA	NULL
was	NULL
resolved	NULL
on	NULL
a	NULL
2.25	NULL
%	NULL
agarose/1X	NULL
TAE/300	NULL
ng	NULL
EtBr/mL	NULL
gel	NULL
.	NULL

DNA	NULL
laddering	NULL
indicative	NULL
of	NULL
apoptosis	NULL
was	NULL
visualized	NULL
using	NULL
UV	NULL
light	NULL
.	NULL

Western	NULL
blot	NULL
analysis	NULL
.	NULL

-	NULL
Tyr	NULL
(	NULL
P	NULL
)	NULL
-containing	NULL
proteins	NULL
and	NULL
STATS	NULL
tyrosine	NULL
phosphorylation	NULL
and	NULL
nuclear	NULL
translocation	NULL
were	NULL
detected	NULL
by	NULL
either	NULL
Western	NULL
blotting	NULL
alone	NULL
or	NULL
the	NULL
immunoprecipitation	NULL
and	NULL
Western	NULL
blotting	NULL
method	NULL
described	NULL
previously	NULL
.	NULL
``	NULL

''	NULL
``	NULL
Polyclonal	NULL
anti-Tyr	NULL
(	NULL
P	NULL
)	NULL
antibodies	NULL
from	NULL
Zymed	NULL
(	NULL
San	NULL
Francisco	NULL
,	NULL
CA	NULL
)	NULL
were	NULL
used	NULL
to	NULL
immunoprecipitate	NULL
and	NULL
concentrate	NULL
the	NULL
Tyr	NULL
(	NULL
P	NULL
)	NULL
-containing	NULL
proteins	NULL
before	NULL
they	NULL
were	NULL
analyzed	NULL
by	NULL
Western	NULL
blot	NULL
.	NULL

The	NULL
blots	NULL
were	NULL
stripped	NULL
of	NULL
bound	NULL
antibody	NULL
and	NULL
reprobed	NULL
with	NULL
anti-JAK2	NULL
(	NULL
Upstate	NULL
Biotechnology	NULL
,	NULL
Inc	NULL
[	NULL
UBI	NULL
]	NULL
,	NULL
Lake	NULL
Placid	NULL
,	NULL
NY	NULL
)	NULL
antisera	NULL
.	NULL

The	NULL
blot	NULL
was	NULL
stripped	NULL
as	NULL
described	NULL
by	NULL
the	NULL
Amersham	NULL
literature	NULL
with	NULL
the	NULL
ECL	NULL
kit	NULL
(	NULL
Amersham	NULL
,	NULL
Arlington	NULL
Heights	NULL
,	NULL
IL	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
the	NULL
bound	NULL
antibody	NULL
was	NULL
released	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
2	NULL
%	NULL
sodium	NULL
dodeyl	NULL
sulfate	NULL
(	NULL
SDS	NULL
)	NULL
and	NULL
reducing	NULL
agents	NULL
at	NULL
50°C	NULL
for	NULL
30	NULL
minutes	NULL
.	NULL

STATS	NULL
tyrosine	NULL
phosphorylation	NULL
and	NULL
nuclear	NULL
translocation	NULL
were	NULL
detected	NULL
by	NULL
Western	NULL
blot	NULL
analysis	NULL
of	NULL
10	NULL
ug	NULL
of	NULL
nuclear	NULL
extracts	NULL
probed	NULL
with	NULL
the	NULL
anti-Tyr	NULL
(	NULL
P	NULL
)	NULL
antisera	NULL
described	NULL
above	NULL
or	NULL
anti-STATS5	NULL
(	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
,	NULL
Santa	NULL
Cruz	NULL
,	NULL
CA	NULL
)	NULL
antisera	NULL
.	NULL

For	NULL
the	NULL
Bel-X1	NULL
and	NULL
Bcl-2	NULL
Western	NULL
blots	NULL
,	NULL
10	NULL
ug	NULL
of	NULL
total	NULL
cellular	NULL
lysate	NULL
were	NULL
probed	NULL
with	NULL
anti-Bcl-X1	NULL
and	NULL
anti-Bcl-2	NULL
antisera	NULL
(	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
)	NULL
.	NULL

For	NULL
PKB/Akt	NULL
assay	NULL
,	NULL
100,000	NULL
cells	NULL
were	NULL
lysed	NULL
in	NULL
SDS	NULL
sample	NULL
buffer	NULL
(	NULL
62.5	NULL
mmol/L	NULL
Tris-HCI	NULL
,	NULL
pH	NULL
6.8	NULL
,	NULL
2	NULL
%	NULL
SDS	NULL
,	NULL
10	NULL
%	NULL
glycerol	NULL
,	NULL
50	NULL
mmol/L	NULL
dithiothreitol	NULL
[	NULL
DTT	NULL
]	NULL
,	NULL
and	NULL
0.1	NULL
%	NULL
bromphenol	NULL
blue	NULL
)	NULL
.	NULL

The	NULL
blots	NULL
were	NULL
probed	NULL
with	NULL
anti-phospho	NULL
Akt	NULL
(	NULL
Ser473	NULL
)	NULL
antibody	NULL
(	NULL
New	NULL
England	NULL
Bio-labs	NULL
,	NULL
Beverly	NULL
,	NULL
MA	NULL
)	NULL
followed	NULL
by	NULL
detection	NULL
using	NULL
the	NULL
Phototope-HRP	NULL
Western	NULL
detection	NULL
system	NULL
(	NULL
New	NULL
England	NULL
Biolabs	NULL
)	NULL
.	NULL

After	NULL
stripping	NULL
of	NULL
phosphospecific	NULL
antibody	NULL
,	NULL
the	NULL
blot	NULL
was	NULL
reprobed	NULL
with	NULL
a	NULL
general	NULL
anti-PKB/	NULL
Akt	NULL
antibody	NULL
(	NULL
New	NULL
England	NULL
Biolabs	NULL
)	NULL
that	NULL
recognizes	NULL
both	NULL
phosphorylated	NULL
and	NULL
unphosphorylated	NULL
PKB/Akt	NULL
.	NULL

Gel	NULL
mobility	NULL
shift	NULL
assay	NULL
of	NULL
STATS	NULL
binding	NULL
.	NULL

-	NULL
Nuclear	NULL
STATS	NULL
binding	NULL
to	NULL
radiolabeled	NULL
DNA	NULL
(	NULL
prolactin	NULL
inducible	NULL
element	NULL
)	NULL
(	NULL
PIE	NULL
)	NULL
was	NULL
done	NULL
as	NULL
described	NULL
previously	NULL
.	NULL
``	NULL

For	NULL
the	NULL
supershift	NULL
assays	NULL
to	NULL
verify	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
STAT	NULL
protein	NULL
in	NULL
the	NULL
DNA	NULL
binding	NULL
complex	NULL
,	NULL
2	NULL
ug	NULL
of	NULL
anti-STAT1	NULL
,	NULL
anti-STAT3	NULL
,	NULL
anti-STATS5A	NULL
or	NULL
anti-STATS5B	NULL
antibodies	NULL
(	NULL
Zymed	NULL
)	NULL
were	NULL
preincubated	NULL
with	NULL
20	NULL
ug	NULL
of	NULL
nuclear	NULL
extract	NULL
for	NULL
15	NULL
minutes	NULL
on	NULL
ice	NULL
before	NULL
addition	NULL
of	NULL
the	NULL
radiolabeled	NULL
DNA	NULL
.	NULL

Detection	NULL
of	NULL
cell-surface	NULL
c-Kit	NULL
expression	NULL
.	NULL

-	NULL
Surface	NULL
c-Kit	NULL
expression	NULL
was	NULL
detected	NULL
using	NULL
flow	NULL
cytometry	NULL
analysis	NULL
.	NULL

For	NULL
each	NULL
sample	NULL
,	NULL
1	NULL
X	NULL
10°	NULL
HCDS57	NULL
or	NULL
HCDS7-SREI	NULL
cells	NULL
were	NULL
washed	NULL
in	NULL
FACS	NULL
buffer	NULL
(	NULL
Tris-buffered	NULL
saline/4	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
)	NULL
.	NULL

After	NULL
preincubation	NULL
of	NULL
the	NULL
cells	NULL
in	NULL
a	NULL
monoclonal	NULL
antibody	NULL
(	NULL
MoAb	NULL
)	NULL
that	NULL
blocks	NULL
nonspecific	NULL
binding	NULL
of	NULL
fluorescein	NULL
isothiocyanate	NULL
(	NULL
FITC	NULL
)	NULL
-conjugated	NULL
antibodies	NULL
to	NULL
IgG	NULL
(	NULL
rat	NULL
MoAb	NULL
2.4G	NULL
;	NULL
;	NULL
a	NULL
generous	NULL
gift	NULL
from	NULL
Dr	NULL
William	NULL
Paul	NULL
,	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
,	NULL
Bethesda	NULL
,	NULL
MD	NULL
)	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
incubated	NULL
with	NULL
FITC	NULL
anti-cKit	NULL
or	NULL
FITC	NULL
anti-CD4	NULL
(	NULL
Becton	NULL
Dickinson	NULL
,	NULL
San	NULL
Diego	NULL
,	NULL
CA	NULL
)	NULL
(	NULL
to	NULL
control	NULL
for	NULL
background	NULL
antibody	NULL
staining	NULL
)	NULL
at	NULL
10	NULL
mg/mL	NULL
for	NULL
30	NULL
minutes	NULL
at	NULL
4°C	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
then	NULL
washed	NULL
in	NULL
fluorescence-activated	NULL
cell	NULL
sorter	NULL
(	NULL
FACS	NULL
)	NULL
buffer	NULL
before	NULL
analysis	NULL
using	NULL
a	NULL
FACScan	NULL
flow	NULL
cytometer	NULL
(	NULL
Becton	NULL
Dickinson	NULL
)	NULL
.	NULL

Sequencing	NULL
of	NULL
the	NULL
EPOR	NULL
in	NULL
HCDS57	NULL
and	NULL
HCD35S7-SREI	NULL
cells	NULL
.	NULL

-	NULL
cDNA	NULL
encoding	NULL
the	NULL
EPOR	NULL
was	NULL
cloned	NULL
using	NULL
reverse	NULL
transcriptase-polymerase	NULL
chain	NULL
reaction	NULL
(	NULL
RT-PCR	NULL
)	NULL
techniques	NULL
.	NULL

Briefly	NULL
,	NULL
mRNA	NULL
was	NULL
isolated	NULL
from	NULL
HCD57	NULL
and	NULL
HCDS57-SREI	NULL
cells	NULL
using	NULL
the	NULL
Quick	NULL
Prep	NULL
Micro	NULL
mRNA	NULL
kit	NULL
(	NULL
Pharmacia	NULL
,	NULL
Piscataway	NULL
,	NULL
NJ	NULL
)	NULL
.	NULL

cDNA	NULL
was	NULL
generated	NULL
from	NULL
mRNA	NULL
using	NULL
the	NULL
First	NULL
Strand	NULL
cDNA	NULL
Synthesis	NULL
kit	NULL
(	NULL
Pharmacia	NULL
)	NULL
.	NULL

The	NULL
cDNA	NULL
was	NULL
subjected	NULL
to	NULL
PCR	NULL
using	NULL
Taq	NULL
polymerase	NULL
(	NULL
GIBCO-BRL	NULL
)	NULL
and	NULL
oligonucleo-tides	NULL
corresponding	NULL
to	NULL
the	NULL
5	NULL
'	NULL
and	NULL
3	NULL
'	NULL
end	NULL
of	NULL
the	NULL
murine	NULL
EPOR	NULL
gene	NULL
.	NULL

PCR	NULL
fragments	NULL
were	NULL
isolated	NULL
using	NULL
the	NULL
Geneclean	NULL
procedure	NULL
(	NULL
BIO	NULL
101	NULL
,	NULL
Vista	NULL
,	NULL
CA	NULL
)	NULL
and	NULL
cloned	NULL
into	NULL
the	NULL
pCrlI	NULL
vector	NULL
(	NULL
Invitrogen	NULL
,	NULL
Carlsbad	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

PKB/Akt	NULL
AND	NULL
STATS	NULL
ACTIVITY	NULL
IN	NULL
ERYTHROID	NULL
CELLS	NULL
Multiple	NULL
clones	NULL
of	NULL
EPOR	NULL
cDNA	NULL
from	NULL
both	NULL
HCD57	NULL
and	NULL
HCD5S7-SREI	NULL
cells	NULL
were	NULL
sequenced	NULL
using	NULL
the	NULL
dideoxy	NULL
method	NULL
described	NULL
by	NULL
Sanger	NULL
et	NULL
al	NULL
``	NULL
using	NULL
the	NULL
Sequenase	NULL
version	NULL
2.0	NULL
kit	NULL
(	NULL
Amersham	NULL
,	NULL
Piscataway	NULL
,	NULL
NJ	NULL
)	NULL
.	NULL

Immunoprecipitation	NULL
,	NULL
ERK-1	NULL
,	NULL
PI3-kinase	NULL
,	NULL
and	NULL
PKB/Akt	NULL
assay	NULL
.	NULL

-	NULL
Immunoprecipitation	NULL
of	NULL
ERK-1	NULL
and	NULL
quantitation	NULL
of	NULL
activity	NULL
as	NULL
determined	NULL
by	NULL
incorporation	NULL
of	NULL
*°P	NULL
from	NULL
[	NULL
y-	NULL
>	NULL
2P	NULL
]	NULL
adenosine	NULL
triphosphate	NULL
(	NULL
ATP	NULL
)	NULL
into	NULL
myelin	NULL
basic	NULL
protein	NULL
was	NULL
performed	NULL
as	NULL
described	NULL
previously	NULL
.	NULL
``	NULL

Immuno-precipitations	NULL
and	NULL
PI3-kinase	NULL
assays	NULL
were	NULL
conducted	NULL
as	NULL
described	NULL
previously	NULL
``	NULL
with	NULL
slight	NULL
modifications	NULL
.	NULL

Briefly	NULL
,	NULL
3	NULL
X	NULL
10°	NULL
cells	NULL
were	NULL
washed	NULL
twice	NULL
with	NULL
ice-cold	NULL
phosphate-buffered	NULL
saline	NULL
(	NULL
PBS	NULL
)	NULL
and	NULL
disrupted	NULL
in	NULL
a	NULL
standard	NULL
lysis	NULL
buffer	NULL
(	NULL
1	NULL
%	NULL
Nonidet	NULL
P-40	NULL
[	NULL
Pierce	NULL
,	NULL
Rockford	NULL
,	NULL
IL	NULL
]	NULL
;	NULL
20	NULL
mmol/L	NULL
Tris-HCI	NULL
,	NULL
pH	NULL
7.5	NULL
,	NULL
150	NULL
mmol/L	NULL
NaCl	NULL
,	NULL
5	NULL
mmol/L	NULL
EDTA	NULL
,	NULL
100	NULL
mmol/L	NULL
sodium	NULL
orthovanadate	NULL
,	NULL
1	NULL
mmol/L	NULL
phenyImethylsulfonyl	NULL
fluoride	NULL
[	NULL
PMSF	NULL
]	NULL
,	NULL
10	NULL
mg/mL	NULL
aprotinin	NULL
)	NULL
.	NULL

Lysates	NULL
were	NULL
centrifuged	NULL
at	NULL
14,0005	NULL
for	NULL
10	NULL
minutes	NULL
at	NULL
4°C	NULL
,	NULL
and	NULL
then	NULL
were	NULL
subjected	NULL
to	NULL
immunoprecipitation	NULL
with	NULL
specific	NULL
antibodies	NULL
to	NULL
EPOR	NULL
,	NULL
p85	NULL
domain	NULL
of	NULL
PI3-kinase	NULL
,	NULL
IRS-2	NULL
,	NULL
JAK2	NULL
,	NULL
STATS	NULL
,	NULL
and	NULL
Vav	NULL
by	NULL
incubation	NULL
at	NULL
4°C	NULL
for	NULL
1	NULL
hour	NULL
.	NULL

Protein	NULL
A-agarose	NULL
beads	NULL
(	NULL
UBI	NULL
,	NULL
Lake	NULL
Placid	NULL
,	NULL
NY	NULL
)	NULL
were	NULL
added	NULL
and	NULL
incubated	NULL
for	NULL
another	NULL
1	NULL
hour	NULL
at	NULL
4°C	NULL
.	NULL

The	NULL
immune	NULL
complexes	NULL
were	NULL
washed	NULL
three	NULL
times	NULL
with	NULL
lysis	NULL
buffer	NULL
,	NULL
once	NULL
with	NULL
PBS	NULL
,	NULL
once	NULL
with	NULL
0.5	NULL
mol/L	NULL
LiCl	NULL
in	NULL
0.1	NULL
mol/L	NULL
Tris-HCl	NULL
(	NULL
pH	NULL
7.5	NULL
)	NULL
,	NULL
once	NULL
with	NULL
distilled	NULL
water	NULL
,	NULL
and	NULL
once	NULL
with	NULL
a	NULL
buffer	NULL
containing	NULL
100	NULL
mmol/L	NULL
NaCl	NULL
,	NULL
0.5	NULL
mmol/L	NULL
EGTA	NULL
,	NULL
and	NULL
20	NULL
mmol/L	NULL
Tris-HCI	NULL
,	NULL
pH	NULL
7.5	NULL
.	NULL

The	NULL
beads	NULL
were	NULL
suspended	NULL
in	NULL
40	NULL
uL	NULL
of	NULL
reaction	NULL
buffer	NULL
(	NULL
100	NULL
mmol/L	NULL
NaCl	NULL
,	NULL
0.5	NULL
mmol/L	NULL
EGTA	NULL
,	NULL
20	NULL
mmol/L	NULL
Tris-HCI	NULL
,	NULL
pH	NULL
7.5	NULL
,	NULL
and	NULL
0.2	NULL
mmol/L	NULL
adenosine	NULL
)	NULL
.	NULL

L-a-phosphatidylinosito	NULL
!	NULL

l	NULL
was	NULL
added	NULL
to	NULL
reaction	NULL
mixture	NULL
at	NULL
a	NULL
final	NULL
concentration	NULL
of	NULL
0.3	NULL
mg/mL..	NULL

The	NULL
reaction	NULL
was	NULL
initiated	NULL
by	NULL
addition	NULL
of	NULL
10	NULL
uCi	NULL
[	NULL
y-	NULL
>	NULL
P	NULL
]	NULL
ATP	NULL
,	NULL
and	NULL
cold	NULL
ATP	NULL
and	NULL
to	NULL
final	NULL
concentrations	NULL
of	NULL
135	NULL
mmol/L	NULL
and	NULL
20	NULL
mmol/L	NULL
,	NULL
respectively	NULL
.	NULL

After	NULL
10	NULL
minutes	NULL
at	NULL
25°C	NULL
,	NULL
the	NULL
reaction	NULL
was	NULL
terminated	NULL
by	NULL
addition	NULL
of	NULL
20	NULL
uL	NULL
of	NULL
6N	NULL
HCI	NULL
.	NULL

Phospholipids	NULL
were	NULL
extracted	NULL
with	NULL
160	NULL
uL	NULL
of	NULL
CHC13	NULL
:	NULL
CH30H	NULL
(	NULL
1:1	NULL
)	NULL
,	NULL
and	NULL
separated	NULL
by	NULL
thin-layer	NULL
chromatography	NULL
(	NULL
TLC	NULL
)	NULL
.	NULL

Spots	NULL
corresponding	NULL
to	NULL
PI3-phosphate	NULL
were	NULL
visualized	NULL
by	NULL
a	NULL
PhosphoImager	NULL
(	NULL
Molecular	NULL
Dynamics	NULL
)	NULL
.	NULL

For	NULL
PKB/Akt	NULL
assay	NULL
,	NULL
cells	NULL
were	NULL
lysed	NULL
in	NULL
ice-cold	NULL
buffer	NULL
A	NULL
(	NULL
50	NULL
mmol/L	NULL
Tris	NULL
,	NULL
pH	NULL
7.5	NULL
,	NULL
1	NULL
mmol/L	NULL
EDTA	NULL
,	NULL
1	NULL
mmol/L	NULL
EGTA	NULL
,	NULL
1	NULL
mmol/L	NULL
NasVO4	NULL
,	NULL
0.1	NULL
%	NULL
2-mercaptoethanol	NULL
,	NULL
0.1	NULL
%	NULL
Triton	NULL
X-100	NULL
[	NULL
Pierce	NULL
]	NULL
,	NULL
50	NULL
mmol/L	NULL
sodium	NULL
fluoride	NULL
,	NULL
5	NULL
mmol/L	NULL
sodium	NULL
pyrophosphate	NULL
,	NULL
10	NULL
mmol/L	NULL
sodium	NULL
B-glycerophosphate	NULL
)	NULL
.	NULL

Lysates	NULL
were	NULL
centrifuged	NULL
at	NULL
14,0005	NULL
for	NULL
10	NULL
minutes	NULL
at	NULL
4°C	NULL
,	NULL
and	NULL
the	NULL
supernatants	NULL
were	NULL
equalized	NULL
for	NULL
protein	NULL
concentration	NULL
(	NULL
1	NULL
mg/mL	NULL
)	NULL
by	NULL
addition	NULL
of	NULL
buffer	NULL
A.	NULL
PKB/Akt	NULL
was	NULL
immunoprecipitated	NULL
from	NULL
the	NULL
supernatants	NULL
containing	NULL
1	NULL
mg	NULL
of	NULL
protein	NULL
with	NULL
an	NULL
anti-PKB/Akt	NULL
antibody	NULL
(	NULL
New	NULL
England	NULL
Biolabs	NULL
Inc	NULL
)	NULL
and	NULL
incubated	NULL
at	NULL
4°C	NULL
for	NULL
1.5	NULL
hour	NULL
.	NULL

Protein	NULL
A-agarose	NULL
beads	NULL
(	NULL
UBI	NULL
)	NULL
were	NULL
added	NULL
and	NULL
incubated	NULL
for	NULL
another	NULL
1	NULL
hour	NULL
at	NULL
4°C	NULL
.	NULL

The	NULL
beads	NULL
were	NULL
washed	NULL
three	NULL
times	NULL
with	NULL
buffer	NULL
A	NULL
containing	NULL
0.5	NULL
mol/L	NULL
NaCl	NULL
,	NULL
twice	NULL
with	NULL
buffer	NULL
B	NULL
(	NULL
50	NULL
mmol/L	NULL
Tris-HCI	NULL
,	NULL
pH	NULL
7.5	NULL
,	NULL
0.03	NULL
%	NULL
Brij-35	NULL
,	NULL
0.1	NULL
mmol/L	NULL
EGTA	NULL
,	NULL
and	NULL
0.1	NULL
%	NULL
2-mercaptoethanol	NULL
)	NULL
,	NULL
and	NULL
twice	NULL
with	NULL
assay	NULL
dilution	NULL
buffer	NULL
(	NULL
20	NULL
mmol/L	NULL
MOPS	NULL
,	NULL
pH	NULL
7.2	NULL
,	NULL
25	NULL
mmol/L	NULL
b-glycerophosphate	NULL
,	NULL
5	NULL
mmol/L	NULL
EGTA	NULL
,	NULL
1	NULL
mmol/L	NULL
NasVO4	NULL
,	NULL
and	NULL
1	NULL
mmol/L	NULL
DTT	NULL
)	NULL
.	NULL

The	NULL
beads	NULL
were	NULL
suspended	NULL
in	NULL
30	NULL
uL	NULL
of	NULL
assay	NULL
dilution	NULL
buffer	NULL
containing	NULL
10	NULL
mmol/L	NULL
PKA	NULL
inhibitor	NULL
peptide	NULL
(	NULL
Sigma	NULL
,	NULL
St	NULL
Louis	NULL
,	NULL
MO	NULL
)	NULL
.	NULL

PKB/Akt-specific	NULL
substrate	NULL
peptide	NULL
(	NULL
UBI	NULL
)	NULL
was	NULL
added	NULL
to	NULL
reaction	NULL
mixture	NULL
at	NULL
a	NULL
final	NULL
concentration	NULL
of	NULL
100	NULL
mmol/L	NULL
.	NULL

The	NULL
reaction	NULL
was	NULL
initiated	NULL
by	NULL
addition	NULL
of	NULL
10	NULL
mCi	NULL
[	NULL
y-	NULL
``	NULL
2P	NULL
]	NULL
ATP	NULL
.	NULL

After	NULL
10	NULL
minutes	NULL
at	NULL
25°C	NULL
,	NULL
the	NULL
supernatants	NULL
were	NULL
mixed	NULL
with	NULL
40	NULL
%	NULL
trichloroacetic	NULL
acid	NULL
(	NULL
TCA	NULL
)	NULL
and	NULL
spotted	NULL
onto	NULL
P81	NULL
phosphocellulose	NULL
paper	NULL
.	NULL

The	NULL
paper	NULL
was	NULL
washed	NULL
three	NULL
times	NULL
with	NULL
0.75	NULL
%	NULL
phosphoric	NULL
acid	NULL
,	NULL
once	NULL
with	NULL
acetone	NULL
,	NULL
and	NULL
counted	NULL
by	NULL
a	NULL
scintillation	NULL
counter	NULL
.	NULL

RESULTS	NULL
Proliferation	NULL
and	NULL
apoptosis	NULL
of	NULL
EPO-independent	NULL
HCDS5S7-SREI	NULL
cells	NULL
.	NULL

-	NULL
Earlier	NULL
studies	NULL
in	NULL
this	NULL
laboratory®	NULL
showed	NULL
that	NULL
the	NULL
treatment	NULL
of	NULL
HCD57	NULL
cells	NULL
with	NULL
SCF	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
EPO	NULL
increased	NULL
proliferation	NULL
for	NULL
3	NULL
days	NULL
but	NULL
the	NULL
effect	NULL
was	NULL
limited	NULL
because	NULL
the	NULL
cells	NULL
underwent	NULL
apoptosis	NULL
.	NULL

While	NULL
SCF	NULL
clearly	NULL
acted	NULL
as	NULL
a	NULL
mitogen	NULL
,	NULL
EPO	NULL
was	NULL
also	NULL
required	NULL
to	NULL
prevent	NULL
apoptosis	NULL
.	NULL

The	NULL
3759	NULL
proliferation	NULL
of	NULL
HCD57	NULL
cells	NULL
in	NULL
either	NULL
EPO	NULL
or	NULL
SCF	NULL
is	NULL
also	NULL
shown	NULL
in	NULL
Fig	NULL
1A	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
other	NULL
workers	NULL
have	NULL
shown	NULL
that	NULL
introduction	NULL
of	NULL
the	NULL
EPOR	NULL
into	NULL
nonerythroid	NULL
cells	NULL
will	NULL
allow	NULL
SCF	NULL
to	NULL
promote	NULL
proliferation	NULL
for	NULL
infinite	NULL
generations	NULL
,	NULL
possibly	NULL
through	NULL
an	NULL
interaction	NULL
of	NULL
c-kit	NULL
with	NULL
the	NULL
EPOR	NULL
.	NULL

*	NULL
``	NULL
*	NULL
We	NULL
subcloned	NULL
the	NULL
HCD57	NULL
cells	NULL
,	NULL
hoping	NULL
to	NULL
select	NULL
for	NULL
an	NULL
exclusively	NULL
SCF-dependent	NULL
cell	NULL
line	NULL
which	NULL
had	NULL
enhanced	NULL
signaling	NULL
of	NULL
SCF	NULL
through	NULL
the	NULL
EPOR	NULL
.	NULL

To	NULL
accomplish	NULL
this	NULL
,	NULL
the	NULL
EPO-dependent	NULL
HCD57	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
EPO	NULL
but	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
100	NULL
ng	NULL
SCF/mL	NULL
.	NULL

After	NULL
5	NULL
days	NULL
in	NULL
medium	NULL
without	NULL
EPO	NULL
but	NULL
containing	NULL
SCF	NULL
,	NULL
virtually	NULL
all	NULL
the	NULL
HCD57	NULL
cells	NULL
had	NULL
undergone	NULL
apoptosis	NULL
such	NULL
that	NULL
viable	NULL
cells	NULL
were	NULL
less	NULL
than	NULL
5	NULL
%	NULL
of	NULL
the	NULL
cell	NULL
population	NULL
(	NULL
Fig	NULL
1A	NULL
,	NULL
left	NULL
panel	NULL
)	NULL
.	NULL

During	NULL
the	NULL
next	NULL
2	NULL
weeks	NULL
,	NULL
the	NULL
number	NULL
of	NULL
viable	NULL
cells	NULL
dropped	NULL
below	NULL
1	NULL
%	NULL
of	NULL
total	NULL
cells	NULL
.	NULL

However	NULL
,	NULL
after	NULL
2	NULL
weeks	NULL
in	NULL
culture	NULL
,	NULL
significant	NULL
numbers	NULL
of	NULL
healthy	NULL
cells	NULL
appeared	NULL
in	NULL
the	NULL
culture	NULL
.	NULL

These	NULL
cells	NULL
were	NULL
cultured	NULL
for	NULL
10	NULL
weeks	NULL
without	NULL
EPO	NULL
,	NULL
at	NULL
which	NULL
point	NULL
greater	NULL
than	NULL
95	NULL
%	NULL
of	NULL
the	NULL
cells	NULL
were	NULL
viable	NULL
as	NULL
determined	NULL
by	NULL
trypan	NULL
blue	NULL
exclusion	NULL
.	NULL

From	NULL
these	NULL
pooled	NULL
cells	NULL
,	NULL
two	NULL
single-cell	NULL
clones	NULL
were	NULL
isolated	NULL
by	NULL
limiting	NULL
dilution	NULL
.	NULL

However	NULL
,	NULL
the	NULL
subcloned	NULL
cell	NULL
lines	NULL
appeared	NULL
to	NULL
be	NULL
identical	NULL
to	NULL
the	NULL
three	NULL
separate	NULL
isolations	NULL
of	NULL
pooled	NULL
cells	NULL
,	NULL
suggesting	NULL
a	NULL
single	NULL
population	NULL
of	NULL
cells	NULL
was	NULL
selected	NULL
by	NULL
these	NULL
conditions	NULL
.	NULL

We	NULL
have	NULL
been	NULL
able	NULL
to	NULL
select	NULL
these	NULL
EPO-independent	NULL
cells	NULL
only	NULL
from	NULL
high-passage	NULL
HCDS57	NULL
cells	NULL
and	NULL
have	NULL
tried	NULL
in	NULL
five	NULL
different	NULL
experiments	NULL
to	NULL
select	NULL
EPO-independent	NULL
cells	NULL
from	NULL
low-passage	NULL
HCD57	NULL
cells	NULL
without	NULL
success	NULL
.	NULL

Therefore	NULL
,	NULL
it	NULL
is	NULL
probable	NULL
that	NULL
the	NULL
selection	NULL
in	NULL
the	NULL
EPO	NULL
minus	NULL
culture	NULL
(	NULL
with	NULL
or	NULL
without	NULL
SCF	NULL
)	NULL
repeatedly	NULL
finds	NULL
the	NULL
same	NULL
subpopulation	NULL
of	NULL
EPO-independent	NULL
cells	NULL
that	NULL
are	NULL
present	NULL
in	NULL
the	NULL
high-passage	NULL
population	NULL
of	NULL
HCD57	NULL
cells	NULL
through	NULL
a	NULL
spontaneous	NULL
mutation	NULL
.	NULL

Whereas	NULL
SCF	NULL
had	NULL
only	NULL
a	NULL
transitory	NULL
effect	NULL
of	NULL
increased	NULL
proliferation	NULL
but	NULL
could	NULL
not	NULL
prevent	NULL
apoptosis	NULL
in	NULL
the	NULL
parental	NULL
HCD57	NULL
cells	NULL
,	NULL
SCF	NULL
stimulated	NULL
proliferation	NULL
of	NULL
these	NULL
surviving	NULL
cells	NULL
(	NULL
HCD57-SREI	NULL
)	NULL
over	NULL
at	NULL
least	NULL
5	NULL
days	NULL
of	NULL
culture	NULL
(	NULL
Fig	NULL
1A	NULL
,	NULL
right	NULL
panel	NULL
)	NULL
.	NULL

EPO	NULL
also	NULL
stimulated	NULL
proliferation	NULL
.	NULL

Surprisingly	NULL
,	NULL
these	NULL
cells	NULL
required	NULL
neither	NULL
EPO	NULL
nor	NULL
SCF	NULL
for	NULL
limited	NULL
proliferation	NULL
and	NULL
total	NULL
protection	NULL
from	NULL
apoptosis	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
1B	NULL
,	NULL
these	NULL
surviving	NULL
cells	NULL
did	NULL
not	NULL
undergo	NULL
apoptosis	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
EPO	NULL
or	NULL
SCF	NULL
(	NULL
Fig	NULL
1B	NULL
,	NULL
SREI-EPO	NULL
)	NULL
whereas	NULL
the	NULL
parental	NULL
HCD57	NULL
cells	NULL
degraded	NULL
DNA	NULL
to	NULL
fragments	NULL
that	NULL
are	NULL
characteristic	NULL
of	NULL
apoptosis	NULL
(	NULL
Fig	NULL
1B	NULL
,	NULL
HCD57-EPO	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
named	NULL
HCD57-SREI	NULL
(	NULL
for	NULL
SCF-Responsive	NULL
but	NULL
EPO-Independent	NULL
for	NULL
protection	NULL
from	NULL
apoptosis	NULL
)	NULL
.	NULL

HCD57-SREI	NULL
cells	NULL
have	NULL
escaped	NULL
apoptosis	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
EPO	NULL
but	NULL
proliferation	NULL
may	NULL
be	NULL
stimulated	NULL
by	NULL
either	NULL
EPO	NULL
or	NULL
SCF	NULL
.	NULL

HCD57-SREI	NULL
do	NULL
not	NULL
produce	NULL
EPO	NULL
.	NULL

-	NULL
Some	NULL
erythroleukemic	NULL
cell	NULL
lines	NULL
may	NULL
produce	NULL
autocrine	NULL
EPO	NULL
.	NULL

To	NULL
investigate	NULL
whether	NULL
the	NULL
HCD57-SREI	NULL
cells	NULL
were	NULL
secreting	NULL
EPO	NULL
into	NULL
the	NULL
medium	NULL
,	NULL
we	NULL
tested	NULL
whether	NULL
the	NULL
parental	NULL
HCD57	NULL
cells	NULL
could	NULL
survive	NULL
in	NULL
medium	NULL
conditioned	NULL
by	NULL
the	NULL
HCD57-SREI	NULL
cells	NULL
.	NULL

HCD57	NULL
cells	NULL
did	NULL
not	NULL
proliferate	NULL
and	NULL
underwent	NULL
apoptosis	NULL
in	NULL
this	NULL
conditioned	NULL
medium	NULL
even	NULL
when	NULL
the	NULL
HCD57-SREI	NULL
medium	NULL
was	NULL
concentrated	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
the	NULL
proliferation	NULL
of	NULL
HCD57-SREI	NULL
cells	NULL
was	NULL
not	NULL
dependent	NULL
on	NULL
a	NULL
high	NULL
concentration	NULL
of	NULL
cells	NULL
in	NULL
culture	NULL
and	NULL
was	NULL
not	NULL
affected	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
an	NULL
anti-EPO	NULL
antibody	NULL
that	NULL
blocked	NULL
the	NULL
proliferation	NULL
of	NULL
HCDS57	NULL
cells	NULL
in	NULL
EPO-containing	NULL
medium	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

To	NULL
investigate	NULL
whether	NULL
HCD57-SREI	NULL
cells	NULL
might	NULL
produce	NULL
EPO	NULL
that	NULL
is	NULL
not	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

3760	NULL
HCD57	NULL
CELLS	NULL
BAO	NULL
ET	NULL
AL	NULL
HCD57-SREI	NULL
CELLS	NULL
=	NULL
--	NULL
-R~	NULL
--	NULL
-	NULL
-O	NULL
500	NULL
NUMBER	NULL
OF	NULL
CELLS	NULL
,	NULL
%	NULL
of	NULL
START	NULL
>	NULL
1500	NULL
-O-	NULL
_	NULL
NO	NULL
ADDITIONS	NULL
-G-	NULL
NO	NULL
ADDITIONS	NULL
...	NULL
...	NULL
.	NULL

$	NULL
-	NULL
»	NULL
SCF	NULL
1	NULL
mange	NULL
-	NULL
SCF	NULL
0	NULL
1000	NULL
|	NULL
--	NULL
0	NULL
--	NULL
EPO	NULL
pil	NULL
<	NULL
-~O	NULL
--	NULL
-	NULL
EPO	NULL
EPO+SCF	NULL
secreted	NULL
,	NULL
we	NULL
probed	NULL
a	NULL
Northern	NULL
blot	NULL
of	NULL
RNA	NULL
prepared	NULL
from	NULL
HCD57-SREI	NULL
cells	NULL
with	NULL
a	NULL
probe	NULL
to	NULL
EPO	NULL
.	NULL

No	NULL
EPO	NULL
mRNA	NULL
was	NULL
detected	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
it	NULL
appeared	NULL
that	NULL
the	NULL
EPO-independent	NULL
phenotype	NULL
of	NULL
the	NULL
HCD57-SREI	NULL
cells	NULL
did	NULL
not	NULL
result	NULL
from	NULL
either	NULL
autocrine	NULL
EPO	NULL
production	NULL
or	NULL
secretion	NULL
of	NULL
another	NULL
factor	NULL
that	NULL
maintains	NULL
the	NULL
viability	NULL
of	NULL
erythroid	NULL
cells	NULL
.	NULL

EPOR	NULL
in	NULL
HCD5S7-SREI	NULL
is	NULL
not	NULL
activated	NULL
through	NULL
an	NULL
autoactivating	NULL
mutation	NULL
.	NULL

-	NULL
We	NULL
tested	NULL
whether	NULL
the	NULL
EPO-independent	NULL
phenotype	NULL
resulted	NULL
from	NULL
a	NULL
mutation	NULL
of	NULL
the	NULL
EPOR	NULL
gene	NULL
.	NULL

The	NULL
arginine	NULL
129	NULL
to	NULL
cysteine	NULL
mutation	NULL
in	NULL
the	NULL
EPOR	NULL
is	NULL
an	NULL
autoactivating	NULL
mutation®	NULL
``	NULL
that	NULL
allows	NULL
sulfhydryl	NULL
bonding	NULL
to	NULL
form	NULL
covalent	NULL
dimers	NULL
of	NULL
EPOR	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
EPO	NULL
.	NULL

Therefore	NULL
,	NULL
we	NULL
isolated	NULL
10	NULL
cDNA	NULL
clones	NULL
of	NULL
the	NULL
EPOR	NULL
from	NULL
these	NULL
HCD57-SREI	NULL
cells	NULL
for	NULL
sequencing	NULL
.	NULL

None	NULL
of	NULL
the	NULL
10	NULL
clones	NULL
were	NULL
found	NULL
to	NULL
have	NULL
the	NULL
arginine	NULL
129	NULL
mutation	NULL
.	NULL

Full-length	NULL
sequencing	NULL
of	NULL
two	NULL
HCD357-SREI	NULL
cDNA	NULL
clones	NULL
showed	NULL
four	NULL
identical	NULL
mutations	NULL
compared	NULL
with	NULL
a	NULL
previously	NULL
published	NULL
sequence*	NULL
'	NULL
(	NULL
amino	NULL
acid	NULL
5	NULL
,	NULL
A	NULL
to	NULL
G	NULL
mutation	NULL
in	NULL
the	NULL
second	NULL
base	NULL
of	NULL
codon	NULL
;	NULL
amino	NULL
acid	NULL
273	NULL
,	NULL
T	NULL
to	NULL
G	NULL
mutation	NULL
of	NULL
the	NULL
first	NULL
base	NULL
of	NULL
the	NULL
codon	NULL
;	NULL
amino	NULL
acid	NULL
334	NULL
,	NULL
mutation	NULL
of	NULL
A	NULL
to	NULL
G	NULL
in	NULL
the	NULL
third	NULL
base	NULL
of	NULL
the	NULL
codon	NULL
;	NULL
amino	NULL
acid	NULL
350	NULL
mutation	NULL
of	NULL
T	NULL
to	NULL
G	NULL
in	NULL
the	NULL
third	NULL
base	NULL
of	NULL
the	NULL
codon	NULL
)	NULL
.	NULL

However	NULL
,	NULL
these	NULL
mutations	NULL
are	NULL
conservative	NULL
such	NULL
that	NULL
the	NULL
amino	NULL
acid	NULL
sequence	NULL
of	NULL
the	NULL
protein	NULL
is	NULL
not	NULL
altered	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
EPOR	NULL
peptide	NULL
Fig	NULL
1	NULL
.	NULL

-	NULL
Proliferation	NULL
and	NULL
survival	NULL
of	NULL
HCDS57	NULL
and	NULL
HCDS57-SREI	NULL
cells	NULL
.	NULL

(	NULL
A	NULL
)	NULL
The	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
the	NULL
indicated	NULL
factor	NULL
,	NULL
1	NULL
U	NULL
EPO/mL	NULL
,	NULL
100	NULL
ng	NULL
SCF/	NULL
mL	NULL
,	NULL
a	NULL
combination	NULL
of	NULL
100	NULL
ng	NULL
SCF	NULL
and	NULL
1	NULL
U	NULL
EPO/mL	NULL
,	NULL
or	NULL
no	NULL
added	NULL
factors	NULL
in	NULL
medium	NULL
containing	NULL
25	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
.	NULL

At	NULL
the	NULL
indicated	NULL
day	NULL
after	NULL
culture	NULL
,	NULL
viable	NULL
cells	NULL
were	NULL
counted	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
trypan	NULL
blue	NULL
.	NULL

Error	NULL
bars	NULL
indicate	NULL
the	NULL
standard	NULL
deviation	NULL
from	NULL
triplicate	NULL
measurements	NULL
.	NULL

(	NULL
B	NULL
)	NULL
HCD57-SREI	NULL
cells	NULL
have	NULL
escaped	NULL
apoptosis	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
EPO	NULL
.	NULL

HCDS57	NULL
cells	NULL
and	NULL
HCDS57-SREI	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
1	NULL
U	NULL
EPO/mL	NULL
(	NULL
+	NULL
)	NULL
absence	NULL
of	NULL
EPO	NULL
(	NULL
-	NULL
)	NULL
for	NULL
72	NULL
hours	NULL
.	NULL

The	NULL
genomic	NULL
DNA	NULL
was	NULL
isolated	NULL
and	NULL
analyzed	NULL
for	NULL
fragmentation	NULL
of	NULL
DNA	NULL
characteristic	NULL
of	NULL
apoptosis	NULL
as	NULL
described	NULL
previously	NULL
.	NULL
``	NULL

in	NULL
HCD57-SREI	NULL
cells	NULL
is	NULL
wild	NULL
type	NULL
and	NULL
has	NULL
not	NULL
undergone	NULL
an	NULL
autoactivating	NULL
mutation	NULL
.	NULL

Processing	NULL
and	NULL
expression	NULL
of	NULL
EPOR	NULL
and	NULL
c-Kit	NULL
in	NULL
HCD57-SRET	NULL
cells	NULL
.	NULL

In	NULL
the	NULL
parental	NULL
HCDS57	NULL
cells	NULL
and	NULL
other	NULL
primary	NULL
erythroid	NULL
cells	NULL
,	NULL
most	NULL
of	NULL
the	NULL
cell-surface	NULL
EPOR	NULL
molecules	NULL
are	NULL
posttranslationally	NULL
processed	NULL
by	NULL
extensive	NULL
N-linked	NULL
glycosyla-tion	NULL
and	NULL
phosphorylation	NULL
of	NULL
nontyrosine	NULL
residues	NULL
into	NULL
a	NULL
78-kD	NULL
form.°	NULL
We	NULL
examined	NULL
the	NULL
posttranslational	NULL
processing	NULL
and	NULL
metabolism	NULL
of	NULL
the	NULL
EPOR	NULL
in	NULL
HCD57-SREI	NULL
cells	NULL
to	NULL
test	NULL
whether	NULL
overexpression	NULL
of	NULL
EPOR	NULL
peptide	NULL
,	NULL
alternative	NULL
posttranslational	NULL
processing	NULL
,	NULL
or	NULL
failure	NULL
to	NULL
downregulate	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
EPO	NULL
might	NULL
contribute	NULL
to	NULL
EPO	NULL
independence	NULL
(	NULL
or	NULL
apparent	NULL
independence	NULL
as	NULL
a	NULL
result	NULL
of	NULL
hypersensitivity	NULL
to	NULL
trace	NULL
levels	NULL
of	NULL
EPO	NULL
)	NULL
.	NULL

Figure	NULL
2A	NULL
shows	NULL
that	NULL
the	NULL
EPOR	NULL
in	NULL
HCD57-SREI	NULL
cells	NULL
appears	NULL
to	NULL
be	NULL
identically	NULL
processed	NULL
from	NULL
the	NULL
62-kD	NULL
peptide	NULL
into	NULL
the	NULL
78-kD	NULL
EPOR	NULL
as	NULL
the	NULL
parental	NULL
HCD57	NULL
cells	NULL
;	NULL
however	NULL
,	NULL
the	NULL
level	NULL
of	NULL
expression	NULL
of	NULL
the	NULL
EPOR	NULL
was	NULL
reduced	NULL
in	NULL
the	NULL
HCD57-SREI	NULL
cells	NULL
.	NULL

This	NULL
reduced	NULL
level	NULL
of	NULL
EPOR	NULL
expression	NULL
correlated	NULL
with	NULL
the	NULL
determination	NULL
that	NULL
HCD57	NULL
cells	NULL
(	NULL
deprived	NULL
of	NULL
EPO	NULL
overnight	NULL
to	NULL
upregulate	NULL
receptors	NULL
)	NULL
had	NULL
3,800	NULL
binding	NULL
sites	NULL
for	NULL
'	NULL
``	NULL
I-EPO	NULL
whereas	NULL
the	NULL
HCD57-SREI	NULL
cells	NULL
only	NULL
expressed	NULL
500	NULL
binding	NULL
sites	NULL
for	NULL
``	NULL
I-EPO	NULL
.	NULL

The	NULL
binding	NULL
affinity	NULL
for	NULL
'	NULL
I-EPO	NULL
was	NULL
similar	NULL
in	NULL
both	NULL
cell	NULL
lines	NULL
(	NULL
kd	NULL
=	NULL
810	NULL
nmol/L	NULL
and	NULL
780	NULL
nmol/L	NULL
)	NULL
.	NULL

In	NULL
the	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

PKB/Akt	NULL
AND	NULL
STATS	NULL
ACTIVITY	NULL
IN	NULL
ERYTHROID	NULL
CELLS	NULL
A	NULL
-	NULL
SRE	NULL
!	NULL

/	NULL
0	NULL
10	NULL
20	NULL
40	NULL
0	NULL
HC-D	NULL
57	NULL
10	NULL
20	NULL
40	NULL
T.min	NULL
«	NULL
a-7	NULL
BK	NULL
<	NULL
a-62K	NULL
<	NULL
-	NULL
g	NULL
G	NULL
400	NULL
m	NULL
320	NULL
gids	NULL
%	NULL
40	NULL
Counts	NULL
2	NULL
1	NULL
wut	NULL
160	NULL
0	NULL
80	NULL
“	NULL
N1	NULL
-~	NULL
nf-H	NULL
``	NULL
--	NULL
[	NULL
I	NULL
cute	NULL
I	NULL
.	NULL

“	NULL
-~	NULL
10	NULL
10	NULL
10	NULL
FL1	NULL
Fig	NULL
2	NULL
.	NULL

Processing	NULL
and	NULL
expression	NULL
of	NULL
c-Kit	NULL
and	NULL
EPOR	NULL
in	NULL
HCDS57	NULL
and	NULL
HCDS7-SRE	NULL
!	NULL

cells	NULL
.	NULL

(	NULL
A	NULL
)	NULL
HCD57	NULL
cells	NULL
deprived	NULL
of	NULL
EPO	NULL
overnight	NULL
(	NULL
lanes	NULL
A	NULL
through	NULL
D	NULL
)	NULL
or	NULL
HCDS7-SRE	NULL
cells	NULL
cultured	NULL
without	NULL
EPO	NULL
(	NULL
lanes	NULL
D	NULL
through	NULL
G	NULL
)	NULL
were	NULL
left	NULL
untreated	NULL
(	NULL
lanes	NULL
A	NULL
and	NULL
E	NULL
)	NULL
,	NULL
or	NULL
treated	NULL
with	NULL
10	NULL
U	NULL
EPO/	NULL
mL	NULL
for	NULL
the	NULL
indicated	NULL
times	NULL
at	NULL
37°C	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
rapidly	NULL
cooled	NULL
,	NULL
and	NULL
the	NULL
forms	NULL
of	NULL
EPOR	NULL
present	NULL
were	NULL
determined	NULL
by	NULL
immunoprecipitation	NULL
of	NULL
the	NULL
EPOR	NULL
and	NULL
detection	NULL
of	NULL
the	NULL
receptor	NULL
proteins	NULL
using	NULL
the	NULL
same	NULL
affinity-purified	NULL
anti-COOH	NULL
terminal	NULL
,	NULL
anti-EPOR	NULL
IgG	NULL
.	NULL

The	NULL
form	NULL
of	NULL
EPOR	NULL
between	NULL
62	NULL
and	NULL
78	NULL
kD	NULL
are	NULL
marked	NULL
(	NULL
upper	NULL
arrow	NULL
s	NULL
)	NULL
.	NULL

The	NULL
IgG	NULL
on	NULL
the	NULL
gel	NULL
from	NULL
the	NULL
heavy	NULL
chain	NULL
of	NULL
anti-EPOR	NULL
present	NULL
in	NULL
the	NULL
immunoprecipitates	NULL
is	NULL
also	NULL
indicated	NULL
(	NULL
lower	NULL
arrow	NULL
)	NULL
.	NULL

(	NULL
B	NULL
)	NULL
HCD57-SREI	NULL
cells	NULL
exhibit	NULL
upregulated	NULL
cell-surface	NULL
c-Kit	NULL
expression	NULL
.	NULL

HCDS57	NULL
and	NULL
HCDS7-SREI	NULL
cells	NULL
were	NULL
incubated	NULL
with	NULL
an	NULL
FITC-conjugated	NULL
c-Kit	NULL
antibody	NULL
and	NULL
detected	NULL
using	NULL
flow	NULL
cytometry	NULL
.	NULL

HCDS57-SREI	NULL
cells	NULL
exhibit	NULL
81.4	NULL
%	NULL
more	NULL
cell	NULL
surface	NULL
c-Kit	NULL
(	NULL
peak	NULL
C	NULL
)	NULL
than	NULL
HCD57	NULL
(	NULL
peak	NULL
B	NULL
)	NULL
.	NULL

Peak	NULL
A	NULL
represents	NULL
background	NULL
staining	NULL
(	NULL
CD4	NULL
)	NULL
.	NULL

presence	NULL
of	NULL
EPO	NULL
,	NULL
the	NULL
high-molecular-weight	NULL
68-	NULL
to	NULL
78-kD	NULL
forms	NULL
of	NULL
EPOR	NULL
in	NULL
both	NULL
HCD357	NULL
and	NULL
HCD57-SREI	NULL
cells	NULL
were	NULL
similarly	NULL
downregulated	NULL
within	NULL
40	NULL
minutes	NULL
(	NULL
Fig	NULL
2A	NULL
,	NULL
lanes	NULL
D	NULL
and	NULL
H	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
there	NULL
appeared	NULL
to	NULL
be	NULL
no	NULL
alteration	NULL
of	NULL
the	NULL
EPOR	NULL
protein	NULL
in	NULL
HCD57-SREI	NULL
cells	NULL
that	NULL
would	NULL
explain	NULL
the	NULL
EPO-independent	NULL
phenotype	NULL
.	NULL

We	NULL
next	NULL
examined	NULL
cell-surface	NULL
expression	NULL
of	NULL
c-Kit	NULL
by	NULL
incubation	NULL
of	NULL
HCDS57	NULL
and	NULL
HCD57-SREI	NULL
cells	NULL
with	NULL
a	NULL
c-Kit	NULL
antibody	NULL
and	NULL
detection	NULL
of	NULL
surface-bound	NULL
antibody	NULL
by	NULL
flow	NULL
cytometry	NULL
.	NULL

Detection	NULL
of	NULL
surface	NULL
c-Kit	NULL
expression	NULL
showed	NULL
an	NULL
81.4	NULL
%	NULL
increase	NULL
in	NULL
c-Kit	NULL
surface	NULL
expression	NULL
in	NULL
HCD57-SREI	NULL
3761	NULL
cells	NULL
(	NULL
Fig	NULL
2B	NULL
,	NULL
peak	NULL
C	NULL
)	NULL
as	NULL
compared	NULL
with	NULL
HCD57	NULL
cells	NULL
(	NULL
Fig	NULL
2B	NULL
,	NULL
peak	NULL
B	NULL
)	NULL
.	NULL

Expression	NULL
of	NULL
Bcl-XL	NULL
and	NULL
Bcl-2	NULL
in	NULL
HCDS57	NULL
and	NULL
HCDS7-SREI	NULL
cells	NULL
.	NULL

-	NULL
The	NULL
above	NULL
experiments	NULL
indicated	NULL
a	NULL
nonreceptor	NULL
explanation	NULL
for	NULL
EPO-independence	NULL
in	NULL
HCD57-SREI	NULL
cells	NULL
.	NULL

Overexpression	NULL
of	NULL
the	NULL
Bel	NULL
family	NULL
of	NULL
apoptosis	NULL
modulating	NULL
proteins	NULL
can	NULL
result	NULL
in	NULL
resistance	NULL
to	NULL
apoptosis	NULL
.	NULL

Previous	NULL
work	NULL
had	NULL
implicated	NULL
Bel-Xl	NULL
but	NULL
not	NULL
Bel-2	NULL
as	NULL
a	NULL
critical	NULL
control	NULL
point	NULL
in	NULL
protecting	NULL
from	NULL
apoptosis	NULL
in	NULL
HCDS57	NULL
cells	NULL
.	NULL
``	NULL

Therefore	NULL
,	NULL
we	NULL
examined	NULL
the	NULL
expression	NULL
of	NULL
Bel-Xl	NULL
and	NULL
Bel-2	NULL
in	NULL
the	NULL
HCD57-SREI	NULL
cells	NULL
.	NULL

There	NULL
was	NULL
a	NULL
similar	NULL
level	NULL
of	NULL
expression	NULL
of	NULL
these	NULL
two	NULL
apoptosis	NULL
suppressing	NULL
proteins	NULL
in	NULL
the	NULL
HCD57-SREI	NULL
cells	NULL
(	NULL
Fig	NULL
3	NULL
,	NULL
lanes	NULL
D	NULL
and	NULL
H	NULL
)	NULL
as	NULL
the	NULL
parental	NULL
HCD57	NULL
cells	NULL
(	NULL
Fig	NULL
3	NULL
,	NULL
lanes	NULL
B	NULL
and	NULL
F	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
protection	NULL
from	NULL
apoptosis	NULL
in	NULL
the	NULL
HCDS57-SREI	NULL
cells	NULL
did	NULL
not	NULL
HCDS7	NULL
-	NULL
HCDS7-SREI	NULL
CELLS	NULL
-o	NULL
+	NULL
-	NULL
=	NULL
+	NULL
EPO	NULL
A	NULL
B	NULL
HCD57	NULL
=o	NULL
F	NULL
o	NULL
wae	NULL
C	NULL
-	NULL
D	NULL
HCD57-SREI	NULL
_+	NULL
EPO	NULL
#	NULL
4.	NULL
d	NULL
l—m	NULL
w-M	NULL
’	NULL
M	NULL
f	NULL
(	NULL
e-	NULL
were	NULL
--	NULL
*	NULL
soi.2	NULL
cuits	NULL
w-	NULL
woe	NULL
426	NULL
K	NULL
E	NULL
F	NULL
G	NULL
H	NULL
Fig	NULL
3	NULL
.	NULL

-	NULL
Bel-XI	NULL
and	NULL
Bcl-2	NULL
are	NULL
maintained	NULL
in	NULL
HCD57-SREI	NULL
cells	NULL
when	NULL
EPO	NULL
is	NULL
withdrawn	NULL
.	NULL

HCD57	NULL
cells	NULL
(	NULL
lanes	NULL
A	NULL
,	NULL
B	NULL
,	NULL
E	NULL
,	NULL
and	NULL
F	NULL
)	NULL
and	NULL
HCDS57-SREI	NULL
cells	NULL
(	NULL
lanes	NULL
C	NULL
,	NULL
D	NULL
,	NULL
G	NULL
,	NULL
and	NULL
H	NULL
)	NULL
were	NULL
cultured	NULL
for	NULL
72	NULL
hours	NULL
in	NULL
either	NULL
medium	NULL
containing	NULL
1	NULL
U	NULL
EPO/mL	NULL
(	NULL
lanes	NULL
B	NULL
,	NULL
D	NULL
,	NULL
F	NULL
,	NULL
H	NULL
)	NULL
or	NULL
no	NULL
EPO	NULL
(	NULL
lanes	NULL
A	NULL
,	NULL
C	NULL
,	NULL
E	NULL
,	NULL
G	NULL
)	NULL
.	NULL

Ten	NULL
micrograms	NULL
of	NULL
cellular	NULL
protein	NULL
w	NULL
as	NULL
analyzed	NULL
by	NULL
Western	NULL
blotting	NULL
using	NULL
anti-Bcl-XI	NULL
(	NULL
lanes	NULL
A	NULL
through	NULL
D	NULL
)	NULL
or	NULL
anti-Bcl-2	NULL
(	NULL
lanes	NULL
E	NULL
through	NULL
H	NULL
)	NULL
antisera	NULL
.	NULL

The	NULL
proteins	NULL
of	NULL
interest	NULL
were	NULL
visualized	NULL
with	NULL
ECL	NULL
and	NULL
are	NULL
marked	NULL
by	NULL
an	NULL
arrow	NULL
.	NULL

From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

3762	NULL
A	NULL
HCD57	NULL
/	NULL
SRE	NULL
CELLS	NULL
C	NULL
E	NULL
S	NULL
$	NULL
C	NULL
E	NULL
S	NULL
$	NULL
Additions	NULL
<	NULL
-	NULL
200	NULL
K	NULL
“	NULL
h	NULL
``	NULL
-	NULL
yas	NULL
:	NULL
:	NULL
a	NULL
wa	NULL
.	NULL

<	NULL
135	NULL
K	NULL
g	NULL
&	NULL
comes	NULL
<	NULL
78	NULL
K	NULL
e	NULL
_.	NULL
un	NULL
<	NULL
4	NULL
52	NULL
K	NULL
wmn	NULL
<	NULL
4	NULL
30	NULL
K	NULL
o-JAK2	NULL
«	NULL
4	NULL
135	NULL
K	NULL
)	NULL
waar	NULL
<	NULL
19G	NULL
ABCDEF	NULL
BAO	NULL
ET	NULL
AL	NULL
P	NULL
srEj	NULL
c	NULL
Ss	NULL
E	NULL
HCD57	NULL
CELLS	NULL
C	NULL
S	NULL
E	NULL
-	NULL
_	NULL
«	NULL
1145	NULL
k	NULL
6	NULL
4	NULL
~	NULL
.	NULL

#	NULL
SHC	NULL
ue	NULL
-	NULL
®	NULL
``	NULL
s	NULL
~	NULL
=-	NULL
she	NULL
-	NULL
«	NULL
oe	NULL
«	NULL
s	NULL
«	NULL
-_-	NULL
»	NULL
4	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
Fig	NULL
4	NULL
.	NULL

Effect	NULL
of	NULL
EPO	NULL
and	NULL
SCF	NULL
on	NULL
tyrosine	NULL
protein	NULL
phosphorylation	NULL
in	NULL
HCD57	NULL
cell	NULL
and	NULL
HCDS7-SRE	NULL
!	NULL

cells	NULL
.	NULL

(	NULL
A	NULL
)	NULL
HCDS57	NULL
cells	NULL
deprived	NULL
of	NULL
EPO	NULL
overnight	NULL
(	NULL
lanes	NULL
A	NULL
,	NULL
B	NULL
,	NULL
C	NULL
)	NULL
or	NULL
HCDS57-SREI	NULL
cells	NULL
cultured	NULL
without	NULL
EPO	NULL
(	NULL
lanes	NULL
D	NULL
,	NULL
E	NULL
,	NULL
F	NULL
)	NULL
were	NULL
left	NULL
untreated	NULL
(	NULL
A	NULL
,	NULL
D	NULL
)	NULL
or	NULL
treated	NULL
with	NULL
10	NULL
U	NULL
EPO/mL	NULL
for	NULL
10	NULL
minutes	NULL
(	NULL
B	NULL
,	NULL
E	NULL
)	NULL
or	NULL
100	NULL
ng	NULL
SCF/	NULL
mL	NULL
for	NULL
10	NULL
minutes	NULL
(	NULL
C	NULL
,	NULL
F	NULL
)	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
then	NULL
rapidly	NULL
chilled	NULL
in	NULL
an	NULL
ice	NULL
bath	NULL
,	NULL
a	NULL
detergent	NULL
lysate	NULL
was	NULL
prepared	NULL
,	NULL
and	NULL
phosphotyrosine	NULL
containing	NULL
proteins	NULL
were	NULL
immunoprecipitated	NULL
with	NULL
a	NULL
polyclonal	NULL
anti-Tyr	NULL
(	NULL
P	NULL
)	NULL
antibody	NULL
.	NULL

The	NULL
immunoprecipitated	NULL
proteins	NULL
were	NULL
then	NULL
run	NULL
on	NULL
SDS-polyacrylamide	NULL
gel	NULL
electrophoresis	NULL
,	NULL
Western	NULL
blotted	NULL
,	NULL
and	NULL
probed	NULL
with	NULL
a	NULL
monoclonal	NULL
anti-Tyr	NULL
(	NULL
P	NULL
)	NULL
antibody	NULL
(	NULL
top	NULL
panel	NULL
)	NULL
and	NULL
then	NULL
stripped	NULL
of	NULL
bound	NULL
antibody	NULL
and	NULL
reprobed	NULL
with	NULL
an	NULL
anti-JAK2	NULL
antiserum	NULL
(	NULL
bottom	NULL
panel	NULL
)	NULL
.	NULL

Bands	NULL
were	NULL
visualized	NULL
with	NULL
ECL	NULL
(	NULL
B	NULL
)	NULL
SHC	NULL
protein	NULL
tyrosine	NULL
phosphorylation	NULL
in	NULL
HCDS57-SREI	NULL
cells	NULL
(	NULL
lanes	NULL
1	NULL
through	NULL
3	NULL
)	NULL
and	NULL
HCDS7	NULL
cells	NULL
(	NULL
lanes	NULL
4	NULL
through	NULL
6	NULL
)	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
nothing	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
4	NULL
)	NULL
,	NULL
SCF	NULL
(	NULL
lanes	NULL
2	NULL
and	NULL
5	NULL
)	NULL
,	NULL
and	NULL
EPO	NULL
(	NULL
lanes	NULL
3	NULL
and	NULL
6	NULL
)	NULL
as	NULL
described	NULL
above	NULL
and	NULL
SHC	NULL
proteins	NULL
were	NULL
immunoprecipitated	NULL
.	NULL

The	NULL
Western	NULL
blot	NULL
was	NULL
probed	NULL
with	NULL
anti-Tyr	NULL
(	NULL
P	NULL
)	NULL
(	NULL
top	NULL
panel	NULL
)	NULL
and	NULL
then	NULL
stripped	NULL
of	NULL
bound	NULL
antibody	NULL
and	NULL
reprobed	NULL
with	NULL
anti-SHC	NULL
antiserum	NULL
(	NULL
bottom	NULL
panel	NULL
)	NULL
.	NULL

result	NULL
from	NULL
overexpression	NULL
of	NULL
the	NULL
Bel	NULL
gene	NULL
products	NULL
.	NULL

However	NULL
,	NULL
we	NULL
found	NULL
that	NULL
whereas	NULL
the	NULL
withdrawal	NULL
of	NULL
EPO	NULL
suppressed	NULL
the	NULL
expression	NULL
of	NULL
both	NULL
Bcel-X1	NULL
and	NULL
Bcl-2	NULL
proteins	NULL
in	NULL
HCD57	NULL
cells	NULL
,	NULL
Bcl-Xl	NULL
levels	NULL
were	NULL
maintained	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
EPO	NULL
in	NULL
HCD57-SREI	NULL
cells	NULL
(	NULL
Fig	NULL
3	NULL
,	NULL
lanes	NULL
C	NULL
and	NULL
G	NULL
)	NULL
.	NULL

The	NULL
EPO-independent	NULL
phenotype	NULL
of	NULL
HCD57-SREI	NULL
cells	NULL
,	NULL
therefore	NULL
,	NULL
may	NULL
be	NULL
caused	NULL
by	NULL
an	NULL
alteration	NULL
in	NULL
signaling	NULL
upstream	NULL
of	NULL
the	NULL
regulation	NULL
of	NULL
Bel-Xl	NULL
gene	NULL
that	NULL
maintains	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
Bcel-X	NULL
]	NULL
protein	NULL
even	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
EPO	NULL
.	NULL

Tyrosine	NULL
protein	NULL
phosphorylation	NULL
in	NULL
HCDS7	NULL
and	NULL
HCDS5S7-SREI	NULL
cells	NULL
.	NULL

-	NULL
Alterations	NULL
in	NULL
cellular	NULL
signaling	NULL
in	NULL
HCD57-SREI	NULL
cells	NULL
might	NULL
explain	NULL
why	NULL
Bcel-Xl	NULL
levels	NULL
were	NULL
maintained	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
EPO	NULL
.	NULL

Therefore	NULL
,	NULL
we	NULL
examined	NULL
the	NULL
phosphotyrosine-containing	NULL
proteins	NULL
in	NULL
either	NULL
untreated	NULL
cells	NULL
or	NULL
cells	NULL
treated	NULL
with	NULL
SCF	NULL
or	NULL
EPO	NULL
in	NULL
HCD57-SREI	NULL
and	NULL
parental	NULL
HCD57	NULL
cells	NULL
.	NULL

If	NULL
an	NULL
autoactivating	NULL
mutation	NULL
in	NULL
the	NULL
EPOR	NULL
or	NULL
a	NULL
mutation	NULL
resulting	NULL
in	NULL
expression	NULL
of	NULL
EPO	NULL
were	NULL
present	NULL
,	NULL
we	NULL
would	NULL
expect	NULL
to	NULL
see	NULL
constitutive	NULL
phosphorylation	NULL
of	NULL
the	NULL
EPOR	NULL
and	NULL
JAK2	NULL
kinase	NULL
as	NULL
previously	NULL
reported	NULL
.	NULL
``	NULL

In	NULL
addition	NULL
,	NULL
the	NULL
constitutive	NULL
secretion	NULL
of	NULL
SCF	NULL
would	NULL
be	NULL
expected	NULL
to	NULL
lead	NULL
to	NULL
constitutive	NULL
tyrosine	NULL
protein	NULL
phosphorylation	NULL
of	NULL
c-Kit	NULL
.	NULL

However	NULL
,	NULL
as	NULL
shown	NULL
in	NULL
Fig	NULL
4A	NULL
(	NULL
top	NULL
panel	NULL
)	NULL
,	NULL
there	NULL
was	NULL
no	NULL
apparent	NULL
constitutive	NULL
phosphorylation	NULL
of	NULL
bands	NULL
corresponding	NULL
to	NULL
EPOR	NULL
,	NULL
JAK2	NULL
,	NULL
c-Kit	NULL
,	NULL
or	NULL
other	NULL
major	NULL
phosphotyrosine	NULL
[	NULL
Tyr	NULL
(	NULL
P	NULL
)	NULL
]	NULL
containing	NULL
protein	NULL
in	NULL
HCD57-SREI	NULL
cells	NULL
,	NULL
virtually	NULL
ruling	NULL
out	NULL
the	NULL
possibility	NULL
of	NULL
an	NULL
autoactivating	NULL
mutation	NULL
in	NULL
either	NULL
EPOR	NULL
or	NULL
JAK2	NULL
or	NULL
autocrine	NULL
production	NULL
of	NULL
EPO	NULL
or	NULL
SCE	NULL
.	NULL

The	NULL
Tyr	NULL
(	NULL
P	NULL
)	NULL
-containing	NULL
proteins	NULL
were	NULL
very	NULL
similar	NULL
in	NULL
the	NULL
HCD57	NULL
and	NULL
HCDS7-SREI	NULL
cells	NULL
after	NULL
either	NULL
EPO	NULL
or	NULL
SCF	NULL
treatment	NULL
with	NULL
the	NULL
exception	NULL
that	NULL
the	NULL
tyrosine-phosphorylated	NULL
78-kD	NULL
band	NULL
corresponding	NULL
to	NULL
EPOR	NULL
was	NULL
more	NULL
prominent	NULL
in	NULL
EPO-treated	NULL
HCD57	NULL
cells	NULL
,	NULL
correlating	NULL
with	NULL
the	NULL
increased	NULL
expression	NULL
of	NULL
the	NULL
78-kD	NULL
EPOR	NULL
.	NULL

As	NULL
shown	NULL
by	NULL
very	NULL
careful	NULL
examination	NULL
of	NULL
Fig	NULL
4A	NULL
,	NULL
there	NULL
was	NULL
only	NULL
a	NULL
trace	NULL
of	NULL
Tyr	NULL
(	NULL
P	NULL
)	NULL
in	NULL
the	NULL
EPOR	NULL
in	NULL
either	NULL
HCD57	NULL
or	NULL
HCDS57-SREI	NULL
cells	NULL
treated	NULL
with	NULL
SCF	NULL
.	NULL

In	NULL
data	NULL
not	NULL
shown	NULL
,	NULL
we	NULL
observed	NULL
that	NULL
there	NULL
was	NULL
twofold	NULL
to	NULL
threefold	NULL
more	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
the	NULL
78-kD	NULL
EPOR	NULL
immunoprecipitated	NULL
from	NULL
HCD57-SREI	NULL
cells	NULL
treated	NULL
with	NULL
SCF	NULL
than	NULL
the	NULL
EPOR	NULL
in	NULL
comparably	NULL
treated	NULL
HCD57	NULL
cells	NULL
.	NULL

This	NULL
level	NULL
of	NULL
EPOR	NULL
phosphorylation	NULL
was	NULL
only	NULL
about	NULL
10	NULL
%	NULL
of	NULL
the	NULL
phosphorylation	NULL
achieved	NULL
with	NULL
EPO	NULL
stimulation	NULL
.	NULL

A	NULL
150-kD	NULL
band	NULL
which	NULL
apparently	NULL
corresponds	NULL
to	NULL
the	NULL
SCF	NULL
receptor	NULL
was	NULL
more	NULL
strongly	NULL
phosphorylated	NULL
in	NULL
SCP-treated	NULL
HCDS57-SREI	NULL
than	NULL
HCDS7	NULL
cells	NULL
,	NULL
correlating	NULL
with	NULL
increased	NULL
expression	NULL
of	NULL
c-Kit	NULL
on	NULL
HCD57-SREI	NULL
cells	NULL
.	NULL

Another	NULL
approximately	NULL
30-kD	NULL
protein	NULL
of	NULL
unknown	NULL
identity	NULL
was	NULL
highly	NULL
phosphorylated	NULL
in	NULL
SCF-treated	NULL
HCD57-SREI	NULL
cells	NULL
compared	NULL
with	NULL
HCD57	NULL
cells	NULL
.	NULL

Stripping	NULL
this	NULL
blot	NULL
and	NULL
reprobing	NULL
with	NULL
anti-JAK2	NULL
antiserum	NULL
showed	NULL
that	NULL
JAK2	NULL
was	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

PKB/Akt	NULL
AND	NULL
STATS	NULL
ACTIVITY	NULL
IN	NULL
ERYTHROID	NULL
CELLS	NULL
CELLS	NULL
EPO	NULL
SERUM	NULL
Fig	NULL
4	NULL
(	NULL
Cont	NULL
'd	NULL
)	NULL
.	NULL

(	NULL
C	NULL
)	NULL
MAP	NULL
kinase	NULL
(	NULL
ERK-1	NULL
)	NULL
activity	NULL
in	NULL
HCDS7	NULL
and	NULL
HCDS7-SRE	NULL
!	NULL

cells	NULL
.	NULL

HCD57	NULL
cells	NULL
were	NULL
deprived	NULL
of	NULL
EPO	NULL
overnight	NULL
in	NULL
IMDM	NULL
containing	NULL
25	NULL
%	NULL
serum	NULL
.	NULL

Aliquots	NULL
of	NULL
HCD57	NULL
cells	NULL
that	NULL
had	NULL
been	NULL
deprived	NULL
of	NULL
EPO	NULL
(	NULL
lanes	NULL
1	NULL
through	NULL
4	NULL
)	NULL
and	NULL
HCDS57-SREI	NULL
cell	NULL
continually	NULL
cultured	NULL
without	NULL
EPO	NULL
(	NULL
lanes	NULL
5	NULL
through	NULL
8	NULL
)	NULL
were	NULL
deprived	NULL
of	NULL
serum	NULL
for	NULL
1	NULL
hour	NULL
.	NULL

After	NULL
this	NULL
1-hour	NULL
incubation	NULL
in	NULL
serumless	NULL
medium	NULL
,	NULL
either	NULL
nothing	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
5	NULL
)	NULL
,	NULL
1.0	NULL
U	NULL
EPO/mL	NULL
(	NULL
lanes	NULL
2	NULL
and	NULL
6	NULL
)	NULL
,	NULL
25	NULL
%	NULL
MBP	NULL
-	NULL
»	NULL
3763	NULL
HCDS57	NULL
HCD57-SREI	NULL
eo	NULL
0	NULL
e	NULL
0	NULL
#	NULL
0	NULL
Ck	NULL
00	NULL
#	NULL
k	NULL
0	NULL
4	NULL
=	NULL
=	NULL
+	NULL
+	NULL
=	NULL
=-	NULL
+	NULL
+	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
fetal	NULL
calf	NULL
serum	NULL
(	NULL
lanes	NULL
3	NULL
and	NULL
7	NULL
)	NULL
,	NULL
or	NULL
a	NULL
combination	NULL
of	NULL
D	NULL
HCDS57-SREI	NULL
HCD5S7	NULL
__HCDS7-SRElI	NULL
_HCDS7	NULL
__CELLS	NULL
25	NULL
%	NULL
serum	NULL
plus	NULL
1.0	NULL
U	NULL
EPO/mL	NULL
was	NULL
added	NULL
for	NULL
10	NULL
Total	NULL
cell	NULL
anti-STATS5	NULL
immunoprecipitate	NULL
minutes	NULL
at	NULL
37°C	NULL
.	NULL

After	NULL
the	NULL
10-minute	NULL
incubation	NULL
,	NULL
the	NULL
0	NULL
5	NULL
10	NULL
0	NULL
5	NULL
10	NULL
0	NULL
5	NULL
40	NULL
0	NULL
5	NULL
10	NULL
min	NULL
,	NULL
EPO	NULL
cells	NULL
were	NULL
rapidly	NULL
chilled	NULL
in	NULL
cold	NULL
medium	NULL
,	NULL
solubilized	NULL
,	NULL
and	NULL
the	NULL
ERK-1	NULL
,	NULL
MAP	NULL
kinase	NULL
activity	NULL
determined	NULL
by	NULL
_	NULL
205k-immunoprecipitation	NULL
and	NULL
phosphorylation	NULL
of	NULL
myelin	NULL
dite	NULL
4	NULL
%	NULL
-JAK2	NULL
basic	NULL
protein	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

=	NULL
®=	NULL
(	NULL
D	NULL
)	NULL
cznsﬁtutive	NULL
STATS	NULL
phosphorylation	NULL
in	NULL
HCDS7-	NULL
115K	NULL
a	NULL
»	NULL
ap	NULL
tat	NULL
n	NULL
``	NULL
-STATS5	NULL
SREI	NULL
cells	NULL
.	NULL

HCDS7-SREI	NULL
cells	NULL
(	NULL
lanes	NULL
A	NULL
through	NULL
C	NULL
,	NULL
G	NULL
80k-	NULL
t	NULL
-EPOR	NULL
,	NULL
78K	NULL
through	NULL
1	NULL
)	NULL
and	NULL
HCDS57	NULL
cells	NULL
(	NULL
lanes	NULL
E	NULL
through	NULL
F	NULL
,	NULL
J	NULL
through	NULL
L	NULL
)	NULL
were	NULL
treated	NULL
with	NULL
nothing	NULL
(	NULL
lanes	NULL
A	NULL
,	NULL
D	NULL
,	NULL
G	NULL
,	NULL
L	NULL
J	NULL
)	NULL
or	NULL
10	NULL
U	NULL
EPO/mL	NULL
for	NULL
either	NULL
5	NULL
minutes	NULL
(	NULL
lanes	NULL
B	NULL
,	NULL
E	NULL
,	NULL
H	NULL
,	NULL
50k-	NULL
*	NULL
r	NULL
E	NULL
SEEK/49K	NULL
)	NULL
K	NULL
)	NULL
or	NULL
10	NULL
minutes	NULL
(	NULL
lanes	NULL
C	NULL
,	NULL
F	NULL
,	NULL
I	NULL
,	NULL
L	NULL
)	NULL
at	NULL
37°C	NULL
.	NULL

Ten	NULL
micro-	NULL
-	NULL
%	NULL
it	NULL
-	NULL
ERK1,2	NULL
grams	NULL
of	NULL
total	NULL
cellular	NULL
extract	NULL
(	NULL
lanes	NULL
A	NULL
through	NULL
F	NULL
)	NULL
or	NULL
ae	NULL
p42/44	NULL
STATS	NULL
immunoprecipitated	NULL
from	NULL
200	NULL
ug	NULL
of	NULL
cellular	NULL
35	NULL
k-	NULL
_	NULL
extract	NULL
(	NULL
lanes	NULL
G	NULL
through	NULL
L	NULL
)	NULL
were	NULL
analyzed	NULL
by	NULL
West-	NULL
«	NULL
--	NULL
au	NULL
»	NULL
db	NULL
amp	NULL
ern	NULL
blotting	NULL
with	NULL
anti-Tyr	NULL
(	NULL
P	NULL
)	NULL
antiserum	NULL
.	NULL

Molecular-	NULL
28k-	NULL
Can-	NULL
coum	NULL
<	NULL
one	NULL
come	NULL
comme	NULL
fft	NULL
weight	NULL
markers	NULL
and	NULL
migration	NULL
of	NULL
proteins	NULL
of	NULL
interest	NULL
are	NULL
indicated	NULL
.	NULL

neither	NULL
autophosphorylated	NULL
in	NULL
HCD57-SREI	NULL
cells	NULL
nor	NULL
tyrosine	NULL
phosphorylated	NULL
after	NULL
SCF	NULL
treatment	NULL
(	NULL
Fig	NULL
4A	NULL
,	NULL
bottom	NULL
panel	NULL
,	NULL
lane	NULL
F	NULL
)	NULL
.	NULL

We	NULL
also	NULL
studied	NULL
the	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
the	NULL
SHC	NULL
proteins	NULL
in	NULL
both	NULL
EPO-treated	NULL
and	NULL
SCP-treated	NULL
HCDS57	NULL
and	NULL
HCD57-SREI	NULL
cells	NULL
(	NULL
Fig	NULL
4B	NULL
)	NULL
.	NULL

As	NULL
suggested	NULL
by	NULL
the	NULL
antiphospho-tyrosine	NULL
Western	NULL
blots	NULL
in	NULL
Fig	NULL
4A	NULL
,	NULL
immunoprecipitated	NULL
SHC	NULL
was	NULL
not	NULL
constitutively	NULL
phosphorylated	NULL
in	NULL
either	NULL
cell	NULL
type	NULL
(	NULL
Fig	NULL
4B	NULL
,	NULL
lanes	NULL
1	NULL
and	NULL
4	NULL
)	NULL
.	NULL

The	NULL
lesser	NULL
effect	NULL
of	NULL
EPO	NULL
on	NULL
SHC	NULL
phosphorylation	NULL
in	NULL
HCD57-SREI	NULL
cells	NULL
reflected	NULL
the	NULL
reduced	NULL
expression	NULL
and	NULL
phosphorylation	NULL
of	NULL
the	NULL
EPOR	NULL
.	NULL

In	NULL
HCDS57	NULL
cells	NULL
,	NULL
neither	NULL
the	NULL
EPO-dependent	NULL
nor	NULL
SCF-dependent	NULL
SHC	NULL
tyrosine	NULL
phosphorylation	NULL
appeared	NULL
to	NULL
correlate	NULL
with	NULL
induced	NULL
ERK-1	NULL
activity	NULL
.	NULL
``	NULL

However	NULL
,	NULL
recent	NULL
information	NULL
shows	NULL
that	NULL
ERK	NULL
may	NULL
be	NULL
activated	NULL
by	NULL
SHC-independent	NULL
mecha-nisms	NULL
.	NULL

``	NULL
*	NULL
Therefore	NULL
,	NULL
we	NULL
tested	NULL
MAP	NULL
kinase	NULL
(	NULL
ERK-1	NULL
)	NULL
activity	NULL
by	NULL
immunoprecipitating	NULL
ERK-1	NULL
proteins	NULL
and	NULL
measuring	NULL
the	NULL
activity	NULL
that	NULL
phosphorylated	NULL
myelin	NULL
basic	NULL
protein	NULL
.	NULL

In	NULL
data	NULL
not	NULL
shown	NULL
,	NULL
a	NULL
low	NULL
level	NULL
of	NULL
constitutive	NULL
activity	NULL
of	NULL
ERK-1	NULL
was	NULL
found	NULL
in	NULL
both	NULL
HCD57	NULL
and	NULL
HCD57-SREI	NULL
cells	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
growth	NULL
factors	NULL
but	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
25	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
.	NULL

This	NULL
observation	NULL
seems	NULL
to	NULL
eliminate	NULL
the	NULL
SHC/ERK	NULL
pathway	NULL
from	NULL
a	NULL
role	NULL
in	NULL
the	NULL
resistance	NULL
to	NULL
apoptosis	NULL
upon	NULL
EPO	NULL
withdrawal	NULL
seen	NULL
in	NULL
HCD57-SREI	NULL
cells	NULL
.	NULL

We	NULL
then	NULL
removed	NULL
the	NULL
serum	NULL
for	NULL
1	NULL
hour	NULL
and	NULL
measured	NULL
the	NULL
basal	NULL
levels	NULL
of	NULL
ERK-1	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
serum	NULL
and	NULL
the	NULL
ERK	NULL
activity	NULL
after	NULL
the	NULL
addition	NULL
of	NULL
25	NULL
%	NULL
serum	NULL
,	NULL
10	NULL
U	NULL
EPO/mL	NULL
,	NULL
or	NULL
a	NULL
combination	NULL
of	NULL
serum	NULL
and	NULL
EPO	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
4C	NULL
,	NULL
there	NULL
was	NULL
A	NULL
B	NULL
C	NULL
D	NULL
E	NULL
F	NULL
G	NULL
H|	NULL
J	NULL
K	NULL
L	NULL
no	NULL
detectable	NULL
ERK-1	NULL
activity	NULL
in	NULL
either	NULL
the	NULL
HCD57	NULL
cells	NULL
or	NULL
HCD57-SREI	NULL
cells	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
serum	NULL
and	NULL
EPO	NULL
.	NULL

It	NULL
is	NULL
interesting	NULL
to	NULL
note	NULL
that	NULL
this	NULL
experiment	NULL
showed	NULL
that	NULL
MAP	NULL
kinase	NULL
activity	NULL
is	NULL
poorly	NULL
activated	NULL
by	NULL
either	NULL
EPO	NULL
alone	NULL
or	NULL
serum	NULL
alone	NULL
and	NULL
that	NULL
there	NULL
is	NULL
a	NULL
strong	NULL
synergistic	NULL
effect	NULL
of	NULL
serum	NULL
and	NULL
EPO	NULL
in	NULL
both	NULL
HCD57	NULL
and	NULL
HCD57-SREI	NULL
cells	NULL
.	NULL

However	NULL
,	NULL
the	NULL
magnitude	NULL
of	NULL
the	NULL
synergistic	NULL
effect	NULL
of	NULL
combining	NULL
EPO	NULL
and	NULL
serum	NULL
was	NULL
much	NULL
greater	NULL
in	NULL
the	NULL
HCD57-SREI	NULL
cells	NULL
than	NULL
observed	NULL
in	NULL
the	NULL
HCD57	NULL
cells	NULL
.	NULL

We	NULL
found	NULL
this	NULL
surprising	NULL
but	NULL
three	NULL
separate	NULL
experiments	NULL
showed	NULL
almost	NULL
identical	NULL
results	NULL
as	NULL
that	NULL
shown	NULL
in	NULL
Fig	NULL
4C	NULL
.	NULL

STATSA/B	NULL
is	NULL
constitutively	NULL
phosphorylated	NULL
,	NULL
translocated	NULL
to	NULL
the	NULL
nucleus	NULL
,	NULL
and	NULL
bound	NULL
to	NULL
DNA	NULL
in	NULL
the	NULL
HCDS7-SREI	NULL
cells	NULL
.	NULL

Although	NULL
not	NULL
evident	NULL
in	NULL
the	NULL
above	NULL
experiments	NULL
,	NULL
a	NULL
band	NULL
of	NULL
about	NULL
100	NULL
kD	NULL
constitutively	NULL
tyrosine	NULL
phosphorylated	NULL
in	NULL
the	NULL
SREI	NULL
subclone	NULL
but	NULL
not	NULL
the	NULL
HCD57	NULL
cells	NULL
,	NULL
was	NULL
seen	NULL
in	NULL
some	NULL
experiments	NULL
.	NULL

To	NULL
test	NULL
whether	NULL
this	NULL
approximately	NULL
100-kD	NULL
band	NULL
might	NULL
be	NULL
an	NULL
activated	NULL
STAT	NULL
protein	NULL
,	NULL
we	NULL
immunoprecipitated	NULL
STATSA/B	NULL
from	NULL
HCD57	NULL
cells	NULL
and	NULL
HCD57-SREI	NULL
cells	NULL
and	NULL
analyzed	NULL
the	NULL
tyrosine	NULL
phosphorylation	NULL
state	NULL
of	NULL
STATS	NULL
in	NULL
the	NULL
presence	NULL
and	NULL
absence	NULL
of	NULL
EPO	NULL
(	NULL
Fig	NULL
4D	NULL
)	NULL
.	NULL

This	NULL
experiment	NULL
confirmed	NULL
that	NULL
STATS	NULL
was	NULL
constitutively	NULL
phosphorylated	NULL
on	NULL
tyrosine	NULL
residues	NULL
in	NULL
the	NULL
HCD57-SREI	NULL
cells	NULL
(	NULL
Fig	NULL
4D	NULL
,	NULL
lane	NULL
G	NULL
)	NULL
.	NULL

Additional	NULL
experiments	NULL
with	NULL
STATSA-	NULL
and	NULL
STATSB-specific	NULL
antisera	NULL
show	NULL
that	NULL
both	NULL
forms	NULL
of	NULL
STATS5	NULL
were	NULL
phosphorylated	NULL
,	NULL
but	NULL
we	NULL
did	NULL
not	NULL
find	NULL
other	NULL
STATs	NULL
to	NULL
be	NULL
constitutively	NULL
active	NULL
.	NULL

Interestingly	NULL
,	NULL
the	NULL
major	NULL
tyrosine	NULL
phosphorylated	NULL
band	NULL
at	NULL
95	NULL
kD	NULL
seen	NULL
in	NULL
EPO-treated	NULL
HCD57	NULL
and	NULL
HCD57-SREI	NULL
cells	NULL
was	NULL
not	NULL
the	NULL
STATS	NULL
protein	NULL
as	NULL
many	NULL
have	NULL
assumed	NULL
.	NULL

STAT5	NULL
was	NULL
a	NULL
minor	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

3764	NULL
component	NULL
of	NULL
this	NULL
95-kD	NULL
band	NULL
(	NULL
STAT5	NULL
migrates	NULL
at	NULL
the	NULL
very	NULL
top	NULL
of	NULL
this	NULL
broad	NULL
band	NULL
)	NULL
.	NULL

Although	NULL
STAT1	NULL
is	NULL
also	NULL
activated	NULL
by	NULL
EPO	NULL
in	NULL
HCD57	NULL
cells	NULL
,	NULL
the	NULL
level	NULL
of	NULL
phosphorylation	NULL
of	NULL
STAT1	NULL
is	NULL
an	NULL
order	NULL
of	NULL
magnitude	NULL
less	NULL
than	NULL
STATS	NULL
and	NULL
,	NULL
therefore	NULL
,	NULL
does	NULL
not	NULL
contribute	NULL
significantly	NULL
to	NULL
this	NULL
band	NULL
,	NULL
leaving	NULL
the	NULL
identity	NULL
of	NULL
the	NULL
band	NULL
a	NULL
mystery	NULL
.	NULL

We	NULL
did	NULL
not	NULL
see	NULL
constitutively	NULL
phosphorylated	NULL
STATS	NULL
in	NULL
the	NULL
Tyr	NULL
(	NULL
P	NULL
)	NULL
immunoprecipitate	NULL
of	NULL
HCD57-SREI	NULL
cells	NULL
(	NULL
Fig	NULL
4A	NULL
)	NULL
;	NULL
however	NULL
,	NULL
this	NULL
was	NULL
due	NULL
to	NULL
the	NULL
inability	NULL
of	NULL
the	NULL
polyclonal	NULL
anti-Tyr	NULL
(	NULL
P	NULL
)	NULL
antibody	NULL
used	NULL
to	NULL
immunoprecipitate	NULL
the	NULL
Tyr	NULL
(	NULL
P	NULL
)	NULL
-containing	NULL
proteins	NULL
(	NULL
Zymed	NULL
)	NULL
to	NULL
recognize	NULL
phosphorylated	NULL
STATS	NULL
.	NULL

Figure	NULL
4D	NULL
shows	NULL
that	NULL
when	NULL
the	NULL
total	NULL
cellular	NULL
extract	NULL
was	NULL
examined	NULL
by	NULL
blotting	NULL
with	NULL
anti-Tyr	NULL
(	NULL
P	NULL
)	NULL
[	NULL
without	NULL
immunoprecipitation	NULL
to	NULL
concentrate	NULL
Tyr	NULL
(	NULL
P	NULL
)	NULL
proteins	NULL
]	NULL
the	NULL
STAT5SA/B	NULL
constitutive	NULL
tyrosine	NULL
phosphorylation	NULL
was	NULL
not	NULL
apparent	NULL
.	NULL

We	NULL
were	NULL
able	NULL
to	NULL
detect	NULL
constitutive	NULL
phosphorylation	NULL
of	NULL
STATS	NULL
only	NULL
when	NULL
20-fold	NULL
more	NULL
HCDS57-SREI	NULL
cells	NULL
were	NULL
used	NULL
to	NULL
immunoprecipitate	NULL
STATS	NULL
A/B	NULL
compared	NULL
with	NULL
the	NULL
number	NULL
of	NULL
cells	NULL
used	NULL
in	NULL
the	NULL
total	NULL
cellular	NULL
extract	NULL
.	NULL

However	NULL
,	NULL
parallel	NULL
experiments	NULL
with	NULL
very	NULL
concentrated	NULL
cell	NULL
extracts	NULL
did	NULL
not	NULL
show	NULL
constitutively	NULL
phosphorylated	NULL
JAK	NULL
kinases	NULL
or	NULL
EPOR	NULL
.	NULL

We	NULL
also	NULL
tested	NULL
whether	NULL
there	NULL
was	NULL
constitutive	NULL
activation	NULL
of	NULL
STAT	NULL
proteins	NULL
in	NULL
the	NULL
nuclear	NULL
fraction	NULL
of	NULL
SREI	NULL
cells	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
5	NULL
,	NULL
HCD57-SREI	NULL
cells	NULL
showed	NULL
constitutive	NULL
nuclear	NULL
localization	NULL
of	NULL
STATS	NULL
proteins	NULL
(	NULL
Fig	NULL
5A	NULL
,	NULL
lane	NULL
5	NULL
)	NULL
,	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
a	NULL
95-kD	NULL
band	NULL
corresponding	NULL
to	NULL
STAT	NULL
5	NULL
(	NULL
Fig	NULL
5B	NULL
,	NULL
lane	NULL
5	NULL
)	NULL
,	NULL
and	NULL
activation	NULL
of	NULL
DNA	NULL
binding	NULL
activity	NULL
characteristic	NULL
of	NULL
STATS	NULL
(	NULL
Fig	NULL
5C	NULL
,	NULL
lane	NULL
5	NULL
)	NULL
.	NULL

The	NULL
addition	NULL
of	NULL
EPO	NULL
to	NULL
HCD57-SREI	NULL
cells	NULL
led	NULL
to	NULL
additional	NULL
activation	NULL
of	NULL
STATS	NULL
phosphorylation	NULL
,	NULL
translocation	NULL
,	NULL
and	NULL
DNA	NULL
binding	NULL
activity	NULL
above	NULL
the	NULL
constitutive	NULL
level	NULL
(	NULL
Fig	NULL
5C	NULL
,	NULL
lane	NULL
6	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
HCD57	NULL
cells	NULL
did	NULL
not	NULL
have	NULL
any	NULL
detectable	NULL
constitutive	NULL
activation	NULL
of	NULL
STATS	NULL
activity	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
EPO	NULL
treatment	NULL
(	NULL
Fig	NULL
5C	NULL
,	NULL
lane	NULL
1	NULL
)	NULL
.	NULL

SCF	NULL
treatment	NULL
of	NULL
HCD57	NULL
cells	NULL
did	NULL
not	NULL
activate	NULL
STATS	NULL
nor	NULL
did	NULL
SCF	NULL
treatment	NULL
of	NULL
HCD57-SREI	NULL
cells	NULL
increase	NULL
the	NULL
activity	NULL
of	NULL
STATS5	NULL
above	NULL
the	NULL
constitutive	NULL
activation	NULL
(	NULL
Fig	NULL
5C	NULL
,	NULL
lane	NULL
7	NULL
)	NULL
.	NULL

To	NULL
confirm	NULL
that	NULL
the	NULL
DNA	NULL
binding	NULL
activity	NULL
to	NULL
the	NULL
PIE	NULL
DNA	NULL
element	NULL
constitutively	NULL
activated	NULL
in	NULL
HCDS7-SREI	NULL
cells	NULL
was	NULL
STATS5	NULL
and	NULL
to	NULL
further	NULL
discriminate	NULL
whether	NULL
that	NULL
activity	NULL
was	NULL
due	NULL
to	NULL
STATSA	NULL
or	NULL
STAT5B	NULL
,	NULL
we	NULL
used	NULL
super-shift	NULL
analysis	NULL
with	NULL
various	NULL
anti-STAT	NULL
antisera	NULL
.	NULL

Antibodies	NULL
to	NULL
STAT1	NULL
,	NULL
STAT3	NULL
,	NULL
STATS5A	NULL
,	NULL
and	NULL
STAT5B	NULL
were	NULL
incubated	NULL
with	NULL
nuclear	NULL
extracts	NULL
to	NULL
test	NULL
the	NULL
identity	NULL
of	NULL
the	NULL
proteins	NULL
binding	NULL
to	NULL
the	NULL
PIE	NULL
DNA	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
5D	NULL
,	NULL
no	NULL
super-shift	NULL
was	NULL
detected	NULL
when	NULL
anti-STAT1	NULL
or	NULL
anti-STAT3	NULL
antibodies	NULL
were	NULL
present	NULL
,	NULL
indicating	NULL
the	NULL
likely	NULL
absence	NULL
or	NULL
low	NULL
abundance	NULL
of	NULL
these	NULL
factors	NULL
in	NULL
the	NULL
DNA	NULL
binding	NULL
complex	NULL
.	NULL

However	NULL
,	NULL
both	NULL
anti-STAT5A	NULL
and	NULL
anti-STAT5B	NULL
antibodies	NULL
super-shifted	NULL
the	NULL
complex	NULL
.	NULL

This	NULL
result	NULL
suggests	NULL
that	NULL
heterodimers	NULL
of	NULL
STAT5A	NULL
and	NULL
STATS5B	NULL
are	NULL
the	NULL
predominant	NULL
members	NULL
of	NULL
the	NULL
PIE	NULL
DNA	NULL
binding	NULL
complex	NULL
constitutively	NULL
bound	NULL
in	NULL
HCD57-SREI	NULL
cells	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
factors	NULL
and	NULL
in	NULL
EPO-treated	NULL
HCD57	NULL
and	NULL
HCD57-SREI	NULL
cells	NULL
.	NULL

Interestingly	NULL
,	NULL
two	NULL
minor	NULL
bands	NULL
present	NULL
in	NULL
the	NULL
complex	NULL
indicated	NULL
that	NULL
both	NULL
STATSA	NULL
homodimers	NULL
and	NULL
STAT5B	NULL
homodimers	NULL
also	NULL
bind	NULL
to	NULL
the	NULL
DNA	NULL
.	NULL

These	NULL
homodimers	NULL
could	NULL
be	NULL
discriminated	NULL
from	NULL
the	NULL
heterodimers	NULL
of	NULL
STAT	NULL
5A	NULL
and	NULL
STATS5B	NULL
by	NULL
faster	NULL
migration	NULL
on	NULL
the	NULL
polyacrylamide	NULL
gel	NULL
,	NULL
with	NULL
STATSA	NULL
:	NULL
STATSA	NULL
homodimers	NULL
migrating	NULL
faster	NULL
than	NULL
the	NULL
STAT5B	NULL
:	NULL
STAT5B	NULL
homodimers	NULL
.	NULL

The	NULL
finding	NULL
of	NULL
constitutive	NULL
STATS	NULL
activity	NULL
without	NULL
a	NULL
corre-	NULL
BAO	NULL
ET	NULL
AL	NULL
sponding	NULL
constitutive	NULL
activity	NULL
of	NULL
JAK2	NULL
led	NULL
us	NULL
to	NULL
further	NULL
investigate	NULL
if	NULL
there	NULL
might	NULL
be	NULL
constitutive	NULL
activation	NULL
of	NULL
other	NULL
members	NULL
of	NULL
the	NULL
Janus	NULL
kinases	NULL
.	NULL

Therefore	NULL
,	NULL
we	NULL
immunoprecipitated	NULL
JAK1	NULL
,	NULL
JAK2	NULL
,	NULL
JAK3	NULL
,	NULL
and	NULL
TYK2	NULL
from	NULL
HCD57-SREI	NULL
cells	NULL
either	NULL
untreated	NULL
or	NULL
treated	NULL
with	NULL
EPO	NULL
.	NULL

When	NULL
the	NULL
immunoprecipitate	NULL
was	NULL
analyzed	NULL
by	NULL
Western	NULL
blotting	NULL
with	NULL
anti-Tyr	NULL
(	NULL
P	NULL
)	NULL
antiserum	NULL
,	NULL
only	NULL
JAK2	NULL
from	NULL
EPO-treated	NULL
cells	NULL
was	NULL
observed	NULL
to	NULL
be	NULL
phosphorylated	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Does	NULL
a	NULL
phosphatase	NULL
defect	NULL
explain	NULL
the	NULL
HCDS5S7-SREI	NULL
resistance	NULL
to	NULL
apoptosis	NULL
?	NULL

The	NULL
observation	NULL
showing	NULL
that	NULL
sodium	NULL
vanadate	NULL
(	NULL
Na	NULL
;	NULL
VO	NULL
,	NULL
)	NULL
,	NULL
an	NULL
inhibitor	NULL
of	NULL
tyrosine	NULL
protein	NULL
phosphatase	NULL
activity	NULL
,	NULL
can	NULL
activate	NULL
STAT	NULL
protein	NULL
independently	NULL
of	NULL
Janus	NULL
kinases	NULL
suggested	NULL
that	NULL
constitutive	NULL
activation	NULL
of	NULL
STATS	NULL
might	NULL
be	NULL
due	NULL
to	NULL
the	NULL
loss	NULL
of	NULL
phosphatase	NULL
activity	NULL
in	NULL
HCD57-SREI	NULL
cells	NULL
.	NULL
``	NULL

The	NULL
SHP-1	NULL
tyrosine	NULL
protein	NULL
phosphatase	NULL
has	NULL
been	NULL
strongly	NULL
implicated	NULL
in	NULL
the	NULL
modulation	NULL
of	NULL
both	NULL
JAK2/EPOR	NULL
and	NULL
STAT	NULL
signaling	NULL
.	NULL

``	NULL
>	NULL
``	NULL
``	NULL
``	NULL
We	NULL
and	NULL
others	NULL
have	NULL
previously	NULL
reported	NULL
that	NULL
HCD57	NULL
cells	NULL
are	NULL
hypersensitive	NULL
to	NULL
EPO	NULL
.	NULL
``	NULL

Therefore	NULL
,	NULL
we	NULL
tested	NULL
the	NULL
hypothesis	NULL
that	NULL
the	NULL
hypersensitivity	NULL
of	NULL
HCD57	NULL
cells	NULL
to	NULL
EPO	NULL
might	NULL
be	NULL
caused	NULL
by	NULL
a	NULL
reduction	NULL
of	NULL
the	NULL
SHP-1	NULL
,	NULL
and	NULL
that	NULL
the	NULL
loss	NULL
of	NULL
EPO-dependence	NULL
in	NULL
the	NULL
HCD57-SREI	NULL
cells	NULL
could	NULL
be	NULL
the	NULL
result	NULL
of	NULL
the	NULL
further	NULL
reduction	NULL
or	NULL
complete	NULL
loss	NULL
of	NULL
this	NULL
phosphatase	NULL
.	NULL

We	NULL
compared	NULL
the	NULL
levels	NULL
of	NULL
SHP-1	NULL
in	NULL
these	NULL
two	NULL
cell	NULL
lines	NULL
with	NULL
a	NULL
population	NULL
of	NULL
CFU-E	NULL
and	NULL
proerythroblasts	NULL
purified	NULL
from	NULL
normal	NULL
human	NULL
blood	NULL
.	NULL

Figure	NULL
6	NULL
shows	NULL
that	NULL
identical	NULL
levels	NULL
of	NULL
SHP-1	NULL
were	NULL
present	NULL
in	NULL
normal	NULL
immature	NULL
human	NULL
erythroid	NULL
cells	NULL
,	NULL
HCD57	NULL
cells	NULL
,	NULL
and	NULL
the	NULL
apoptosis-resistant	NULL
HCD57-SREI	NULL
cells	NULL
.	NULL

Constitutive	NULL
activation	NULL
of	NULL
PI3-kinase	NULL
in	NULL
HCDS57	NULL
and	NULL
HCDS5S7-SRET	NULL
cells	NULL
.	NULL

PI3	NULL
kinase	NULL
has	NULL
been	NULL
reported	NULL
to	NULL
be	NULL
activated	NULL
as	NULL
part	NULL
of	NULL
the	NULL
EPO	NULL
signaling	NULL
pathway	NULL
.	NULL

Because	NULL
PI3-kinase	NULL
has	NULL
been	NULL
implicated	NULL
in	NULL
several	NULL
cell	NULL
types	NULL
as	NULL
critical	NULL
to	NULL
the	NULL
regulation	NULL
of	NULL
cell	NULL
proliferation	NULL
,	NULL
differentiation	NULL
,	NULL
and	NULL
survival	NULL
,	NULL
``	NULL
we	NULL
measured	NULL
PT3-kinase	NULL
activity	NULL
and	NULL
tested	NULL
for	NULL
interaction	NULL
of	NULL
PI3-kinase	NULL
with	NULL
proteins	NULL
known	NULL
to	NULL
associate	NULL
with	NULL
PI3-kinase	NULL
.	NULL

This	NULL
study	NULL
compared	NULL
these	NULL
parameters	NULL
in	NULL
the	NULL
EPO-dependent	NULL
HCD57	NULL
cells	NULL
and	NULL
the	NULL
EPO-independent	NULL
HCD57-SREI	NULL
cells	NULL
.	NULL

Figure	NULL
7A	NULL
shows	NULL
that	NULL
the	NULL
PI3-kinase	NULL
activity	NULL
measured	NULL
by	NULL
incorporation	NULL
of	NULL
*2P	NULL
from	NULL
gamma-labeled	NULL
ATP	NULL
into	NULL
phosphatidylinositol	NULL
by	NULL
the	NULL
immunoprecipitated	NULL
PI3-kinase	NULL
(	NULL
anti-p85	NULL
subunit	NULL
of	NULL
PI3-kinase	NULL
)	NULL
appeared	NULL
constitutive	NULL
in	NULL
both	NULL
HCD57	NULL
and	NULL
HCD57-SREI	NULL
cells	NULL
and	NULL
was	NULL
not	NULL
additionally	NULL
increased	NULL
by	NULL
treatment	NULL
of	NULL
EPO	NULL
.	NULL

The	NULL
bottom	NULL
panel	NULL
of	NULL
Fig	NULL
7A	NULL
shows	NULL
the	NULL
combined	NULL
results	NULL
from	NULL
five	NULL
experiments	NULL
that	NULL
confirm	NULL
the	NULL
lack	NULL
of	NULL
EPO	NULL
effect	NULL
.	NULL

To	NULL
verify	NULL
that	NULL
this	NULL
unexpected	NULL
constitutive	NULL
activity	NULL
which	NULL
phosphorylated	NULL
phosphatidylinositol	NULL
was	NULL
truly	NULL
PI3-kinase	NULL
activity	NULL
,	NULL
we	NULL
added	NULL
the	NULL
PI3-kinase	NULL
inhibitor	NULL
,	NULL
LY294002	NULL
,	NULL
to	NULL
the	NULL
reaction	NULL
mixture	NULL
and	NULL
showed	NULL
that	NULL
the	NULL
activity	NULL
was	NULL
inhibited	NULL
in	NULL
a	NULL
dose-responsive	NULL
fashion	NULL
at	NULL
concentrations	NULL
of	NULL
inhibitor	NULL
known	NULL
to	NULL
specifically	NULL
block	NULL
PI3-kinase	NULL
activity	NULL
(	NULL
shown	NULL
in	NULL
Fig	NULL
7B	NULL
)	NULL
.	NULL

For	NULL
a	NULL
further	NULL
control	NULL
,	NULL
we	NULL
examined	NULL
the	NULL
PI3-kinase	NULL
activity	NULL
in	NULL
immunoprecipitated	NULL
STAT5	NULL
,	NULL
JAK2	NULL
,	NULL
Vav	NULL
,	NULL
as	NULL
well	NULL
as	NULL
PI3-kinase	NULL
.	NULL

PI3-kinase	NULL
activity	NULL
was	NULL
only	NULL
detected	NULL
in	NULL
the	NULL
immunoprecipitated	NULL
PI3-kinase	NULL
(	NULL
anti-p85	NULL
immunoprecipitate	NULL
)	NULL
,	NULL
as	NULL
shown	NULL
in	NULL
Fig	NULL
7C	NULL
.	NULL

As	NULL
a	NULL
further	NULL
control	NULL
that	NULL
the	NULL
EPO	NULL
signaling	NULL
pathway	NULL
was	NULL
not	NULL
activated	NULL
in	NULL
the	NULL
EPO-independent	NULL
HCD57-SREI	NULL
cells	NULL
,	NULL
we	NULL
also	NULL
measured	NULL
the	NULL
PI3-kinase	NULL
activity	NULL
that	NULL
associated	NULL
with	NULL
the	NULL
EPOR	NULL
in	NULL
either	NULL
untreated	NULL
or	NULL
EPO	NULL
treated	NULL
HCD57	NULL
and	NULL
HCD57-SREI	NULL
cells	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
8A	NULL
,	NULL
in	NULL
either	NULL
cell	NULL
,	NULL
there	NULL
was	NULL
no	NULL
PI3-kinase	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

PKB/Akt	NULL
AND	NULL
STATS	NULL
ACTIVITY	NULL
IN	NULL
ERYTHROID	NULL
CELLS	NULL
3765	NULL
HCD5S7	NULL
/-	NULL
SRE	NULL
CELLS	NULL
C	NULL
HCD57	NULL
/	NULL
SREI	NULL
CELLS	NULL
C	NULL
E	NULL
Ss	NULL
1C	NULL
E	NULL
s	NULL
C	NULL
E	NULL
S	NULL
I	NULL
-	NULL
-C	NULL
OE	NULL
s	NULL
Le	NULL
e	NULL
«	NULL
-STAT5	NULL
1	NULL
2	NULL
3	NULL
4	NULL
506	NULL
7	NULL
D	NULL
HCD57-SREI	NULL
HCD57-SREI	NULL
HCDS7	NULL
CELLS	NULL
NO	NULL
EPO	NULL
PLUS	NULL
EPO	NULL
PLUS	NULL
EPO	NULL
<	NULL
m	NULL
<	NULL
m	NULL
<	NULL
m	NULL
__	NULL
Y	NULL
``	NULL
M	NULL
wo	NULL
)	NULL
_	NULL
m	NULL
M	NULL
wo	NULL
wo	NULL
_	NULL
m	NULL
®	NULL
wo	NULL
w	NULL
0	NULL
k	NULL
Ek	NULL
kok	NULL
6	NULL
E-	NULL
koko	NULL
06	NULL
E-	NULL
o	NULL
i	NULL
E	NULL
4	NULL
4	NULL
4	NULL
4	NULL
kL	NULL
4	NULL
4	NULL
4	NULL
4	NULL
k	NULL
4	NULL
4	NULL
4	NULL
4	NULL
c	NULL
bob	NULL
C	NULL
b-Ekok	NULL
oE	NULL
C	NULL
bo	NULL
o	NULL
bob	NULL
o	NULL
w	NULL
m	NULL
w	NULL
wm	NULL
0	NULL
wm	NULL
w	NULL
in	NULL
wm	NULL
0	NULL
w	NULL
wm	NULL
wn	NULL
w	NULL
9	NULL
°	NULL
|	NULL
0	NULL
|	NULL
)	NULL
d	NULL
)	NULL
d	NULL
)	NULL
6	NULL
Gd	NULL
)	NULL
d	NULL
o	NULL
o	NULL
9	NULL
@	NULL
doo	NULL
oo	NULL
od	NULL
s	NULL
s	NULL
s	NULL
s	NULL
4	NULL
s	NULL
#	NULL
38	NULL
s	NULL
s	NULL
s	NULL
38	NULL
_	NULL
``	NULL
~	NULL
és	NULL
A	NULL
&	NULL
L	NULL
alb	NULL
STATS	NULL
supershift	NULL
<	NULL
€4STAT5A	NULL
:	NULL
A	NULL
4§STATSB	NULL
:	NULL
B	NULL
|I.I|	NULL
“	NULL
Ml	NULL
D	NULL
E	NULL
F	NULL
G	NULL
J	NULL
K	NULL
L	NULL
M	NULL
NO	NULL
Fig	NULL
5	NULL
.	NULL

Characterization	NULL
of	NULL
nuclear	NULL
extracts	NULL
made	NULL
from	NULL
EPO-	NULL
and	NULL
SCF-treated	NULL
HCDS57	NULL
(	NULL
lanes	NULL
1	NULL
through	NULL
4	NULL
)	NULL
and	NULL
HCDS7-SRE	NULL
!	NULL

cells	NULL
(	NULL
lanes	NULL
5	NULL
through	NULL
7	NULL
)	NULL
.	NULL

Cells	NULL
(	NULL
2	NULL
x	NULL
10	NULL
``	NULL
)	NULL
were	NULL
treated	NULL
with	NULL
nothing	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
5	NULL
)	NULL
,	NULL
EPO	NULL
(	NULL
10	NULL
U/mL	NULL
)	NULL
(	NULL
lanes	NULL
2	NULL
and	NULL
6	NULL
)	NULL
,	NULL
interferon-y	NULL
(	NULL
5	NULL
ng/mL	NULL
)	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
,	NULL
or	NULL
SCF	NULL
(	NULL
100	NULL
ng/mL	NULL
)	NULL
(	NULL
lanes	NULL
3	NULL
and	NULL
6	NULL
)	NULL
for	NULL
10	NULL
minutes	NULL
at	NULL
37°C	NULL
.	NULL

The	NULL
immunoblot	NULL
was	NULL
probed	NULL
with	NULL
MoAb	NULL
to	NULL
STATS	NULL
(	NULL
A	NULL
)	NULL
and	NULL
reprobed	NULL
with	NULL
MoAbs	NULL
to	NULL
PY	NULL
(	NULL
B	NULL
)	NULL
.	NULL

The	NULL
95K	NULL
arrow	NULL
s	NULL
mark	NULL
the	NULL
molecular	NULL
weight	NULL
and	NULL
position	NULL
where	NULL
the	NULL
STATS	NULL
proteins	NULL
migrate	NULL
on	NULL
the	NULL
gel	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Mobility-shift	NULL
assays	NULL
of	NULL
the	NULL
PIE	NULL
binding	NULL
nuclear	NULL
proteins	NULL
from	NULL
EPO	NULL
and	NULL
SCF	NULL
treatment	NULL
.	NULL

Nuclear	NULL
protein	NULL
preparation	NULL
and	NULL
gel	NULL
shift	NULL
analyses	NULL
with	NULL
the	NULL
PIE	NULL
sequence	NULL
were	NULL
performed	NULL
as	NULL
previously	NULL
described	NULL
.	NULL
``	NULL

Nuclear	NULL
protein	NULL
(	NULL
20	NULL
g	NULL
)	NULL
from	NULL
control	NULL
(	NULL
C	NULL
)	NULL
lanes	NULL
1	NULL
and	NULL
5	NULL
,	NULL
and	NULL
EPO-treated	NULL
extracts	NULL
(	NULL
lanes	NULL
2	NULL
and	NULL
6	NULL
)	NULL
and	NULL
SCF-treated	NULL
cells	NULL
(	NULL
lanes	NULL
3	NULL
and	NULL
7	NULL
)	NULL
were	NULL
incubated	NULL
with	NULL
the	NULL
radiolabeled	NULL
oligonucleotide	NULL
,	NULL
and	NULL
shifted	NULL
bands	NULL
were	NULL
visualized	NULL
by	NULL
autoradiography	NULL
.	NULL

Only	NULL
upon	NULL
a	NULL
very	NULL
dark	NULL
exposure	NULL
can	NULL
a	NULL
minor	NULL
band	NULL
below	NULL
the	NULL
position	NULL
of	NULL
the	NULL
major	NULL
band	NULL
be	NULL
seen	NULL
that	NULL
arises	NULL
from	NULL
STAT1	NULL
binding	NULL
in	NULL
either	NULL
EPO-	NULL
or	NULL
interferon-treated	NULL
HCDS57	NULL
cells	NULL
.	NULL

The	NULL
HCD57	NULL
cells	NULL
seem	NULL
to	NULL
be	NULL
very	NULL
unresponsive	NULL
to	NULL
interferon-y	NULL
compared	NULL
with	NULL
primary	NULL
erythroid	NULL
cells	NULL
.	NULL

(	NULL
D	NULL
)	NULL
Super-shift	NULL
analysis	NULL
shows	NULL
that	NULL
STATSA/	NULL
B	NULL
heterodimers	NULL
are	NULL
the	NULL
constitutively	NULL
active	NULL
DNA-binding	NULL
proteins	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
treated	NULL
as	NULL
before	NULL
,	NULL
or	NULL
left	NULL
untreated	NULL
and	NULL
the	NULL
gel	NULL
mobility	NULL
shift	NULL
assay	NULL
was	NULL
performed	NULL
as	NULL
above	NULL
except	NULL
that	NULL
either	NULL
anti-STAT1	NULL
,	NULL
anti-STAT3	NULL
,	NULL
anti-STATSA	NULL
,	NULL
or	NULL
anti-STATSB	NULL
were	NULL
preincubated	NULL
for	NULL
15	NULL
minutes	NULL
on	NULL
ice	NULL
with	NULL
the	NULL
nuclear	NULL
extracts	NULL
before	NULL
the	NULL
addition	NULL
of	NULL
the	NULL
radiolabeled	NULL
PIE	NULL
DNA	NULL
.	NULL

The	NULL
bar	NULL
indicates	NULL
the	NULL
supershift	NULL
of	NULL
DNA	NULL
binding	NULL
that	NULL
occurred	NULL
with	NULL
either	NULL
anti-STATS5A	NULL
or	NULL
anti-STATSB	NULL
antisera	NULL
.	NULL

The	NULL
deduced	NULL
positions	NULL
of	NULL
apparent	NULL
shifts	NULL
resulting	NULL
from	NULL
either	NULL
STATSA	NULL
:	NULL
STATSB	NULL
heterodimers	NULL
(	NULL
STAT5A	NULL
:	NULL
B	NULL
)	NULL
,	NULL
STATS5A	NULL
homodimers	NULL
(	NULL
STATSA	NULL
:	NULL
A	NULL
)	NULL
,	NULL
or	NULL
STAT5B	NULL
homodimers	NULL
(	NULL
STATSB	NULL
:	NULL
B	NULL
)	NULL
are	NULL
indicated	NULL
by	NULL
arrow	NULL
s.	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

3766	NULL
o	NULL
T	NULL
L	NULL
pr	NULL
r	NULL
[	NULL
a	NULL
19	NULL
E	NULL
[	NULL
4p	NULL
]	NULL
A	NULL
U	NULL
Ko-	NULL
0	NULL
PS	NULL
C	NULL
.C	NULL
SHP-1	NULL
am	NULL
»	NULL
ap	NULL
»	NULL
14G63-kD	NULL
a	NULL
A	NULL
B	NULL
C	NULL
Fig	NULL
6	NULL
.	NULL

The	NULL
tyrosine	NULL
protein	NULL
phosphatase	NULL
,	NULL
SHP-1	NULL
,	NULL
is	NULL
equally	NULL
expressed	NULL
in	NULL
HCDS57	NULL
,	NULL
HCDS57-SRE	NULL
!	NULL

cells	NULL
and	NULL
primary	NULL
human	NULL
erythroid	NULL
cells	NULL
.	NULL

Frozen	NULL
HCD57	NULL
and	NULL
HCDS57-SREI	NULL
cells	NULL
were	NULL
sent	NULL
to	NULL
Dr	NULL
Amittha	NULL
Wickrema	NULL
who	NULL
compared	NULL
10	NULL
mg	NULL
of	NULL
total	NULL
cellular	NULL
protein	NULL
from	NULL
these	NULL
cell	NULL
lines	NULL
with	NULL
an	NULL
equal	NULL
amount	NULL
of	NULL
primary	NULL
erythroid	NULL
cells	NULL
at	NULL
the	NULL
CFU-E	NULL
stage	NULL
of	NULL
development	NULL
that	NULL
develop	NULL
in	NULL
culture	NULL
from	NULL
more	NULL
immature	NULL
erythroid	NULL
cells	NULL
purified	NULL
from	NULL
human	NULL
blood	NULL
.	NULL

The	NULL
Western	NULL
blot	NULL
was	NULL
probed	NULL
with	NULL
anti-SHP-1	NULL
antiserum	NULL
and	NULL
visualized	NULL
by	NULL
ECL	NULL
.	NULL

activity	NULL
in	NULL
untreated	NULL
cells	NULL
,	NULL
but	NULL
EPO	NULL
treatment	NULL
led	NULL
to	NULL
a	NULL
large	NULL
increase	NULL
in	NULL
PI3-kinase	NULL
activity	NULL
bound	NULL
to	NULL
the	NULL
EPOR	NULL
.	NULL

During	NULL
this	NULL
study	NULL
we	NULL
noticed	NULL
that	NULL
there	NULL
was	NULL
a	NULL
constitutively	NULL
tyrosine-phosphorylated	NULL
protein	NULL
of	NULL
185-kD	NULL
that	NULL
coprecipitated	NULL
with	NULL
PI3-kinase	NULL
in	NULL
both	NULL
HCD57	NULL
and	NULL
HCD57-SREI	NULL
cells	NULL
.	NULL

In	NULL
unpublished	NULL
work	NULL
(	NULL
H.B	NULL
.	NULL

and	NULL
S.T.S	NULL
.	NULL

,	NULL
1998	NULL
)	NULL
,	NULL
we	NULL
found	NULL
that	NULL
this	NULL
protein	NULL
was	NULL
insulin	NULL
receptor	NULL
substrate-2	NULL
(	NULL
IRS-2	NULL
)	NULL
.	NULL

To	NULL
verify	NULL
that	NULL
the	NULL
PI3-kinase	NULL
that	NULL
was	NULL
associated	NULL
with	NULL
the	NULL
IRS-2	NULL
protein	NULL
was	NULL
active	NULL
,	NULL
we	NULL
measured	NULL
the	NULL
PI3-kinase	NULL
activity	NULL
in	NULL
the	NULL
IRS-2	NULL
immunoprecipitates	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
8B	NULL
,	NULL
PI3-kinase	NULL
activity	NULL
was	NULL
constitutive	NULL
and	NULL
unaffected	NULL
by	NULL
EPO	NULL
treatment	NULL
in	NULL
either	NULL
HCD57	NULL
or	NULL
HCD57-SREI	NULL
cells	NULL
,	NULL
strongly	NULL
suggesting	NULL
that	NULL
IRS-2	NULL
is	NULL
responsible	NULL
for	NULL
the	NULL
constitutive	NULL
activity	NULL
of	NULL
PI3-kinase	NULL
in	NULL
the	NULL
in	NULL
vitro	NULL
assay	NULL
.	NULL

It	NULL
is	NULL
possible	NULL
that	NULL
the	NULL
PI3-kinase	NULL
is	NULL
activated	NULL
and	NULL
becomes	NULL
associated	NULL
with	NULL
the	NULL
tyrosine-phosphorylated	NULL
IRS	NULL
only	NULL
after	NULL
the	NULL
cells	NULL
are	NULL
disrupted	NULL
and	NULL
does	NULL
not	NULL
reflect	NULL
the	NULL
in	NULL
vivo	NULL
activity	NULL
of	NULL
PI3-kinase	NULL
.	NULL

To	NULL
test	NULL
the	NULL
physiological	NULL
role	NULL
of	NULL
either	NULL
the	NULL
constitutive	NULL
or	NULL
factor-stimulated	NULL
PI3-kinase	NULL
in	NULL
the	NULL
EPO-dependent	NULL
HCDS57	NULL
cells	NULL
and	NULL
the	NULL
EPO-independent	NULL
HCD57-SREI	NULL
cells	NULL
,	NULL
the	NULL
effect	NULL
of	NULL
inhibiting	NULL
PI3-kinase	NULL
activity	NULL
by	NULL
the	NULL
PI3-kinase	NULL
selective	NULL
inhibitor	NULL
,	NULL
LY294002	NULL
,	NULL
was	NULL
tested	NULL
by	NULL
measuring	NULL
the	NULL
number	NULL
of	NULL
viable	NULL
cells	NULL
and	NULL
DNA	NULL
fragmentation	NULL
as	NULL
indicators	NULL
of	NULL
proliferation	NULL
and	NULL
apoptosis	NULL
,	NULL
respectively	NULL
.	NULL

Figure	NULL
9A	NULL
shows	NULL
the	NULL
effect	NULL
of	NULL
the	NULL
indicated	NULL
concentrations	NULL
of	NULL
the	NULL
LY294002	NULL
on	NULL
viable	NULL
cell	NULL
number	NULL
of	NULL
either	NULL
HCD57	NULL
cells	NULL
in	NULL
EPO	NULL
or	NULL
the	NULL
EPO-independent	NULL
HCD57-SREI	NULL
cells	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
EPO	NULL
.	NULL

The	NULL
HCD57-SREI	NULL
cells	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
EPO	NULL
are	NULL
more	NULL
sensitive	NULL
to	NULL
BAO	NULL
ET	NULL
AL	NULL
the	NULL
inhibitor	NULL
compared	NULL
with	NULL
either	NULL
HCD57	NULL
or	NULL
HCD57-SREI	NULL
cells	NULL
exposed	NULL
to	NULL
EPO	NULL
.	NULL

At	NULL
10	NULL
umol/L	NULL
LY294002	NULL
,	NULL
there	NULL
are	NULL
only	NULL
half	NULL
as	NULL
many	NULL
viable	NULL
HCD57-SREI	NULL
cells	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
EPO	NULL
surviving	NULL
compared	NULL
with	NULL
HCD57	NULL
or	NULL
HCD57-SREI	NULL
cells	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
EPO	NULL
.	NULL

At	NULL
25	NULL
umol/L	NULL
LY294002	NULL
,	NULL
HCD57-SREI	NULL
cells	NULL
minus	NULL
EPO	NULL
have	NULL
fallen	NULL
to	NULL
20	NULL
%	NULL
of	NULL
control	NULL
while	NULL
either	NULL
the	NULL
HCD57	NULL
or	NULL
HCD57-SREI	NULL
cells	NULL
in	NULL
EPO	NULL
were	NULL
only	NULL
moderately	NULL
diminished	NULL
(	NULL
50	NULL
%	NULL
to	NULL
70	NULL
%	NULL
the	NULL
number	NULL
of	NULL
cells	NULL
that	NULL
have	NULL
proliferated	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
inhibitor	NULL
)	NULL
.	NULL

To	NULL
test	NULL
whether	NULL
the	NULL
effect	NULL
of	NULL
the	NULL
PI3-kinase	NULL
inhibitor	NULL
could	NULL
be	NULL
determined	NULL
to	NULL
be	NULL
an	NULL
effect	NULL
only	NULL
on	NULL
proliferation	NULL
versus	NULL
an	NULL
effect	NULL
that	NULL
might	NULL
be	NULL
the	NULL
summation	NULL
of	NULL
eliminating	NULL
cells	NULL
by	NULL
inducing	NULL
apoptosis	NULL
or	NULL
programmed	NULL
cell	NULL
death	NULL
,	NULL
we	NULL
isolated	NULL
DNA	NULL
from	NULL
cells	NULL
treated	NULL
with	NULL
various	NULL
concentration	NULL
of	NULL
LY294002	NULL
for	NULL
24	NULL
hours	NULL
and	NULL
analyzed	NULL
whether	NULL
this	NULL
DNA	NULL
was	NULL
intact	NULL
or	NULL
degraded	NULL
into	NULL
the	NULL
ladder	NULL
pattern	NULL
that	NULL
distinguished	NULL
apoptosis	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
9B	NULL
,	NULL
no	NULL
DNA	NULL
fragmentation	NULL
was	NULL
observed	NULL
in	NULL
HCD57	NULL
until	NULL
the	NULL
highest	NULL
concentration	NULL
of	NULL
inhibitor	NULL
was	NULL
used	NULL
.	NULL

However	NULL
,	NULL
in	NULL
the	NULL
EPO-independent	NULL
HCD57-SREI	NULL
cells	NULL
(	NULL
no	NULL
EPO	NULL
)	NULL
,	NULL
DNA	NULL
fragments	NULL
characteristic	NULL
of	NULL
the	NULL
intranucleosomal	NULL
cleavage	NULL
induced	NULL
in	NULL
apoptosis	NULL
were	NULL
observed	NULL
in	NULL
the	NULL
lowest	NULL
concentration	NULL
of	NULL
LY294002	NULL
used	NULL
.	NULL

Therefore	NULL
,	NULL
the	NULL
reduction	NULL
in	NULL
viable	NULL
HCDS57-SREI	NULL
cells	NULL
that	NULL
results	NULL
from	NULL
inhibition	NULL
of	NULL
PI3-kinase	NULL
certainly	NULL
is	NULL
in	NULL
part	NULL
caused	NULL
by	NULL
apoptosis	NULL
.	NULL

Factor-dependent	NULL
and	NULL
constitutive	NULL
activation	NULL
of	NULL
PKB/Aki	NULL
.	NULL

The	NULL
observation	NULL
of	NULL
both	NULL
EPO-dependent	NULL
and	NULL
constitutive	NULL
PI3-kinase	NULL
activity	NULL
led	NULL
us	NULL
to	NULL
test	NULL
if	NULL
the	NULL
downstream	NULL
effectors	NULL
of	NULL
PI3-kinase	NULL
correlated	NULL
with	NULL
observed	NULL
PI3-kinase	NULL
activity	NULL
.	NULL

Activity	NULL
of	NULL
PKB/Akt	NULL
was	NULL
assessed	NULL
two	NULL
ways	NULL
,	NULL
by	NULL
activity	NULL
(	NULL
phosphory-lation	NULL
)	NULL
-specific	NULL
antibodies	NULL
and	NULL
the	NULL
ability	NULL
of	NULL
immunoprecipitated	NULL
PKB/Akt	NULL
to	NULL
phosphorylate	NULL
a	NULL
peptide	NULL
substrate	NULL
.	NULL

In	NULL
sharp	NULL
contrast	NULL
to	NULL
the	NULL
finding	NULL
of	NULL
constitutive	NULL
activity	NULL
of	NULL
PI3-kinase	NULL
in	NULL
the	NULL
anti-p85	NULL
PI3-kinase	NULL
immunoprecipitate	NULL
in	NULL
both	NULL
EPO-dependent	NULL
HCD57	NULL
cells	NULL
and	NULL
EPO-independent	NULL
HCD57-SREI	NULL
cells	NULL
(	NULL
in	NULL
Fig	NULL
7	NULL
)	NULL
,	NULL
there	NULL
was	NULL
constitutive	NULL
activity	NULL
of	NULL
PKB/Akt	NULL
activity	NULL
only	NULL
in	NULL
the	NULL
EPO-independent	NULL
HCD57-SREI	NULL
.	NULL

There	NULL
was	NULL
no	NULL
detectable	NULL
phosphorylation	NULL
of	NULL
PKB/Akt	NULL
in	NULL
the	NULL
HCD357	NULL
cells	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
added	NULL
factors	NULL
(	NULL
Fig	NULL
10	NULL
)	NULL
.	NULL

The	NULL
constitutive	NULL
activation	NULL
of	NULL
PKB/Akt	NULL
in	NULL
HCDS57-SREI	NULL
cells	NULL
and	NULL
EPO-dependent	NULL
activation	NULL
in	NULL
HCD57	NULL
cells	NULL
was	NULL
confirmed	NULL
by	NULL
the	NULL
in	NULL
vitro	NULL
assay	NULL
of	NULL
PKB/Akt	NULL
.	NULL

The	NULL
in	NULL
vitro	NULL
assay	NULL
of	NULL
PKB/Akt	NULL
gave	NULL
the	NULL
following	NULL
result	NULL
when	NULL
PKB/AKt	NULL
activity	NULL
was	NULL
determined	NULL
(	NULL
as-sayed	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
and	NULL
expressed	NULL
as	NULL
the	NULL
average	NULL
of	NULL
three	NULL
assays	NULL
to	NULL
determine	NULL
the	NULL
cpm	NULL
of	NULL
*P	NULL
from	NULL
ATP	NULL
incorporated	NULL
into	NULL
a	NULL
substrate	NULL
peptide	NULL
+	NULL
standard	NULL
devia-tion	NULL
)	NULL
:	NULL
HCDS57	NULL
-	NULL
EPO	NULL
=	NULL
132	NULL
+	NULL
94	NULL
cpm	NULL
;	NULL
HCD537	NULL
+	NULL
EPO	NULL
=	NULL
6,725	NULL
+	NULL
163	NULL
cpm	NULL
;	NULL
and	NULL
HCD57-SREI	NULL
cells	NULL
-	NULL
EPO	NULL
=	NULL
933	NULL
+	NULL
328	NULL
cpm	NULL
.	NULL

Moreover	NULL
,	NULL
treatment	NULL
of	NULL
the	NULL
HCD57	NULL
cells	NULL
with	NULL
either	NULL
EPO	NULL
or	NULL
SCF	NULL
led	NULL
to	NULL
a	NULL
rapid	NULL
activation	NULL
of	NULL
PKB/Akt	NULL
(	NULL
Fig	NULL
10A	NULL
)	NULL
.	NULL

Comparison	NULL
of	NULL
the	NULL
EPO-dependent	NULL
and	NULL
SCE-dependent	NULL
time	NULL
course	NULL
of	NULL
PKB/Akt	NULL
phosphorylation	NULL
showed	NULL
that	NULL
the	NULL
EPO	NULL
effect	NULL
was	NULL
greater	NULL
in	NULL
magnitude	NULL
than	NULL
the	NULL
SCF	NULL
effect	NULL
.	NULL

PKB/Akt	NULL
phosphorylation	NULL
was	NULL
maximal	NULL
after	NULL
5	NULL
minutes	NULL
of	NULL
treatment	NULL
with	NULL
either	NULL
EPO	NULL
or	NULL
SCF	NULL
,	NULL
it	NULL
then	NULL
declined	NULL
by	NULL
1	NULL
hour	NULL
and	NULL
was	NULL
virtually	NULL
undetectable	NULL
after	NULL
6	NULL
hours	NULL
(	NULL
Fig	NULL
10B	NULL
)	NULL
.	NULL

Because	NULL
of	NULL
the	NULL
possibility	NULL
that	NULL
the	NULL
PKB/Akt	NULL
might	NULL
be	NULL
activated	NULL
by	NULL
upstream	NULL
activators	NULL
not	NULL
in	NULL
the	NULL
PI3-kinase	NULL
pathway	NULL
(	NULL
due	NULL
to	NULL
lack	NULL
of	NULL
correlation	NULL
of	NULL
PKB/Akt	NULL
activity	NULL
with	NULL
the	NULL
constitutive	NULL
PI3-kinase	NULL
activity	NULL
in	NULL
HCD57	NULL
cells	NULL
)	NULL
,	NULL
the	NULL
activity	NULL
of	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

PKB/Akt	NULL
AND	NULL
STATS	NULL
ACTIVITY	NULL
IN	NULL
ERYTHROID	NULL
CELLS	NULL
3767	NULL
A	NULL
B	NULL
C	NULL
IP	NULL
:	NULL
e-p85/P1	NULL
3-KINASE	NULL
L	NULL
k-	NULL
o	NULL
``	NULL
f	NULL
2	NULL
BON	NULL
C	NULL
1M	NULL
OC	NULL
*	NULL
ony	NULL
.	NULL

L	NULL
wm	NULL
-	NULL
<	NULL
CG	NULL
>	NULL
CELLS	NULL
-	NULL
HCDS57	NULL
HCDS7-SREI	NULL
PWE	NULL
in	NULL
;	NULL
€	NULL
qos	NULL
$	NULL
EPO	NULL
-	NULL
+	NULL
-	NULL
+	NULL
-	NULL
”	NULL
(	NULL
231313	NULL
)	NULL
”	NULL
Do	NULL
8004	NULL
4	NULL
%	NULL
PBPr	NULL
``	NULL
®	NULL
.	NULL

*	NULL
.	NULL

%	NULL
a	NULL
PI3-.p	NULL
»	NULL
>	NULL
-	NULL
_	NULL
>	NULL
PI3P	NULL
»	NULL
>	NULL
0	NULL
¢	NULL
¢	NULL
orcn	NULL
»	NULL
>	NULL
0	NULL
0	NULL
%	NULL
ORIGIN	NULL
»	NULL
¢	NULL
o	NULL
4	NULL
-*	NULL
occ	NULL
»	NULL
@	NULL
C	NULL
#	NULL
®	NULL
«	NULL
B	NULL
ma	NULL
1.6	NULL
.-gs	NULL
;	NULL
a	NULL
-	NULL
12	NULL
9	NULL
10	NULL
11	NULL
12	NULL
ic	NULL
,	NULL
LL	NULL
141	NULL
2	NULL
1	NULL
>	NULL
9	NULL
1.2	NULL
s.	NULL
E	NULL
2	NULL
EG	NULL
os	NULL
.	NULL

2	NULL
4	NULL
1	NULL
>	NULL
5	NULL
f	NULL
0.8	NULL
5	NULL
&	NULL
06	NULL
I	NULL
o	NULL
<	NULL
O	NULL
A	NULL
u	NULL
U	NULL
u	NULL
*	NULL
<	NULL
4	NULL
A	NULL
0.4	NULL
<	NULL
4	NULL
6	NULL
Z	NULL
0	NULL
€	NULL
-	NULL
0.2.	NULL
yI	NULL
0.2	NULL
¥	NULL
Ca	NULL
&	NULL
a	NULL
O0	NULL
o	NULL
1	NULL
a	NULL
.	NULL

0	NULL
10	NULL
20	NULL
3	NULL
4	NULL
5	NULL
-	NULL
6	NULL
7	NULL
8	NULL
Fig	NULL
7	NULL
.	NULL

-	NULL
PI	NULL
3-kinase	NULL
was	NULL
constitutively	NULL
activated	NULL
in	NULL
HCDS57	NULL
and	NULL
HCDS57-SREI	NULL
cells	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Analysis	NULL
of	NULL
PI	NULL
3-kinase	NULL
activity	NULL
in	NULL
HCDS7	NULL
and	NULL
HCDS7-SREI	NULL
cells	NULL
.	NULL

(	NULL
Top	NULL
panel	NULL
,	NULL
A	NULL
)	NULL
3	NULL
x	NULL
10°	NULL
HCD57	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
and	NULL
HCD57-SREI	NULL
(	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
)	NULL
cells	NULL
were	NULL
deprived	NULL
of	NULL
EPO	NULL
overnight	NULL
and	NULL
treated	NULL
with	NULL
10	NULL
U/mL	NULL
EPO	NULL
(	NULL
lanes	NULL
2	NULL
and	NULL
4	NULL
)	NULL
for	NULL
5	NULL
minutes	NULL
or	NULL
left	NULL
untreated	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
3	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
lysed	NULL
and	NULL
immunoprecipitated	NULL
by	NULL
anti-p85	NULL
subunit	NULL
of	NULL
PI	NULL
3-kinase	NULL
antibody	NULL
,	NULL
and	NULL
the	NULL
precipitates	NULL
were	NULL
assayed	NULL
for	NULL
PI3-kinase	NULL
activity	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

The	NULL
positions	NULL
of	NULL
the	NULL
PI	NULL
3-phosphate	NULL
product	NULL
(	NULL
PI3-P	NULL
)	NULL
and	NULL
the	NULL
origin	NULL
are	NULL
indicated	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Inhibition	NULL
of	NULL
in	NULL
vitro	NULL
PI3-kinase	NULL
activity	NULL
by	NULL
LY294002	NULL
.	NULL

(	NULL
Top	NULL
panel	NULL
,	NULL
B	NULL
)	NULL
HCDS7	NULL
cells	NULL
were	NULL
deprived	NULL
of	NULL
EPO	NULL
overnight	NULL
and	NULL
treated	NULL
with	NULL
EPO	NULL
for	NULL
5	NULL
minutes	NULL
.	NULL

Immunoprecipitates	NULL
were	NULL
prepared	NULL
from	NULL
HCD-57	NULL
cells	NULL
as	NULL
described	NULL
previously	NULL
.	NULL

PI	NULL
3-kinase	NULL
assay	NULL
was	NULL
performed	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
various	NULL
concentrations	NULL
of	NULL
LY294002	NULL
(	NULL
lanes	NULL
5	NULL
through	NULL
8	NULL
)	NULL
as	NULL
indicated	NULL
.	NULL

(	NULL
Bottom	NULL
panels	NULL
,	NULL
A	NULL
and	NULL
B	NULL
)	NULL
PI	NULL
3-kinase	NULL
activities	NULL
were	NULL
quantified	NULL
and	NULL
the	NULL
results	NULL
were	NULL
expressed	NULL
as	NULL
fold	NULL
activity	NULL
compared	NULL
to	NULL
the	NULL
activity	NULL
of	NULL
HCDS57	NULL
cells	NULL
not	NULL
treated	NULL
with	NULL
EPO	NULL
.	NULL

Data	NULL
are	NULL
means	NULL
+	NULL
SD	NULL
from	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Analysis	NULL
of	NULL
PI	NULL
3-kinase	NULL
activity	NULL
in	NULL
different	NULL
immunoprecipitates	NULL
.	NULL

Cell	NULL
lysates	NULL
were	NULL
prepared	NULL
from	NULL
HCD-57	NULL
cells	NULL
cultured	NULL
in	NULL
normal	NULL
medium	NULL
and	NULL
immunoprecipitated	NULL
by	NULL
anti-p85	NULL
subunit	NULL
of	NULL
PI	NULL
3-kinase	NULL
(	NULL
lane	NULL
9	NULL
)	NULL
,	NULL
anti-JAK2	NULL
(	NULL
lane	NULL
10	NULL
)	NULL
,	NULL
anti-STAT5	NULL
(	NULL
lane	NULL
11	NULL
)	NULL
,	NULL
or	NULL
anti-Vav	NULL
(	NULL
lane	NULL
12	NULL
)	NULL
antibodies	NULL
.	NULL

The	NULL
precipitates	NULL
were	NULL
assayed	NULL
for	NULL
PI	NULL
3-kinase	NULL
activity	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

The	NULL
positions	NULL
of	NULL
the	NULL
PI3-phosphate	NULL
product	NULL
(	NULL
PI3-P	NULL
)	NULL
and	NULL
the	NULL
origin	NULL
are	NULL
indicated	NULL
.	NULL

PKB/Akt	NULL
detected	NULL
with	NULL
the	NULL
activation	NULL
(	NULL
phospho	NULL
)	NULL
-specific	NULL
anti-	NULL
PKB/Akt	NULL
activity	NULL
when	NULL
exposed	NULL
to	NULL
LY294002	NULL
(	NULL
Fig	NULL
10C	NULL
)	NULL
than	NULL
body	NULL
was	NULL
tested	NULL
after	NULL
inhibition	NULL
of	NULL
PI3-kinase	NULL
activity	NULL
with	NULL
either	NULL
the	NULL
HCD57-SREI	NULL
cells	NULL
exposed	NULL
to	NULL
EPO	NULL
or	NULL
HCD357	NULL
cells	NULL
LY294002	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
10C	NULL
,	NULL
treatment	NULL
of	NULL
the	NULL
HCD57-	NULL
in	NULL
EPO	NULL
treated	NULL
in	NULL
parallel	NULL
with	NULL
LY294002	NULL
.	NULL

SREI	NULL
cells	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
EPO	NULL
resulted	NULL
in	NULL
inhibition	NULL
of	NULL
PKB/Akt	NULL
,	NULL
establishing	NULL
that	NULL
PI3-kinase	NULL
was	NULL
the	NULL
DISCUSSION	NULL
upstream	NULL
activator	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
LY294002	NULL
on	NULL
PKB/Akt	NULL
Experiments	NULL
reported	NULL
here	NULL
strongly	NULL
suggest	NULL
a	NULL
major	NULL
role	NULL
of	NULL
activation	NULL
was	NULL
also	NULL
tested	NULL
in	NULL
HCD57	NULL
cells	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
PI3-kinase/PKB	NULL
(	NULL
Akt	NULL
)	NULL
signaling	NULL
pathway	NULL
in	NULL
maintaining	NULL
the	NULL
EPO	NULL
and	NULL
PKB/Akt	NULL
inhibition	NULL
was	NULL
very	NULL
similar	NULL
to	NULL
inhibition	NULL
viability	NULL
and/or	NULL
proliferation	NULL
of	NULL
erythroid	NULL
cells	NULL
.	NULL

Interestingly	NULL
,	NULL
observed	NULL
in	NULL
HCD57-SREI	NULL
cells	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
EPO	NULL
(	NULL
data	NULL
not	NULL
whether	NULL
PI3-kinase/PKB	NULL
activity	NULL
is	NULL
stimulated	NULL
by	NULL
EPO	NULL
treat-shown	NULL
)	NULL
;	NULL
however	NULL
,	NULL
in	NULL
the	NULL
EPO-independent	NULL
,	NULL
HCD57-SREI	NULL
cells	NULL
ment	NULL
or	NULL
is	NULL
constitutively	NULL
activated	NULL
through	NULL
an	NULL
unknown	NULL
mecha-in	NULL
the	NULL
absence	NULL
of	NULL
EPO	NULL
,	NULL
PKB/Akt	NULL
phosphorylation	NULL
was	NULL
more	NULL
nism	NULL
in	NULL
EPO-independent	NULL
,	NULL
apoptosis-resistant	NULL
cells	NULL
,	NULL
blocking	NULL
sensitive	NULL
to	NULL
LY294002	NULL
.	NULL

PKB/Akt	NULL
activity	NULL
in	NULL
HCD57-SREI	NULL
cells	NULL
the	NULL
activity	NULL
of	NULL
this	NULL
pathway	NULL
results	NULL
in	NULL
apoptosis	NULL
of	NULL
either	NULL
cell	NULL
without	NULL
EPO	NULL
was	NULL
greatly	NULL
reduced	NULL
by	NULL
treatment	NULL
with	NULL
5	NULL
umol/L	NULL
type	NULL
.	NULL

This	NULL
strongly	NULL
implicates	NULL
PI3-kinase/PKB	NULL
activity	NULL
as	NULL
a	NULL
LY294002	NULL
whereas	NULL
treatment	NULL
with	NULL
25	NULL
umol/L	NULL
LY294002	NULL
was	NULL
necessary	NULL
signal	NULL
for	NULL
survival	NULL
.	NULL

The	NULL
observation	NULL
that	NULL
SCF	NULL
treat-required	NULL
for	NULL
the	NULL
same	NULL
magnitude	NULL
of	NULL
inhibition	NULL
of	NULL
PKB/Akt	NULL
ment	NULL
also	NULL
activates	NULL
PI3-kinase/PKB	NULL
in	NULL
erythroid	NULL
cells	NULL
but	NULL
does	NULL
phosphorylation	NULL
in	NULL
either	NULL
HCD57	NULL
cells	NULL
or	NULL
HCD57-SREI	NULL
cells	NULL
in	NULL
not	NULL
protect	NULL
these	NULL
cells	NULL
from	NULL
apoptosis®	NULL
(	NULL
and	NULL
Fig	NULL
1A	NULL
)	NULL
indicates	NULL
EPO	NULL
.	NULL

This	NULL
result	NULL
established	NULL
a	NULL
correlation	NULL
between	NULL
the	NULL
level	NULL
of	NULL
that	NULL
PI3-kinase/PKB	NULL
signals	NULL
may	NULL
be	NULL
necessary	NULL
,	NULL
but	NULL
PI3-kinase/	NULL
PKB/Akt	NULL
activity	NULL
and	NULL
cell	NULL
proliferation	NULL
and/or	NULL
viability	NULL
.	NULL

HCD57-	NULL
PKB	NULL
activity	NULL
are	NULL
not	NULL
sufficient	NULL
for	NULL
the	NULL
protection	NULL
from	NULL
apoptosis	NULL
.	NULL

SREI	NULL
cells	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
EPO	NULL
proliferated	NULL
less	NULL
(	NULL
Fig	NULL
9A	NULL
)	NULL
,	NULL
had	NULL
Therefore	NULL
,	NULL
another	NULL
signaling	NULL
pathway	NULL
in	NULL
addition	NULL
to	NULL
PI3-kinase/	NULL
a	NULL
higher	NULL
percentage	NULL
of	NULL
cells	NULL
in	NULL
apoptosis	NULL
(	NULL
Fig	NULL
9B	NULL
)	NULL
,	NULL
and	NULL
had	NULL
less	NULL
PKB	NULL
pathway	NULL
must	NULL
also	NULL
be	NULL
active	NULL
to	NULL
maintain	NULL
the	NULL
viability	NULL
of	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

3768	NULL
A	NULL
IP	NULL
:	NULL
c-EPOR	NULL
CELLS	NULL
HCD57	NULL
_HCD57-SREI	NULL
EPO	NULL
0	NULL
-	NULL
0	NULL
#	NULL
0	NULL
-	NULL
+	NULL
PI3-P	NULL
»	NULL
a	NULL
*	NULL
ORIGIN	NULL
»	NULL
z	NULL
1	NULL
2	NULL
o	NULL
o	NULL
“	NULL
orRicin	NULL
>	NULL
-B	NULL
3	NULL
4	NULL
BAO	NULL
ET	NULL
AL	NULL
B	NULL
IP	NULL
:	NULL
«	NULL
-IRS-2	NULL
CELLS	NULL
__HCD57	NULL
_HCDS7-SREI	NULL
EPO	NULL
_	NULL
-	NULL
0	NULL
+	NULL
0	NULL
-	NULL
0	NULL
+	NULL
PI3-P	NULL
>	NULL
_	NULL
a	NULL
0	NULL
ee	NULL
n	NULL
e	NULL
0	NULL
C	NULL
e	NULL
&	NULL
5	NULL
6	NULL
7	NULL
8	NULL
Fig	NULL
8	NULL
.	NULL

-	NULL
PI	NULL
3-kinase	NULL
activity	NULL
associates	NULL
with	NULL
the	NULL
EPOR	NULL
and	NULL
IRS-2	NULL
.	NULL

(	NULL
A	NULL
)	NULL
HCD57	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
and	NULL
HCDS57-SREI	NULL
(	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
)	NULL
cells	NULL
were	NULL
deprived	NULL
of	NULL
EPO	NULL
overnight	NULL
and	NULL
treated	NULL
with	NULL
10	NULL
U/mL	NULL
EPO	NULL
(	NULL
lanes	NULL
2	NULL
and	NULL
4	NULL
)	NULL
for	NULL
5	NULL
minutes	NULL
or	NULL
left	NULL
untreated	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
3	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
lysed	NULL
and	NULL
immunoprecipitated	NULL
by	NULL
anti-EPOR	NULL
antiserum	NULL
,	NULL
and	NULL
the	NULL
precipitates	NULL
were	NULL
assayed	NULL
for	NULL
PI3-kinase	NULL
activity	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

The	NULL
positions	NULL
of	NULL
the	NULL
PI3-phosphate	NULL
product	NULL
(	NULL
PI3-P	NULL
)	NULL
and	NULL
the	NULL
origin	NULL
are	NULL
indicated	NULL
.	NULL

(	NULL
B	NULL
)	NULL
HCD57	NULL
(	NULL
lanes	NULL
5	NULL
and	NULL
6	NULL
)	NULL
and	NULL
HCDS7-SREI	NULL
(	NULL
lanes	NULL
7	NULL
and	NULL
8	NULL
)	NULL
cells	NULL
were	NULL
deprived	NULL
of	NULL
EPO	NULL
overnight	NULL
and	NULL
treated	NULL
with	NULL
10	NULL
U/	NULL
mL	NULL
EPO	NULL
(	NULL
lanes	NULL
6	NULL
and	NULL
8	NULL
)	NULL
for	NULL
5	NULL
minutes	NULL
or	NULL
left	NULL
untreated	NULL
(	NULL
lanes	NULL
5	NULL
and	NULL
7	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
lysed	NULL
and	NULL
immunoprecipitated	NULL
by	NULL
anti-IRS-2	NULL
antibody	NULL
,	NULL
and	NULL
the	NULL
precipitates	NULL
w	NULL
ere	NULL
assayed	NULL
for	NULL
PI3-kinase	NULL
activity	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

The	NULL
positions	NULL
of	NULL
the	NULL
PI3-phosphate	NULL
product	NULL
(	NULL
PI3-P	NULL
)	NULL
and	NULL
the	NULL
origin	NULL
are	NULL
indicated	NULL
.	NULL

erythroid	NULL
cells	NULL
.	NULL

The	NULL
above-described	NULL
study	NULL
suggests	NULL
that	NULL
constitutive	NULL
STATS	NULL
activity	NULL
in	NULL
combination	NULL
with	NULL
PI3-kinase/PKB	NULL
signals	NULL
might	NULL
be	NULL
sufficient	NULL
to	NULL
protect	NULL
the	NULL
EPO-independent	NULL
cells	NULL
from	NULL
apoptosis	NULL
;	NULL
however	NULL
,	NULL
signaling	NULL
pathways	NULL
yet	NULL
to	NULL
be	NULL
discovered	NULL
or	NULL
known	NULL
signaling	NULL
pathways	NULL
not	NULL
tested	NULL
could	NULL
also	NULL
be	NULL
active	NULL
and	NULL
required	NULL
for	NULL
survival	NULL
and	NULL
proliferation	NULL
.	NULL

We	NULL
undertook	NULL
the	NULL
subcloning	NULL
of	NULL
the	NULL
HCD57	NULL
cells	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
SCF	NULL
to	NULL
test	NULL
if	NULL
SCF	NULL
was	NULL
capable	NULL
of	NULL
activating	NULL
the	NULL
complete	NULL
EPO	NULL
signaling	NULL
pathway	NULL
through	NULL
the	NULL
interaction	NULL
of	NULL
the	NULL
EPOR	NULL
and	NULL
c-Kit	NULL
molecules	NULL
.	NULL
``	NULL

Although	NULL
we	NULL
established	NULL
the	NULL
HCD57-SREI	NULL
cell	NULL
line	NULL
and	NULL
found	NULL
long-term	NULL
responsiveness	NULL
to	NULL
SCF	NULL
,	NULL
no	NULL
subclones	NULL
depended	NULL
on	NULL
SCF	NULL
for	NULL
survival	NULL
.	NULL

This	NULL
strongly	NULL
suggests	NULL
that	NULL
SCF	NULL
(	NULL
either	NULL
through	NULL
c-Kit	NULL
or	NULL
the	NULL
EPOR	NULL
)	NULL
can	NULL
not	NULL
generate	NULL
the	NULL
same	NULL
anti-apoptotic	NULL
signal	NULL
in	NULL
the	NULL
HCD57	NULL
erythroid	NULL
cell	NULL
that	NULL
is	NULL
triggered	NULL
through	NULL
the	NULL
EPOR	NULL
by	NULL
EPO	NULL
.	NULL

The	NULL
current	NULL
study	NULL
is	NULL
consistent	NULL
with	NULL
our	NULL
past	NULL
work	NULL
indicating	NULL
a	NULL
role	NULL
of	NULL
JAK2/STATS5	NULL
upstream	NULL
of	NULL
the	NULL
EPO-dependent	NULL
prevention	NULL
of	NULL
apoptosis	NULL
.	NULL
``	NULL

Whereas	NULL
EPO	NULL
activated	NULL
the	NULL
JAK2/STATS5	NULL
pathway	NULL
and	NULL
prevented	NULL
apoptosis	NULL
,	NULL
SCF	NULL
failed	NULL
to	NULL
protect	NULL
from	NULL
apoptosis	NULL
and	NULL
did	NULL
not	NULL
activate	NULL
JAK2/STATS5	NULL
.	NULL

However	NULL
,	NULL
we	NULL
can	NULL
not	NULL
determine	NULL
that	NULL
STATS	NULL
activity	NULL
is	NULL
required	NULL
for	NULL
protection	NULL
from	NULL
apoptosis	NULL
in	NULL
the	NULL
current	NULL
study	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
antisense	NULL
RNA	NULL
or	NULL
a	NULL
dominant	NULL
negative	NULL
STAT5	NULL
mutant	NULL
may	NULL
shed	NULL
some	NULL
further	NULL
light	NULL
on	NULL
the	NULL
role	NULL
of	NULL
STATS	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
EPO-independent	NULL
proliferation	NULL
and	NULL
survival	NULL
.	NULL

The	NULL
SCF	NULL
effect	NULL
on	NULL
preventing	NULL
apoptosis	NULL
may	NULL
be	NULL
dependent	NULL
on	NULL
the	NULL
cell	NULL
line	NULL
selected	NULL
for	NULL
study	NULL
.	NULL

SCF	NULL
can	NULL
prevent	NULL
apoptosis	NULL
in	NULL
the	NULL
nonerythroid	NULL
,	NULL
hematopoietic	NULL
cell	NULL
line	NULL
FDC-2	NULL
.	NULL
``	NULL

Wu	NULL
et	NULL
al	NULL
found	NULL
that	NULL
SCF	NULL
could	NULL
completely	NULL
replace	NULL
the	NULL
requirement	NULL
for	NULL
other	NULL
hematopoietic	NULL
factors	NULL
only	NULL
through	NULL
the	NULL
cooperation	NULL
of	NULL
the	NULL
c-Kit	NULL
and	NULL
EPOR	NULL
.	NULL

The	NULL
study	NULL
by	NULL
Joneja	NULL
et	NULL
al	NULL
``	NULL
contradicts	NULL
Wu	NULL
et	NULL
al	NULL
and	NULL
confirms	NULL
that	NULL
SCF	NULL
does	NULL
not	NULL
activate	NULL
JAK2	NULL
,	NULL
but	NULL
the	NULL
differences	NULL
in	NULL
these	NULL
published	NULL
results	NULL
may	NULL
simply	NULL
reflect	NULL
that	NULL
some	NULL
cells	NULL
are	NULL
inherently	NULL
more	NULL
resistant	NULL
to	NULL
apoptosis	NULL
after	NULL
growth	NULL
factor	NULL
withdrawal	NULL
.	NULL

We	NULL
report	NULL
here	NULL
that	NULL
HCD57-SREI	NULL
cells	NULL
have	NULL
escaped	NULL
the	NULL
apoptosis	NULL
normally	NULL
triggered	NULL
by	NULL
EPO	NULL
withdrawal	NULL
.	NULL

However	NULL
,	NULL
these	NULL
cells	NULL
will	NULL
readily	NULL
undergo	NULL
apoptosis	NULL
when	NULL
kinases	NULL
are	NULL
inhibited	NULL
by	NULL
a	NULL
wide	NULL
spectrum	NULL
inhibitor	NULL
,	NULL
staurospo-rine	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
or	NULL
the	NULL
inhibition	NULL
of	NULL
PI3-kinase	NULL
activity	NULL
by	NULL
LY294002	NULL
(	NULL
Fig	NULL
9B	NULL
)	NULL
,	NULL
proving	NULL
that	NULL
the	NULL
machinery	NULL
for	NULL
carrying	NULL
out	NULL
the	NULL
final	NULL
stages	NULL
of	NULL
apoptosis	NULL
is	NULL
intact	NULL
in	NULL
HCD57-SREI	NULL
cells	NULL
.	NULL

HCD57-SREI	NULL
cells	NULL
have	NULL
evolved	NULL
a	NULL
mechanism	NULL
of	NULL
resisting	NULL
apoptosis	NULL
that	NULL
includes	NULL
the	NULL
EPO-independent	NULL
expression	NULL
of	NULL
the	NULL
Bel	NULL
family	NULL
of	NULL
proteins	NULL
.	NULL

We	NULL
previously	NULL
showed	NULL
the	NULL
induction	NULL
of	NULL
JunB	NULL
and	NULL
AP1	NULL
DNA	NULL
binding	NULL
activity	NULL
after	NULL
EPO	NULL
withdrawal	NULL
in	NULL
HCD57	NULL
cells	NULL
and	NULL
that	NULL
a	NULL
dominant	NULL
negative	NULL
form	NULL
of	NULL
API	NULL
prevented	NULL
both	NULL
the	NULL
apoptosis	NULL
and	NULL
the	NULL
loss	NULL
of	NULL
expression	NULL
of	NULL
Bcl-Xl	NULL
after	NULL
EPO	NULL
withdrawal	NULL
.	NULL
``	NULL

In	NULL
contrast	NULL
to	NULL
the	NULL
EPO-dependent	NULL
cells	NULL
,	NULL
the	NULL
apoptosis-resistant	NULL
HCD57-SREI	NULL
cells	NULL
did	NULL
not	NULL
show	NULL
any	NULL
changes	NULL
in	NULL
API	NULL
binding	NULL
activity	NULL
or	NULL
express	NULL
junB	NULL
when	NULL
the	NULL
cells	NULL
were	NULL
deprived	NULL
of	NULL
Because	NULL
the	NULL
apoptosis-inducing	NULL
activity	NULL
of	NULL
AP1	NULL
is	NULL
suppressed	NULL
in	NULL
HCD57-SREI	NULL
cells	NULL
,	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

PKB/Akt	NULL
AND	NULL
STATS	NULL
ACTIVITY	NULL
IN	NULL
ERYTHROID	NULL
CELLS	NULL
_	NULL
,	NULL
A1oo	NULL
J	NULL
!	NULL

-o-	NULL
HCD57	NULL
cells+EPO	NULL
O	NULL
&	NULL
-x-	NULL
HCDS7-SREI	NULL
cells-EPO	NULL
Z	NULL
g	NULL
89	NULL
4	NULL
[	NULL
-6-HCDS7-SREIcells+EPO	NULL
3	NULL
x	NULL
&	NULL
sol	NULL
4	NULL
w	NULL
_	NULL
]	NULL
t	NULL
&	NULL
404	NULL
LL	NULL
O	NULL
fir	NULL
th	NULL
20	NULL
{	NULL
3	NULL
Z	NULL
o	NULL
.	NULL

o	NULL
10	NULL
20	NULL
30	NULL
40	NULL
50	NULL
LY294002	NULL
,	NULL
uM	NULL
B	NULL
CELLS	NULL
HCDS57	NULL
3769	NULL
HCD57-SREI	NULL
LY294002	NULL
O0	NULL
V	NULL
10	NULL
25	NULL
50	NULL
0	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
9	NULL
10	NULL
11	NULL
control	NULL
of	NULL
expression	NULL
of	NULL
Bcel-X1	NULL
through	NULL
an	NULL
AP1-dependent	NULL
mechanism	NULL
is	NULL
consistent	NULL
with	NULL
the	NULL
hypothesis	NULL
we	NULL
have	NULL
suggested	NULL
previously	NULL
.	NULL
``	NULL

The	NULL
observation	NULL
of	NULL
a	NULL
correlation	NULL
of	NULL
Bel-X1	NULL
expression	NULL
with	NULL
resistance	NULL
to	NULL
apoptosis	NULL
extends	NULL
earlier	NULL
work	NULL
of	NULL
Silva	NULL
et	NULL
al	NULL
,	NULL
``	NULL
who	NULL
showed	NULL
that	NULL
unregulated	NULL
expression	NULL
of	NULL
human	NULL
Bel-Xl	NULL
could	NULL
prevent	NULL
the	NULL
murine	NULL
HCD57	NULL
cells	NULL
from	NULL
undergoing	NULL
apoptosis	NULL
.	NULL

The	NULL
LY294002	NULL
study	NULL
showed	NULL
that	NULL
PI3-kinase	NULL
activity	NULL
was	NULL
necessary	NULL
for	NULL
erythroid	NULL
cell	NULL
survival	NULL
and	NULL
proliferation	NULL
,	NULL
even	NULL
if	NULL
other	NULL
signaling	NULL
pathways	NULL
were	NULL
active	NULL
.	NULL

PKB/Akt	NULL
activity	NULL
correlated	NULL
inversely	NULL
with	NULL
susceptibility	NULL
to	NULL
apoptosis	NULL
;	NULL
PKB	NULL
activity	NULL
was	NULL
inhibited	NULL
by	NULL
fivefold	NULL
lower	NULL
concentrations	NULL
of	NULL
LY294002	NULL
and	NULL
more	NULL
apoptosis	NULL
was	NULL
induced	NULL
in	NULL
HCD57-SREI	NULL
cells	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
EPO	NULL
than	NULL
either	NULL
cell	NULL
line	NULL
treated	NULL
with	NULL
EPO	NULL
.	NULL

IRS-2	NULL
and	NULL
PI3-kinase	NULL
have	NULL
both	NULL
been	NULL
reported	NULL
to	NULL
be	NULL
activated	NULL
by	NULL
EPO	NULL
binding	NULL
to	NULL
the	NULL
EPOR.2	NULL
%	NULL
24	NULL
``	NULL
675	NULL
``	NULL
However	NULL
,	NULL
the	NULL
constitutive	NULL
activation	NULL
of	NULL
these	NULL
signals	NULL
in	NULL
either	NULL
the	NULL
HCD57	NULL
cells	NULL
or	NULL
the	NULL
HCD57-SREI	NULL
cells	NULL
does	NULL
not	NULL
involve	NULL
JAK2	NULL
or	NULL
the	NULL
EPOR	NULL
.	NULL

The	NULL
HCD57-SREI	NULL
cells	NULL
neither	NULL
produced	NULL
nor	NULL
secreted	NULL
EPO	NULL
,	NULL
did	NULL
not	NULL
appear	NULL
to	NULL
secrete	NULL
another	NULL
factor	NULL
that	NULL
allowed	NULL
HCD357	NULL
cells	NULL
to	NULL
V	NULL
10	NULL
25	NULL
50	NULL
Fig	NULL
9	NULL
.	NULL

Effect	NULL
of	NULL
inhibition	NULL
of	NULL
PI3-kinase	NULL
activity	NULL
on	NULL
the	NULL
proliferation	NULL
and	NULL
apoptosis	NULL
of	NULL
HCDS57	NULL
and	NULL
HCD-SREI	NULL
cells	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Cells	NULL
cultured	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
1	NULL
U	NULL
EPO/mL	NULL
(	NULL
HCDS7	NULL
,	NULL
<	NULL
>	NULL
;	NULL
HCDS57-SREI	NULL
,	NULL
©	NULL
)	NULL
or	NULL
absence	NULL
of	NULL
EPO	NULL
(	NULL
HCD57-SREI	NULL
,	NULL
x	NULL
)	NULL
were	NULL
treated	NULL
with	NULL
LY294002	NULL
at	NULL
the	NULL
indicated	NULL
concentrations	NULL
for	NULL
72	NULL
hours	NULL
,	NULL
and	NULL
the	NULL
viable	NULL
cells	NULL
were	NULL
counted	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
trypan	NULL
blue	NULL
.	NULL

Values	NULL
are	NULL
expressed	NULL
as	NULL
a	NULL
percentage	NULL
of	NULL
the	NULL
corresponding	NULL
control	NULL
(	NULL
treated	NULL
with	NULL
vehicle	NULL
dimethyl-sulfoxide	NULL
[	NULL
DMSO	NULL
]	NULL
)	NULL
.	NULL

Data	NULL
are	NULL
means	NULL
+	NULL
SE	NULL
of	NULL
at	NULL
least	NULL
triplicate	NULL
measurements	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Cells	NULL
were	NULL
cultured	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
1	NULL
U	NULL
EPO/mL	NULL
(	NULL
HCD57	NULL
)	NULL
or	NULL
absence	NULL
of	NULL
EPO	NULL
(	NULL
HCDS57-SREI	NULL
)	NULL
.	NULL

HCD-57	NULL
(	NULL
lanes	NULL
2	NULL
through	NULL
6	NULL
)	NULL
and	NULL
HCD57-SRE	NULL
!	NULL

(	NULL
lanes	NULL
7	NULL
through	NULL
11	NULL
)	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
vehicle	NULL
DMSO	NULL
(	NULL
lanes	NULL
3	NULL
and	NULL
8	NULL
)	NULL
,	NULL
LY294002	NULL
at	NULL
indicated	NULL
concentrations	NULL
(	NULL
lanes	NULL
4	NULL
through	NULL
6	NULL
and	NULL
9	NULL
through	NULL
11	NULL
)	NULL
,	NULL
or	NULL
untreated	NULL
(	NULL
lanes	NULL
2	NULL
and	NULL
7	NULL
)	NULL
for	NULL
24	NULL
hours	NULL
.	NULL

The	NULL
genomic	NULL
DNA	NULL
was	NULL
isolated	NULL
and	NULL
analyzed	NULL
for	NULL
fragmentation	NULL
of	NULL
DNA	NULL
characteristic	NULL
of	NULL
apoptosis	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

survive	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
EPO	NULL
,	NULL
and	NULL
did	NULL
not	NULL
have	NULL
a	NULL
mutated	NULL
EPOR	NULL
activated	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
EPO	NULL
.	NULL

The	NULL
EPOR	NULL
also	NULL
did	NULL
not	NULL
become	NULL
tyrosine	NULL
phosphorylated	NULL
without	NULL
the	NULL
binding	NULL
of	NULL
EPO	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
there	NULL
was	NULL
no	NULL
detectable	NULL
association	NULL
of	NULL
IRS-2	NULL
or	NULL
PI3-kinase	NULL
until	NULL
EPO	NULL
interacted	NULL
with	NULL
the	NULL
EPOR	NULL
.	NULL

We	NULL
report	NULL
here	NULL
that	NULL
IRS-2	NULL
and	NULL
PI3-kinase	NULL
were	NULL
constitutively	NULL
active	NULL
in	NULL
both	NULL
HCD57	NULL
and	NULL
HCD57-SREI	NULL
cells	NULL
;	NULL
however	NULL
,	NULL
only	NULL
constitutive	NULL
PKB/Akt	NULL
activity	NULL
appeared	NULL
to	NULL
be	NULL
a	NULL
signal	NULL
that	NULL
protected	NULL
the	NULL
HCD57-SREI	NULL
cells	NULL
from	NULL
apoptosis	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
EPO	NULL
.	NULL

It	NULL
is	NULL
puzzling	NULL
that	NULL
the	NULL
apparent	NULL
constitutive	NULL
activity	NULL
of	NULL
PI3-kinase	NULL
in	NULL
the	NULL
EPO-dependent	NULL
HCD357	NULL
cells	NULL
did	NULL
not	NULL
result	NULL
in	NULL
the	NULL
downstream	NULL
constitutive	NULL
activity	NULL
of	NULL
the	NULL
PKB/Akt	NULL
activity	NULL
.	NULL

There	NULL
are	NULL
at	NULL
least	NULL
two	NULL
explanations	NULL
for	NULL
this	NULL
paradox	NULL
:	NULL
the	NULL
first	NULL
is	NULL
that	NULL
the	NULL
PI3-kinase	NULL
detected	NULL
in	NULL
the	NULL
in	NULL
vitro	NULL
activity	NULL
is	NULL
an	NULL
artifact	NULL
of	NULL
disrupting	NULL
the	NULL
cells	NULL
and	NULL
immunoprecipitating	NULL
PI3-kinase	NULL
or	NULL
IRS-2	NULL
.	NULL

The	NULL
second	NULL
possibility	NULL
is	NULL
that	NULL
the	NULL
PI3-kinase	NULL
may	NULL
truly	NULL
be	NULL
activated	NULL
by	NULL
IRS-2	NULL
in	NULL
HCD57	NULL
cells	NULL
but	NULL
that	NULL
this	NULL
activity	NULL
is	NULL
not	NULL
translocated	NULL
to	NULL
the	NULL
plasma	NULL
membrane	NULL
until	NULL
either	NULL
EPO	NULL
or	NULL
SCF	NULL
is	NULL
added	NULL
to	NULL
the	NULL
cells	NULL
.	NULL

There	NULL
are	NULL
reports	NULL
that	NULL
link	NULL
constitutive	NULL
activity	NULL
of	NULL
PI-3	NULL
kinase	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

3770	NULL
BAO	NULL
ET	NULL
AL	NULL
A	NULL
HCDS7	NULL
__HCDS7-SREL	NULL
_	NULL
HCDS7__HCDS7-SREI	NULL
HCDS7	NULL
CELLS	NULL
EPO	NULL
TL	NULL
L0	NULL
00	NULL
0k	NULL
00	NULL
00	NULL
#	NULL
000	NULL
+	NULL
#	NULL
|	NULL
-	NULL
»	NULL
]	NULL
o	NULL
e	NULL
e	NULL
e	NULL
rr	NULL
sor	NULL
T-	NULL
E	NULL
-E-	NULL
:	NULL
-	NULL
Co	NULL
irr	NULL
r	NULL
ra	NULL
:	NULL
TIME	NULL
0	NULL
5	NULL
60	NULL
360	NULL
0	NULL
5	NULL
60	NULL
360	NULL
min	NULL
TGK®	NULL
seems	NULL
sommes	NULL
CHD	NULL
«	NULL
--	NULL
amiP	NULL
-	NULL
C	NULL
P-AKt	NULL
57K	NULL
»	NULL
``	NULL
as	NULL
``	NULL
Css	NULL
o-P-Akt	NULL
57K	NULL
76K-	NULL
>	NULL
§	NULL
ppc	NULL
»	NULL
[	NULL
em	NULL
n*	NULL
ses	NULL
ee	NULL
®	NULL
``	NULL
oo	NULL
Akt	NULL
0	NULL
gek	NULL
»	NULL
may	NULL
``	NULL
ue	NULL
mame	NULL
-	NULL
C-~AKt	NULL
100	NULL
20030	NULL
400	NULL
500	NULL
60	NULL
708	NULL
STK	NULL
»	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+o	NULL
EPO	NULL
0	NULL
D	NULL
5102550	NULL
0	NULL
D	NULL
51025	NULL
50	NULL
LY294002	NULL
T6KP®	NULL
(	NULL
LM	NULL
)	NULL
76KP	NULL
57K	NULL
»	NULL
*=	NULL
aam	NULL
»	NULL
cAkt	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
9101112	NULL
Fig	NULL
10	NULL
.	NULL

PKB/Akt	NULL
activity	NULL
is	NULL
constitutive	NULL
in	NULL
HCD57-SREI	NULL
cells	NULL
but	NULL
activity	NULL
is	NULL
induced	NULL
by	NULL
EPO	NULL
and	NULL
SCF	NULL
in	NULL
HCDS57	NULL
cells	NULL
.	NULL

(	NULL
Top	NULL
,	NULL
A	NULL
)	NULL
HCDS7	NULL
cells	NULL
deprived	NULL
of	NULL
EPO	NULL
overnight	NULL
(	NULL
lanes	NULL
1	NULL
,	NULL
2	NULL
,	NULL
5	NULL
,	NULL
6	NULL
)	NULL
or	NULL
HCD57-SREI	NULL
cells	NULL
cultured	NULL
without	NULL
EPO	NULL
(	NULL
lanes	NULL
3	NULL
,	NULL
4	NULL
,	NULL
7	NULL
,	NULL
8	NULL
)	NULL
were	NULL
left	NULL
untreated	NULL
(	NULL
1	NULL
,	NULL
3	NULL
,	NULL
5	NULL
,	NULL
7	NULL
)	NULL
or	NULL
treated	NULL
with	NULL
10	NULL
U	NULL
EPO/mL	NULL
for	NULL
5	NULL
minutes	NULL
(	NULL
lanes	NULL
6	NULL
,	NULL
8	NULL
)	NULL
or	NULL
100	NULL
ng	NULL
SCF/	NULL
mL	NULL
for	NULL
5	NULL
minutes	NULL
(	NULL
lanes	NULL
2	NULL
,	NULL
4	NULL
)	NULL
.	NULL

Cell	NULL
lysates	NULL
were	NULL
prepared	NULL
and	NULL
subjected	NULL
to	NULL
Western	NULL
blot	NULL
analysis	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

The	NULL
blot	NULL
was	NULL
probed	NULL
with	NULL
anti-phospho-PKB/	NULL
Akt	NULL
antibody	NULL
(	NULL
top	NULL
panel	NULL
)	NULL
.	NULL

After	NULL
being	NULL
stripped	NULL
,	NULL
the	NULL
blot	NULL
was	NULL
reprobed	NULL
with	NULL
a	NULL
general	NULL
anti-PKB/	NULL
Akt	NULL
antibody	NULL
that	NULL
recognizes	NULL
all	NULL
forms	NULL
of	NULL
the	NULL
protein	NULL
(	NULL
bottom	NULL
panel	NULL
)	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Time	NULL
course	NULL
of	NULL
EPO	NULL
and	NULL
SCF-induced	NULL
PKB/	NULL
Akt	NULL
activation	NULL
.	NULL

HCDS57	NULL
cells	NULL
deprived	NULL
of	NULL
EPO	NULL
overnight	NULL
were	NULL
left	NULL
untreated	NULL
(	NULL
lanes	NULL
1	NULL
,	NULL
5	NULL
)	NULL
or	NULL
treated	NULL
with	NULL
10	NULL
U	NULL
EPO/mL	NULL
(	NULL
lanes	NULL
2	NULL
through	NULL
4	NULL
)	NULL
or	NULL
100	NULL
ng	NULL
SCF/	NULL
mL	NULL
(	NULL
lanes	NULL
6	NULL
through	NULL
8	NULL
)	NULL
for	NULL
indicated	NULL
time	NULL
periods	NULL
.	NULL

Cell	NULL
lysates	NULL
were	NULL
prepared	NULL
and	NULL
subjected	NULL
to	NULL
Western	NULL
blot	NULL
analysis	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

The	NULL
blot	NULL
was	NULL
probed	NULL
with	NULL
anti-phospho-PKB/	NULL
Akt	NULL
antibody	NULL
(	NULL
top	NULL
panel	NULL
)	NULL
.	NULL

After	NULL
being	NULL
stripped	NULL
,	NULL
the	NULL
blot	NULL
was	NULL
reprobed	NULL
with	NULL
the	NULL
general	NULL
anti-PKB/Akt	NULL
antibody	NULL
used	NULL
above	NULL
(	NULL
bottom	NULL
panel	NULL
)	NULL
.	NULL

(	NULL
C	NULL
)	NULL
PI3-kinase	NULL
inhibitor	NULL
blocked	NULL
EPO-induced	NULL
PKB/Akt	NULL
phosphorylation	NULL
in	NULL
HCD57-SREI	NULL
cells	NULL
.	NULL

HCD57-SRE	NULL
!	NULL

cells	NULL
cultured	NULL
without	NULL
EPO	NULL
were	NULL
left	NULL
untreated	NULL
(	NULL
lanes	NULL
1	NULL
,	NULL
7	NULL
)	NULL
,	NULL
pretreated	NULL
with	NULL
DMSO	NULL
(	NULL
lanes	NULL
2	NULL
,	NULL
8	NULL
)	NULL
,	NULL
or	NULL
pretreated	NULL
with	NULL
LY294002	NULL
(	NULL
lanes	NULL
3	NULL
through	NULL
6	NULL
,	NULL
9	NULL
through	NULL
12	NULL
)	NULL
at	NULL
the	NULL
indicated	NULL
concentration	NULL
for	NULL
4	NULL
hours	NULL
.	NULL

Then	NULL
cells	NULL
were	NULL
left	NULL
untreated	NULL
(	NULL
lanes	NULL
1	NULL
through	NULL
6	NULL
)	NULL
or	NULL
treated	NULL
with	NULL
10	NULL
U	NULL
EPO/	NULL
mL	NULL
for	NULL
5	NULL
minutes	NULL
(	NULL
lanes	NULL
7	NULL
through	NULL
12	NULL
)	NULL
.	NULL

Cell	NULL
lysates	NULL
were	NULL
prepared	NULL
and	NULL
subjected	NULL
to	NULL
Western	NULL
blot	NULL
analysis	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

The	NULL
blot	NULL
was	NULL
probed	NULL
with	NULL
anti-phospho-PKB/Akt	NULL
antibody	NULL
(	NULL
top	NULL
panel	NULL
)	NULL
.	NULL

The	NULL
blot	NULL
was	NULL
stripped	NULL
of	NULL
the	NULL
phospho-specific	NULL
antibody	NULL
and	NULL
reprobed	NULL
with	NULL
an	NULL
antibody	NULL
that	NULL
recognizes	NULL
both	NULL
phosphorylated	NULL
and	NULL
nonphosphophorylated	NULL
PKB/	NULL
Akt	NULL
to	NULL
verify	NULL
equal	NULL
loading	NULL
(	NULL
bottom	NULL
panel	NULL
)	NULL
.	NULL

to	NULL
carcinogenesis	NULL
``	NULL
;	NULL
however	NULL
,	NULL
the	NULL
apparent	NULL
constitutive	NULL
activation	NULL
of	NULL
IRS-2/PI3-kinase	NULL
in	NULL
the	NULL
HCD57	NULL
cells	NULL
does	NULL
not	NULL
allow	NULL
these	NULL
cells	NULL
to	NULL
proliferate	NULL
or	NULL
survive	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
EPO	NULL
.	NULL

This	NULL
study	NULL
suggests	NULL
that	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
downstream	NULL
modulator	NULL
of	NULL
PI3-kinase	NULL
,	NULL
PKB/Akt	NULL
,	NULL
is	NULL
a	NULL
better	NULL
marker	NULL
of	NULL
transformed	NULL
cells	NULL
.	NULL

BCR/ABL	NULL
is	NULL
known	NULL
to	NULL
activate	NULL
the	NULL
PI3-kinase/PKB	NULL
signaling	NULL
pathway	NULL
,	NULL
implicating	NULL
this	NULL
signal	NULL
in	NULL
the	NULL
pathology	NULL
of	NULL
chronic	NULL
myelogenous	NULL
leukemia	NULL
.	NULL
``	NULL

PKB	NULL
was	NULL
initially	NULL
identified	NULL
as	NULL
the	NULL
cellular	NULL
homologue	NULL
of	NULL
the	NULL
v-akt	NULL
oncogene	NULL
and	NULL
PKB/c-Akt	NULL
is	NULL
overexpressed	NULL
in	NULL
tumors	NULL
.	NULL

*	NULL
``	NULL
Preliminary	NULL
evidence	NULL
suggests	NULL
that	NULL
overexpressed	NULL
PKB/Akt	NULL
better	NULL
correlates	NULL
with	NULL
tumor	NULL
aggressiveness	NULL
rather	NULL
than	NULL
tumor	NULL
induction	NULL
.	NULL

This	NULL
possibility	NULL
is	NULL
consistent	NULL
with	NULL
the	NULL
finding	NULL
here	NULL
of	NULL
an	NULL
erythroleukemic	NULL
cell	NULL
line	NULL
progressing	NULL
from	NULL
a	NULL
hormone-dependent	NULL
cell	NULL
line	NULL
to	NULL
a	NULL
hormone-independent	NULL
cell	NULL
line	NULL
as	NULL
a	NULL
result	NULL
of	NULL
acquiring	NULL
constitutively	NULL
active	NULL
PKB/Akt	NULL
.	NULL

Klingmiiller	NULL
et	NULL
al	NULL
``	NULL
``	NULL
have	NULL
recently	NULL
suggested	NULL
that	NULL
PI3-kinase	NULL
acts	NULL
in	NULL
the	NULL
EPO	NULL
signaling	NULL
pathway	NULL
as	NULL
an	NULL
intermediate	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
MAP	NULL
kinase	NULL
cascade	NULL
.	NULL

The	NULL
current	NULL
study	NULL
does	NULL
not	NULL
support	NULL
this	NULL
hypothesis	NULL
.	NULL

Constitutive	NULL
activity	NULL
of	NULL
the	NULL
PI3-kinase/PKB	NULL
pathway	NULL
(	NULL
even	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
serum	NULL
)	NULL
compared	NULL
with	NULL
the	NULL
lack	NULL
of	NULL
detectable	NULL
ERK-1	NULL
activity	NULL
in	NULL
unstimulated	NULL
cells	NULL
strongly	NULL
suggests	NULL
that	NULL
PI3-kinase	NULL
activity	NULL
alone	NULL
is	NULL
insufficient	NULL
to	NULL
trigger	NULL
MAP	NULL
kinase	NULL
activation	NULL
.	NULL

It	NULL
is	NULL
interesting	NULL
to	NULL
note	NULL
that	NULL
the	NULL
synergistic	NULL
effect	NULL
of	NULL
serum	NULL
and	NULL
EPO	NULL
on	NULL
MAP	NULL
kinase	NULL
activation	NULL
is	NULL
magnified	NULL
in	NULL
the	NULL
HCD57-SREI	NULL
cells	NULL
compared	NULL
with	NULL
the	NULL
parental	NULL
HCD57	NULL
cells	NULL
(	NULL
Fig	NULL
4C	NULL
)	NULL
.	NULL

It	NULL
is	NULL
possible	NULL
that	NULL
the	NULL
constitutive	NULL
PI3-kinase/PKB/Akt	NULL
activity	NULL
in	NULL
the	NULL
HCD57-SREI	NULL
cells	NULL
may	NULL
act	NULL
upstream	NULL
to	NULL
magnify	NULL
the	NULL
synergistic	NULL
activation	NULL
of	NULL
the	NULL
MAP	NULL
kinase	NULL
cascade	NULL
by	NULL
serum	NULL
and	NULL
EPO	NULL
,	NULL
even	NULL
though	NULL
the	NULL
PI3-kinase/	NULL
PKB	NULL
pathway	NULL
does	NULL
not	NULL
activate	NULL
either	NULL
SHC	NULL
or	NULL
MAP	NULL
kinase	NULL
.	NULL

The	NULL
HCD57-SREI	NULL
cells	NULL
expressed	NULL
constitutively	NULL
activated	NULL
STAT5a	NULL
and	NULL
STAT5b	NULL
,	NULL
yet	NULL
this	NULL
signaling	NULL
pathway	NULL
was	NULL
com	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

PKB/Akt	NULL
AND	NULL
STATS	NULL
ACTIVITY	NULL
IN	NULL
ERYTHROID	NULL
CELLS	NULL
pletely	NULL
dependent	NULL
on	NULL
EPO	NULL
in	NULL
the	NULL
parental	NULL
,	NULL
EPO-dependent	NULL
HCD57	NULL
cells	NULL
.	NULL

Therefore	NULL
,	NULL
STAT5	NULL
may	NULL
act	NULL
upstream	NULL
of	NULL
an	NULL
intracellular	NULL
signal	NULL
that	NULL
protects	NULL
erythroid	NULL
cells	NULL
from	NULL
apoptosis	NULL
(	NULL
but	NULL
this	NULL
study	NULL
shows	NULL
that	NULL
signals	NULL
such	NULL
as	NULL
PKB/Akt	NULL
are	NULL
also	NULL
required	NULL
)	NULL
.	NULL

Recent	NULL
studies	NULL
showing	NULL
that	NULL
``	NULL
knock	NULL
out	NULL
``	NULL
of	NULL
STAT	NULL
does	NULL
not	NULL
have	NULL
significant	NULL
effects	NULL
on	NULL
erythroid	NULL
cell	NULL
development	NULL
do	NULL
not	NULL
rule	NULL
out	NULL
the	NULL
role	NULL
of	NULL
constitutive	NULL
STATS	NULL
activation	NULL
acting	NULL
to	NULL
prevent	NULL
apoptosis	NULL
.	NULL
``	NULL

Indeed	NULL
,	NULL
even	NULL
if	NULL
STATS	NULL
may	NULL
not	NULL
be	NULL
required	NULL
for	NULL
erythroid	NULL
cell	NULL
proliferation	NULL
and	NULL
protection	NULL
from	NULL
apoptosis	NULL
,	NULL
constitutive	NULL
activation	NULL
of	NULL
STATS	NULL
may	NULL
,	NULL
nevertheless	NULL
,	NULL
have	NULL
consequences	NULL
in	NULL
erythroid	NULL
cell	NULL
signaling	NULL
.	NULL

Our	NULL
experiments	NULL
failed	NULL
to	NULL
show	NULL
any	NULL
constitutive	NULL
activation	NULL
of	NULL
JAK2	NULL
or	NULL
other	NULL
known	NULL
member	NULL
of	NULL
the	NULL
Janus	NULL
kinase	NULL
family	NULL
.	NULL

Therefore	NULL
,	NULL
the	NULL
mechanism	NULL
by	NULL
which	NULL
STATS5	NULL
becomes	NULL
phosphorylated	NULL
and	NULL
activated	NULL
to	NULL
bind	NULL
to	NULL
DNA	NULL
in	NULL
HCDS57-SREI	NULL
cells	NULL
is	NULL
not	NULL
apparent	NULL
.	NULL

It	NULL
has	NULL
been	NULL
reported	NULL
that	NULL
sodium	NULL
vanadate	NULL
activates	NULL
STAT	NULL
proteins	NULL
independently	NULL
of	NULL
JAK	NULL
kinase	NULL
.	NULL

``	NULL
>	NULL
>	NULL
``	NULL
``	NULL
This	NULL
work	NULL
suggests	NULL
a	NULL
low	NULL
level	NULL
of	NULL
STAT	NULL
activation	NULL
by	NULL
non-Janus	NULL
kinase	NULL
(	NULL
s	NULL
)	NULL
that	NULL
only	NULL
becomes	NULL
apparent	NULL
when	NULL
tyrosine	NULL
protein	NULL
phosphatase	NULL
activity	NULL
is	NULL
inhibited	NULL
.	NULL

This	NULL
observation	NULL
and	NULL
our	NULL
own	NULL
finding	NULL
that	NULL
sodium	NULL
vanadate	NULL
can	NULL
activate	NULL
STATS5	NULL
in	NULL
FVA	NULL
cells	NULL
``	NULL
``	NULL
suggests	NULL
that	NULL
a	NULL
possible	NULL
reduction	NULL
or	NULL
loss	NULL
of	NULL
tyrosine	NULL
phosphatase	NULL
activity	NULL
in	NULL
HCD57-SREI	NULL
cells	NULL
.	NULL

The	NULL
tyrosine	NULL
protein	NULL
phosphatase	NULL
SHP-1	NULL
has	NULL
been	NULL
implicated	NULL
in	NULL
regulating	NULL
both	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
EPOR/JAK2	NULL
>	NULL
and	NULL
has	NULL
been	NULL
reported	NULL
to	NULL
dephosphorylate	NULL
STAT	NULL
proteins	NULL
in	NULL
the	NULL
nucleus	NULL
.	NULL
``	NULL

We	NULL
tested	NULL
the	NULL
hypothesis	NULL
that	NULL
SHP-1	NULL
might	NULL
be	NULL
reduced	NULL
or	NULL
absent	NULL
in	NULL
the	NULL
EPO-independent	NULL
HCD57-SREI	NULL
cells	NULL
by	NULL
measuring	NULL
the	NULL
expression	NULL
of	NULL
SHP-1	NULL
by	NULL
Western	NULL
blotting	NULL
(	NULL
Fig	NULL
6	NULL
)	NULL
.	NULL

We	NULL
found	NULL
that	NULL
the	NULL
levels	NULL
of	NULL
SHP-1	NULL
proteins	NULL
in	NULL
both	NULL
HCD357	NULL
and	NULL
HCD57-SREI	NULL
cell	NULL
lines	NULL
were	NULL
identical	NULL
to	NULL
that	NULL
of	NULL
primary	NULL
human	NULL
erythroid	NULL
cells	NULL
.	NULL

Although	NULL
this	NULL
result	NULL
suggests	NULL
that	NULL
the	NULL
defect	NULL
in	NULL
HCD57-SREI	NULL
cells	NULL
responsible	NULL
for	NULL
the	NULL
escape	NULL
from	NULL
apoptosis	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
EPO	NULL
is	NULL
not	NULL
due	NULL
to	NULL
SHP-1	NULL
,	NULL
this	NULL
experiment	NULL
does	NULL
not	NULL
rule	NULL
out	NULL
the	NULL
loss	NULL
of	NULL
other	NULL
phosphatase	NULL
activity	NULL
in	NULL
these	NULL
cells	NULL
.	NULL

Constitutive	NULL
activity	NULL
of	NULL
the	NULL
JAK/STAT	NULL
pathway	NULL
is	NULL
linked	NULL
to	NULL
leukemogenesis	NULL
and	NULL
the	NULL
transformation	NULL
of	NULL
other	NULL
cancerous	NULL
cells	NULL
.	NULL
``	NULL

Recent	NULL
reports	NULL
have	NULL
identified	NULL
the	NULL
constitutive	NULL
activation	NULL
of	NULL
STATS5	NULL
and	NULL
STAT1	NULL
in	NULL
peripheral	NULL
cells	NULL
from	NULL
acute	NULL
lymphoblastic	NULL
leukemia	NULL
and	NULL
constitutive	NULL
STAT1	NULL
,	NULL
STAT3	NULL
,	NULL
and	NULL
STATS	NULL
activity	NULL
in	NULL
peripheral	NULL
cells	NULL
from	NULL
patients	NULL
with	NULL
acute	NULL
myeloid	NULL
leukemia	NULL
.	NULL
``	NULL

Constitutive	NULL
activation	NULL
of	NULL
STATS	NULL
is	NULL
found	NULL
in	NULL
a	NULL
variety	NULL
of	NULL
primary	NULL
lymphoid	NULL
and	NULL
myeloid	NULL
leukemia	NULL
cells	NULL
and	NULL
constitutive	NULL
STAT1	NULL
and	NULL
STAT3	NULL
Epstein-Barr	NULL
virus-related	NULL
lymphoma	NULL
cells	NULL
.	NULL
``	NULL

''	NULL
Constitutive	NULL
STAT3	NULL
has	NULL
been	NULL
associated	NULL
with	NULL
breast	NULL
cancer	NULL
cells	NULL
.	NULL

``	NULL
``	NULL
``	NULL
8	NULL
The	NULL
observation	NULL
that	NULL
oncogenes	NULL
like	NULL
v-Src	NULL
,	NULL
v-Abl	NULL
,	NULL
and	NULL
Ber/abl	NULL
may	NULL
activate	NULL
the	NULL
JAK/STAT	NULL
pathway	NULL
independently	NULL
of	NULL
growth	NULL
further	NULL
suggests	NULL
that	NULL
constitutive	NULL
STAT	NULL
activity	NULL
may	NULL
contribute	NULL
to	NULL
the	NULL
transformation	NULL
of	NULL
cells	NULL
from	NULL
factor-dependent	NULL
to	NULL
factor-independent	NULL
proliferation	NULL
.	NULL

This	NULL
study	NULL
suggests	NULL
a	NULL
role	NULL
for	NULL
constitutive	NULL
activity	NULL
in	NULL
a	NULL
supporting	NULL
role	NULL
to	NULL
constitutive	NULL
PKB/Akt	NULL
activity	NULL
in	NULL
the	NULL
progression	NULL
of	NULL
an	NULL
erythroleukemic	NULL
cell	NULL
line	NULL
to	NULL
factor-independent	NULL
viability	NULL
and	NULL
proliferation	NULL
.	NULL

ACKNOWLEDGMENT	NULL
The	NULL
authors	NULL
thank	NULL
Dr	NULL
John	NULL
Ryan	NULL
(	NULL
Virginia	NULL
Commonwealth	NULL
University	NULL
,	NULL
Richmond	NULL
,	NULL
VA	NULL
)	NULL
for	NULL
his	NULL
assistance	NULL
with	NULL
the	NULL
flow	NULL
cytometry	NULL
analysis	NULL
.	NULL

3771	NULL
REFERENCES	NULL
1	NULL
.	NULL

Koury	NULL
MJ	NULL
,	NULL
Bondurant	NULL
MC	NULL
:	NULL
The	NULL
molecular	NULL
mechanism	NULL
of	NULL
erythropoietin	NULL
action	NULL
.	NULL

Eur	NULL
J	NULL
Biochem	NULL
210:649	NULL
,	NULL
1992	NULL
2	NULL
.	NULL

Krantz	NULL
SB	NULL
:	NULL
Erythropoietin	NULL
.	NULL

Blood	NULL
77:419	NULL
,	NULL
1991	NULL
3	NULL
.	NULL

Sawyer	NULL
ST	NULL
,	NULL
Penta	NULL
K	NULL
:	NULL
Erythropoietin	NULL
cell	NULL
biology	NULL
.	NULL

Hematol	NULL
Oncol	NULL
Clin	NULL
North	NULL
Am	NULL
8:895	NULL
,	NULL
1994	NULL
4	NULL
.	NULL

Wu	NULL
H	NULL
,	NULL
Liu	NULL
X	NULL
,	NULL
Jaenish	NULL
R	NULL
,	NULL
Lodish	NULL
H	NULL
;	NULL
Generation	NULL
of	NULL
committed	NULL
erythroid	NULL
BFU-E	NULL
and	NULL
CFU-E	NULL
progenitors	NULL
does	NULL
not	NULL
require	NULL
erythropoietin	NULL
or	NULL
the	NULL
erythropoietin	NULL
receptor	NULL
.	NULL

Cell	NULL
83:59	NULL
,	NULL
1995	NULL
5	NULL
.	NULL

Jacobs-Helber	NULL
SM	NULL
,	NULL
Penta	NULL
K	NULL
,	NULL
Sun	NULL
Z	NULL
,	NULL
Lawson	NULL
A	NULL
,	NULL
Sawyer	NULL
ST	NULL
:	NULL
Distinct	NULL
signaling	NULL
from	NULL
stem	NULL
cell	NULL
factor	NULL
and	NULL
erythropoietin	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
272:6850	NULL
,	NULL
1997	NULL
6	NULL
.	NULL

Sawyer	NULL
ST	NULL
,	NULL
Hankins	NULL
WD	NULL
:	NULL
The	NULL
functional	NULL
form	NULL
of	NULL
the	NULL
erythropoietin	NULL
receptor	NULL
is	NULL
a	NULL
78	NULL
kDa	NULL
protein	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
90:6849	NULL
,	NULL
1993	NULL
7	NULL
.	NULL

Hanazono	NULL
Y	NULL
,	NULL
Chiba	NULL
S	NULL
,	NULL
Sasaki	NULL
K	NULL
,	NULL
Mano	NULL
H	NULL
,	NULL
Yazaki	NULL
Y	NULL
,	NULL
Hirai	NULL
H	NULL
:	NULL
Erythropoietin	NULL
induces	NULL
tyrosine	NULL
phosphorylation	NULL
and	NULL
kinase	NULL
activity	NULL
of	NULL
the	NULL
c-fps/fes	NULL
proto-oncogene	NULL
product	NULL
in	NULL
human	NULL
erythropoietin-responsive	NULL
cells	NULL
.	NULL

Blood	NULL
81:3193	NULL
,	NULL
1993	NULL
8	NULL
.	NULL

Witthuhn	NULL
B	NULL
,	NULL
Quelle	NULL
F	NULL
,	NULL
Silvennoinen	NULL
O	NULL
,	NULL
Yi	NULL
T	NULL
,	NULL
Tang	NULL
B	NULL
,	NULL
Miura	NULL
O	NULL
,	NULL
Ihle	NULL
J	NULL
:	NULL
JAK2	NULL
association	NULL
with	NULL
the	NULL
erythropoietin	NULL
receptor	NULL
and	NULL
is	NULL
tyrosine	NULL
phosphorylated	NULL
and	NULL
activated	NULL
following	NULL
stimulation	NULL
with	NULL
erythropoietin	NULL
.	NULL

Cell	NULL
74:227	NULL
,	NULL
1993	NULL
9	NULL
.	NULL

Miura	NULL
O	NULL
,	NULL
Makamura	NULL
N	NULL
,	NULL
Quelle	NULL
FW	NULL
,	NULL
Witthuhn	NULL
BA	NULL
,	NULL
Ihle	NULL
JN	NULL
,	NULL
Aoki	NULL
N	NULL
:	NULL
Erythropoietin	NULL
induces	NULL
the	NULL
association	NULL
of	NULL
JAK2	NULL
protein	NULL
tyrosine	NULL
kinase	NULL
with	NULL
the	NULL
erythropoietin	NULL
receptor	NULL
in	NULL
vivo	NULL
.	NULL

Blood	NULL
84:1501	NULL
,	NULL
1994	NULL
10	NULL
.	NULL

Sawyer	NULL
S	NULL
,	NULL
Penta	NULL
K	NULL
:	NULL
Association	NULL
of	NULL
JAK2	NULL
and	NULL
STATS	NULL
with	NULL
erythropoietin	NULL
receptors	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
271:32430	NULL
,	NULL
1996	NULL
11	NULL
.	NULL

Penta	NULL
K	NULL
,	NULL
Sawyer	NULL
ST	NULL
:	NULL
Erythropoietin	NULL
induces	NULL
the	NULL
tyrosine	NULL
phosphorylation	NULL
,	NULL
nuclear	NULL
translocation	NULL
,	NULL
and	NULL
DNA	NULL
binding	NULL
of	NULL
STAT1	NULL
and	NULL
STATS	NULL
in	NULL
erythroid	NULL
cells	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
270:31282	NULL
,	NULL
1995	NULL
12	NULL
.	NULL

Gouilleux	NULL
F	NULL
,	NULL
Pallard	NULL
C	NULL
,	NULL
Dusanter-Fourt	NULL
I	NULL
,	NULL
Wakao	NULL
H	NULL
,	NULL
Haldosen	NULL
L	NULL
,	NULL
Norstedt	NULL
G	NULL
,	NULL
Levy	NULL
D	NULL
,	NULL
Groner	NULL
B	NULL
:	NULL
Prolactin	NULL
,	NULL
growth	NULL
hormone	NULL
,	NULL
erythropoietin	NULL
,	NULL
and	NULL
GM-CSF	NULL
induce	NULL
MGF-STAT5	NULL
DNA-binding	NULL
activity	NULL
.	NULL

EMBO	NULL
J	NULL
14:2005	NULL
,	NULL
1995	NULL
13	NULL
.	NULL

Pallard	NULL
C	NULL
,	NULL
Gouilleux	NULL
F	NULL
,	NULL
Charon	NULL
M	NULL
,	NULL
Groner	NULL
B	NULL
,	NULL
Gisselbrecht	NULL
S	NULL
,	NULL
Dusanter-Fourt	NULL
I	NULL
:	NULL
Interleukin-3	NULL
,	NULL
erythropoietin	NULL
,	NULL
and	NULL
prolactin	NULL
activate	NULL
a	NULL
STAT5-like	NULL
factor	NULL
in	NULL
lymphoid	NULL
cells	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
270:15942	NULL
,	NULL
1995	NULL
14	NULL
.	NULL

Mui	NULL
AL-F	NULL
,	NULL
Wakao	NULL
H	NULL
,	NULL
O'Farrel	NULL
A-M	NULL
,	NULL
Harada	NULL
N	NULL
,	NULL
Miyajima	NULL
A	NULL
:	NULL
IL-3	NULL
,	NULL
GM-CSF	NULL
,	NULL
and	NULL
IL-5	NULL
transduce	NULL
signal	NULL
through	NULL
two	NULL
STATS	NULL
ho-mologs	NULL
.	NULL

EMBO	NULL
J	NULL
14:1166	NULL
,	NULL
1995	NULL
15	NULL
.	NULL

Damen	NULL
J	NULL
,	NULL
Krystal	NULL
G	NULL
:	NULL
Early	NULL
events	NULL
in	NULL
erythropoietin	NULL
signaling	NULL
.	NULL

Exp	NULL
Hematol	NULL
24:1455	NULL
,	NULL
1996	NULL
16	NULL
.	NULL

Wakao	NULL
H	NULL
,	NULL
Harada	NULL
H	NULL
,	NULL
Kitamura	NULL
T	NULL
,	NULL
Mui	NULL
AL-F	NULL
,	NULL
Miyajima	NULL
A	NULL
:	NULL
IL-2	NULL
and	NULL
erythropoietin	NULL
activate	NULL
STATS	NULL
via	NULL
distinct	NULL
signals	NULL
EMBO	NULL
J	NULL
14:2527	NULL
,	NULL
1995	NULL
17	NULL
.	NULL

Taniguchi	NULL
T	NULL
:	NULL
Cytokine	NULL
signaling	NULL
through	NULL
nonreceptor	NULL
protein	NULL
tyrosine	NULL
kinases	NULL
.	NULL

Science	NULL
268:251	NULL
,	NULL
1995	NULL
18	NULL
.	NULL

Thle	NULL
J	NULL
:	NULL
The	NULL
Janus	NULL
protein	NULL
tyrosine	NULL
kinase	NULL
family	NULL
and	NULL
its	NULL
role	NULL
in	NULL
cytokine	NULL
signaling	NULL
.	NULL

Adv	NULL
Immunol	NULL
60:1	NULL
,	NULL
1995	NULL
19	NULL
.	NULL

Damen	NULL
J	NULL
,	NULL
Wakao	NULL
H	NULL
,	NULL
Miyajima	NULL
A	NULL
,	NULL
Kros	NULL
!	NULL

T	NULL
,	NULL
Humphries	NULL
R	NULL
,	NULL
Cutler	NULL
R	NULL
,	NULL
Krystal	NULL
G	NULL
:	NULL
Tyrosine	NULL
343	NULL
in	NULL
the	NULL
erythropoietin	NULL
receptor	NULL
positively	NULL
regulates	NULL
erythropoietin-induced	NULL
cell	NULL
proliferation	NULL
and	NULL
Stat5	NULL
activation	NULL
.	NULL

EMBO	NULL
J	NULL
14:5557	NULL
,	NULL
1995	NULL
20	NULL
.	NULL

Miura	NULL
O0	NULL
,	NULL
Nakamura	NULL
N	NULL
,	NULL
Ihle	NULL
J	NULL
,	NULL
Aoki	NULL
N	NULL
:	NULL
Erythropoietin-dependent	NULL
association	NULL
of	NULL
phosphatidylinositol	NULL
3-kinase	NULL
with	NULL
tyrosine-phosphorylated	NULL
erythropoietin	NULL
receptor	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
269:614	NULL
,	NULL
1994	NULL
21	NULL
.	NULL

Machide	NULL
M	NULL
,	NULL
Mano	NULL
H	NULL
,	NULL
Todokoro	NULL
K	NULL
:	NULL
Interleukin	NULL
3	NULL
and	NULL
erythropoietin	NULL
induce	NULL
association	NULL
of	NULL
Vav	NULL
with	NULL
Tec	NULL
kinase	NULL
through	NULL
Tec	NULL
homology	NULL
domain	NULL
.	NULL

Oncogene	NULL
11:619	NULL
,	NULL
1995	NULL
22	NULL
.	NULL

Klingmuller	NULL
U	NULL
,	NULL
Lorenz	NULL
U	NULL
,	NULL
Cantley	NULL
L	NULL
,	NULL
Neel	NULL
B	NULL
,	NULL
Lodish	NULL
H	NULL
:	NULL
Specific	NULL
recruitment	NULL
of	NULL
SH-PTP1	NULL
to	NULL
the	NULL
erythropoietin	NULL
receptor	NULL
causes	NULL
inactivation	NULL
of	NULL
JAK2	NULL
and	NULL
termination	NULL
of	NULL
proliferative	NULL
signals	NULL
.	NULL

Cell	NULL
80:729	NULL
,	NULL
1995	NULL
23	NULL
.	NULL

Tauchi	NULL
T	NULL
,	NULL
Feng	NULL
G	NULL
,	NULL
Shen	NULL
R	NULL
,	NULL
Hostlin	NULL
M	NULL
,	NULL
Bagby	NULL
G	NULL
,	NULL
Kabat	NULL
D	NULL
,	NULL
Lu	NULL
L	NULL
,	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

3772	NULL
Broxmeyer	NULL
H	NULL
;	NULL
Involvement	NULL
of	NULL
SH2-containing	NULL
phosphotyrosine	NULL
phosphatase	NULL
Syp	NULL
in	NULL
erythropoietin	NULL
receptor	NULL
signal	NULL
transduction	NULL
pathways	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
270:5631	NULL
,	NULL
1995	NULL
24	NULL
.	NULL

Wu	NULL
H	NULL
,	NULL
Klingmuller	NULL
U	NULL
,	NULL
Besmer	NULL
P	NULL
,	NULL
Lodish	NULL
H	NULL
:	NULL
Interaction	NULL
of	NULL
the	NULL
erythropoietin	NULL
and	NULL
stem	NULL
cell	NULL
factor	NULL
receptors	NULL
.	NULL

Nature	NULL
377:242	NULL
,	NULL
1995	NULL
25	NULL
.	NULL

Gouilleux-Gruart	NULL
V	NULL
,	NULL
Gouilleux	NULL
F	NULL
,	NULL
Desaint	NULL
C	NULL
,	NULL
Claisse	NULL
J	NULL
,	NULL
Capiod	NULL
J	NULL
,	NULL
Delobel	NULL
J	NULL
,	NULL
Weber-Nordt	NULL
R	NULL
,	NULL
Dusanter-Fourt	NULL
I	NULL
,	NULL
Dreyfus	NULL
F	NULL
,	NULL
Groner	NULL
B	NULL
,	NULL
Prin	NULL
L	NULL
:	NULL
STAT-related	NULL
transcription	NULL
factors	NULL
are	NULL
constitutively	NULL
activated	NULL
in	NULL
peripheral	NULL
blood	NULL
cells	NULL
from	NULL
acute	NULL
leukemia	NULL
patients	NULL
.	NULL

Blood	NULL
87:1692	NULL
,	NULL
1996	NULL
26	NULL
.	NULL

Weber-Nordt	NULL
R	NULL
,	NULL
Egen	NULL
C	NULL
,	NULL
Wehinger	NULL
J	NULL
,	NULL
Ludwig	NULL
W	NULL
,	NULL
Gouilleux-Gruart	NULL
V	NULL
,	NULL
Merteismann	NULL
R	NULL
,	NULL
Finke	NULL
J	NULL
;	NULL
Constitutive	NULL
activation	NULL
of	NULL
STAT	NULL
proteins	NULL
in	NULL
primary	NULL
lymphoid	NULL
and	NULL
myeloid	NULL
leukemia	NULL
cells	NULL
and	NULL
in	NULL
Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
-related	NULL
lymphoma	NULL
cell	NULL
lines	NULL
.	NULL

Blood	NULL
88:809	NULL
,	NULL
1996	NULL
27	NULL
.	NULL

Sartor	NULL
C	NULL
,	NULL
Dziubinski	NULL
M	NULL
,	NULL
Yu	NULL
C	NULL
,	NULL
Jove	NULL
R	NULL
,	NULL
Ethier	NULL
S	NULL
:	NULL
Role	NULL
of	NULL
epidermal	NULL
growth	NULL
factor	NULL
receptor	NULL
and	NULL
STAT-3	NULL
activation	NULL
in	NULL
autonomous	NULL
proliferation	NULL
of	NULL
SUM-102PT	NULL
human	NULL
breast	NULL
cancer	NULL
cells	NULL
.	NULL

Cancer	NULL
Res	NULL
57:978	NULL
,	NULL
1997	NULL
28	NULL
.	NULL

Watson	NULL
C	NULL
,	NULL
Miller	NULL
W	NULL
:	NULL
Elevated	NULL
levels	NULL
of	NULL
members	NULL
of	NULL
the	NULL
STAT	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
in	NULL
breast	NULL
carcinoma	NULL
nuclear	NULL
extracts	NULL
.	NULL

Br	NULL
J	NULL
Cancer	NULL
71:840	NULL
,	NULL
1995	NULL
29	NULL
.	NULL

Zhang	NULL
Q	NULL
,	NULL
Nowak	NULL
I	NULL
,	NULL
Vonderheid	NULL
E	NULL
,	NULL
Rook	NULL
A	NULL
,	NULL
Kadin	NULL
M	NULL
,	NULL
Nowell	NULL
P	NULL
,	NULL
Shaw	NULL
L	NULL
,	NULL
Wasik	NULL
M	NULL
:	NULL
Activation	NULL
of	NULL
Jak/STAT	NULL
proteins	NULL
involved	NULL
in	NULL
signal	NULL
transduction	NULL
pathway	NULL
mediated	NULL
by	NULL
receptor	NULL
for	NULL
interleukin	NULL
2	NULL
in	NULL
malignant	NULL
T	NULL
lymphocytes	NULL
derived	NULL
from	NULL
cutaneous	NULL
anaplastic	NULL
large	NULL
T-cell	NULL
lymphoma	NULL
and	NULL
Sezary	NULL
syndrome	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
93:9148	NULL
,	NULL
1996	NULL
30	NULL
.	NULL

Danial	NULL
N	NULL
,	NULL
Pernis	NULL
A	NULL
,	NULL
Rothman	NULL
P	NULL
:	NULL
Jak-STAT	NULL
signaling	NULL
induced	NULL
by	NULL
the	NULL
v-abl	NULL
oncogene	NULL
.	NULL

Science	NULL
269:1875	NULL
,	NULL
1995	NULL
31	NULL
.	NULL

Ohashi	NULL
T	NULL
,	NULL
Masuda	NULL
M	NULL
,	NULL
Ruscetti	NULL
S	NULL
:	NULL
Induction	NULL
of	NULL
sequence-specific	NULL
DNA-binding	NULL
factors	NULL
by	NULL
erythropoietin	NULL
and	NULL
the	NULL
spleen	NULL
focus-forming	NULL
virus	NULL
.	NULL

Blood	NULL
85:1454	NULL
,	NULL
1995	NULL
32	NULL
.	NULL

Migone	NULL
T	NULL
,	NULL
Lin	NULL
J	NULL
,	NULL
Cereseto	NULL
A	NULL
,	NULL
Mulloy	NULL
J	NULL
,	NULL
O'Shea	NULL
J	NULL
,	NULL
Franchini	NULL
G	NULL
,	NULL
Leonard	NULL
W	NULL
:	NULL
Constitutively	NULL
activated	NULL
JAK-STAT	NULL
pathway	NULL
in	NULL
T	NULL
cells	NULL
transformed	NULL
with	NULL
HTLV-I	NULL
.	NULL

Science	NULL
269:79	NULL
,	NULL
1995	NULL
33	NULL
.	NULL

Campbell	NULL
G	NULL
,	NULL
Yu	NULL
C	NULL
,	NULL
Jove	NULL
R	NULL
,	NULL
Carter-Su	NULL
C	NULL
:	NULL
Constitutive	NULL
activation	NULL
of	NULL
JAK1	NULL
in	NULL
Src-transformed	NULL
cells	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
272:2591	NULL
,	NULL
1997	NULL
34	NULL
.	NULL

Nielsen	NULL
M	NULL
,	NULL
Kaltoft	NULL
K	NULL
,	NULL
Nordah	NULL
]	NULL
M	NULL
,	NULL
Ropke	NULL
C	NULL
,	NULL
Geisler	NULL
C	NULL
,	NULL
Mustelin	NULL
T	NULL
,	NULL
Dobson	NULL
P	NULL
,	NULL
Svejgaard	NULL
A	NULL
,	NULL
Dum	NULL
N	NULL
:	NULL
Constitutive	NULL
activation	NULL
of	NULL
a	NULL
slowly	NULL
migrating	NULL
isoform	NULL
of	NULL
Stat3	NULL
in	NULL
mycosis	NULL
fungoides	NULL
:	NULL
Tyrphostin	NULL
AG490	NULL
inhibits	NULL
Stat3	NULL
activation	NULL
and	NULL
growth	NULL
of	NULL
mycosis	NULL
fungoides	NULL
tumor	NULL
cell	NULL
lines	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
94:6764	NULL
,	NULL
1997	NULL
35	NULL
.	NULL

Carlesso	NULL
N	NULL
,	NULL
Frank	NULL
D	NULL
,	NULL
Griffin	NULL
J	NULL
:	NULL
;	NULL
Tyrosyl	NULL
phosphorylation	NULL
and	NULL
DNA	NULL
binding	NULL
activity	NULL
of	NULL
signal	NULL
transducers	NULL
and	NULL
activators	NULL
of	NULL
transcription	NULL
(	NULL
STAT	NULL
)	NULL
proteins	NULL
in	NULL
hematopoietic	NULL
cell	NULL
lines	NULL
transformed	NULL
by	NULL
Ber/Abl	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
183:811	NULL
,	NULL
1996	NULL
36	NULL
.	NULL

Gobert	NULL
S	NULL
,	NULL
Chretien	NULL
S	NULL
,	NULL
Gouilleux	NULL
F	NULL
,	NULL
Muller	NULL
O	NULL
,	NULL
Pallard	NULL
C	NULL
,	NULL
Dusanter-Fourt	NULL
I	NULL
,	NULL
Gromer	NULL
B	NULL
,	NULL
Lacombe	NULL
C	NULL
,	NULL
Gisselbrecht	NULL
S	NULL
,	NULL
Mayeux	NULL
P	NULL
:	NULL
Identification	NULL
of	NULL
tyrosine	NULL
residues	NULL
within	NULL
the	NULL
intracellular	NULL
domain	NULL
of	NULL
the	NULL
erythropoietin	NULL
receptor	NULL
crucial	NULL
for	NULL
Stat5	NULL
activation	NULL
.	NULL

EMBO	NULL
J	NULL
15:2434	NULL
,	NULL
1996	NULL
37	NULL
.	NULL

Quelle	NULL
F	NULL
,	NULL
Wang	NULL
D	NULL
,	NULL
Nosaka	NULL
T	NULL
,	NULL
Thierfelder	NULL
W	NULL
,	NULL
Stravopodis	NULL
D	NULL
,	NULL
Weinstein	NULL
Y	NULL
,	NULL
Thle	NULL
J	NULL
:	NULL
Erythropoietin	NULL
induces	NULL
activation	NULL
of	NULL
Stat5	NULL
through	NULL
association	NULL
with	NULL
specific	NULL
tyrosines	NULL
on	NULL
the	NULL
receptor	NULL
that	NULL
are	NULL
not	NULL
required	NULL
for	NULL
a	NULL
mitogenic	NULL
response	NULL
.	NULL

Mol	NULL
Cell	NULL
Biol	NULL
16:1622	NULL
,	NULL
1996	NULL
38	NULL
.	NULL

Wakao	NULL
H	NULL
,	NULL
Chida	NULL
D	NULL
,	NULL
Damen	NULL
J	NULL
,	NULL
Krystal	NULL
G	NULL
,	NULL
Miyajima	NULL
A	NULL
:	NULL
A	NULL
possible	NULL
involvement	NULL
of	NULL
Stat5	NULL
in	NULL
erythropoietin-induced	NULL
hemoglobin	NULL
synthesis	NULL
.	NULL

Biochem	NULL
Biophys	NULL
Res	NULL
Commun	NULL
234:198	NULL
,	NULL
1997	NULL
39	NULL
.	NULL

Iwatsuki	NULL
K	NULL
,	NULL
Endo	NULL
T	NULL
,	NULL
Misawa	NULL
H	NULL
,	NULL
Yokouchi	NULL
M	NULL
,	NULL
Matsumoto	NULL
A	NULL
,	NULL
Ohtsubo	NULL
M	NULL
,	NULL
More	NULL
K	NULL
,	NULL
Yoshimura	NULL
A	NULL
:	NULL
STATS	NULL
activation	NULL
correlates	NULL
with	NULL
erythropoietin	NULL
receptor-mediated	NULL
erythroid	NULL
differentiation	NULL
of	NULL
an	NULL
erythro-leukemia	NULL
cell	NULL
line	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
272:8149	NULL
,	NULL
1997	NULL
40	NULL
.	NULL

Liu	NULL
X	NULL
,	NULL
Robinson	NULL
G	NULL
,	NULL
Wagner	NULL
K	NULL
,	NULL
Garrett	NULL
L	NULL
,	NULL
Wynshaw-Boris	NULL
A	NULL
,	NULL
BAO	NULL
ET	NULL
AL	NULL
Hennighausen	NULL
L	NULL
:	NULL
StatSa	NULL
is	NULL
mandatory	NULL
for	NULL
adult	NULL
mammary	NULL
gland	NULL
development	NULL
and	NULL
lactogenesis	NULL
.	NULL

Genes	NULL
Dev	NULL
11:179	NULL
,	NULL
1997	NULL
41	NULL
.	NULL

Udy	NULL
GB	NULL
,	NULL
Towers	NULL
RP	NULL
,	NULL
Snell	NULL
RG	NULL
,	NULL
Wikins	NULL
RJ	NULL
,	NULL
Park	NULL
S-H	NULL
,	NULL
Ram	NULL
PA	NULL
,	NULL
Waxman	NULL
DJ	NULL
,	NULL
Davey	NULL
HW	NULL
:	NULL
Requirement	NULL
of	NULL
STAT5b	NULL
for	NULL
sexual	NULL
dimor-phism	NULL
of	NULL
body	NULL
growth	NULL
rates	NULL
and	NULL
liver	NULL
gene	NULL
expression	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
94:7239	NULL
,	NULL
1997	NULL
42	NULL
.	NULL

Teglund	NULL
S	NULL
,	NULL
McKay	NULL
C	NULL
,	NULL
Schuetz	NULL
E	NULL
,	NULL
van	NULL
Deuren	NULL
JM	NULL
,	NULL
Stravopodi	NULL
D	NULL
,	NULL
Wang	NULL
D	NULL
,	NULL
Brown	NULL
M	NULL
,	NULL
Bodner	NULL
S	NULL
,	NULL
Grosveld	NULL
G	NULL
,	NULL
Ihle	NULL
JN	NULL
:	NULL
STATS5a	NULL
and	NULL
STAT5b	NULL
proteins	NULL
have	NULL
essential	NULL
,	NULL
or	NULL
redundant	NULL
,	NULL
roles	NULL
in	NULL
cytokine	NULL
responses	NULL
.	NULL

Cell	NULL
93:841	NULL
,	NULL
1998	NULL
43	NULL
.	NULL

Moscatello	NULL
DK	NULL
,	NULL
Holgado-Madruga	NULL
M	NULL
,	NULL
Emlet	NULL
DR	NULL
,	NULL
Montgomery	NULL
RB	NULL
,	NULL
Wong	NULL
AJ	NULL
:	NULL
Constitutive	NULL
activation	NULL
of	NULL
phosphatidylinositol	NULL
3-kinase	NULL
by	NULL
a	NULL
naturally	NULL
occurring	NULL
mutant	NULL
epidermal	NULL
growth	NULL
factor	NULL
receptor	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
273:200	NULL
,	NULL
1998	NULL
44	NULL
.	NULL

Amundadottit	NULL
TL	NULL
,	NULL
Leder	NULL
P	NULL
:	NULL
Signal	NULL
transduction	NULL
pathways	NULL
activated	NULL
and	NULL
required	NULL
for	NULL
mammary	NULL
carcinogenesis	NULL
in	NULL
response	NULL
to	NULL
specific	NULL
oncogenes	NULL
.	NULL

Oncogene	NULL
16:737	NULL
,	NULL
1998	NULL
45	NULL
.	NULL

Yamauchi	NULL
T	NULL
,	NULL
Kaburagi	NULL
Y	NULL
,	NULL
Ueki	NULL
K	NULL
,	NULL
Tsuji	NULL
Y	NULL
,	NULL
Stark	NULL
GR	NULL
,	NULL
Kerr	NULL
IM	NULL
,	NULL
Tsushima	NULL
T	NULL
,	NULL
Akanuma	NULL
Y	NULL
,	NULL
Komuro	NULL
I	NULL
,	NULL
Tobe	NULL
K	NULL
,	NULL
Yazaki	NULL
Y	NULL
,	NULL
Kadowaki	NULL
T	NULL
:	NULL
Growth	NULL
hormone	NULL
and	NULL
prolactin	NULL
stimulate	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
insulin	NULL
receptor	NULL
substrate-1	NULL
,	NULL
-2	NULL
,	NULL
and	NULL
-3	NULL
,	NULL
their	NULL
association	NULL
with	NULL
p85	NULL
phosphatidylinosito	NULL
!	NULL

3-kinase	NULL
(	NULL
PI	NULL
3-kinase	NULL
)	NULL
,	NULL
and	NULL
concomitantly	NULL
PI	NULL
3-kinase	NULL
activation	NULL
via	NULL
JAK2	NULL
kinase	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
273:16719	NULL
,	NULL
1998	NULL
46	NULL
.	NULL

Verdier	NULL
F	NULL
,	NULL
Chretien	NULL
S	NULL
,	NULL
Billat	NULL
C	NULL
,	NULL
Gisselbrecht	NULL
S	NULL
,	NULL
Lacombe	NULL
C	NULL
,	NULL
Mayeux	NULL
P	NULL
:	NULL
Erythropoietin	NULL
induces	NULL
the	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
insulin	NULL
receptor	NULL
substrate-2	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
272:26173	NULL
,	NULL
1997	NULL
47	NULL
.	NULL

Coffer	NULL
PJ	NULL
,	NULL
Jin	NULL
J	NULL
,	NULL
Woodgett	NULL
JR	NULL
:	NULL
Protein	NULL
Kinase	NULL
B	NULL
(	NULL
c-Akt	NULL
)	NULL
:	NULL
A	NULL
multifunctional	NULL
mediator	NULL
of	NULL
phosphatidylinositol	NULL
3-kinase	NULL
activation	NULL
.	NULL

Biochem	NULL
J	NULL
335:1	NULL
,	NULL
1998	NULL
48	NULL
.	NULL

Sanger	NULL
F	NULL
,	NULL
Nicklen	NULL
S	NULL
,	NULL
Coulson	NULL
A	NULL
:	NULL
DNA	NULL
sequencing	NULL
with	NULL
chain	NULL
terminating	NULL
inhibitors	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
74:5463	NULL
,	NULL
1977	NULL
49	NULL
.	NULL

Shigematsu	NULL
H	NULL
,	NULL
Iwasaki	NULL
H	NULL
,	NULL
Otsuka	NULL
T	NULL
,	NULL
Ohno	NULL
Y	NULL
,	NULL
Arima	NULL
F	NULL
,	NULL
Niho	NULL
Y	NULL
:	NULL
Role	NULL
of	NULL
the	NULL
vav	NULL
proto-oncogene	NULL
product	NULL
(	NULL
Vav	NULL
)	NULL
in	NULL
erythropoictin-mediated	NULL
cell	NULL
proliferation	NULL
and	NULL
phosphatidylinositol	NULL
3-kinase	NULL
activity	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
272:14334	NULL
,	NULL
1997	NULL
50	NULL
.	NULL

Yoshimura	NULL
A	NULL
,	NULL
Longmore	NULL
G	NULL
,	NULL
Lodish	NULL
H	NULL
;	NULL
Point	NULL
mutation	NULL
in	NULL
the	NULL
exoplasmic	NULL
domain	NULL
of	NULL
the	NULL
erythropoietin	NULL
receptor	NULL
resulting	NULL
in	NULL
hormone-independent	NULL
activation	NULL
and	NULL
tumorigenicity	NULL
.	NULL

Nature	NULL
348:647	NULL
,	NULL
1990	NULL
51	NULL
.	NULL

D'Andrea	NULL
AD	NULL
,	NULL
Lodish	NULL
HF	NULL
,	NULL
Wong	NULL
GG	NULL
:	NULL
Expression	NULL
cloning	NULL
of	NULL
the	NULL
murine	NULL
erythropoietin	NULL
receptor	NULL
.	NULL

Cell	NULL
57:277	NULL
,	NULL
1989	NULL
52	NULL
.	NULL

Silva	NULL
M	NULL
,	NULL
Grillot	NULL
D	NULL
,	NULL
Benito	NULL
A	NULL
,	NULL
Richard	NULL
C	NULL
,	NULL
Nunez	NULL
G	NULL
,	NULL
Fernadez-Luna	NULL
JL	NULL
:	NULL
Erythropoietin	NULL
can	NULL
promote	NULL
erythroid	NULL
progenitor	NULL
survival	NULL
by	NULL
repressing	NULL
apoptosis	NULL
through	NULL
Bcl-XL	NULL
and	NULL
Bel-2	NULL
.	NULL

Blood	NULL
88:1576	NULL
,	NULL
1996	NULL
53	NULL
.	NULL

Watowich	NULL
SS	NULL
,	NULL
Hilton	NULL
DJ	NULL
,	NULL
Lodish	NULL
HF	NULL
:	NULL
Activation	NULL
and	NULL
inhibition	NULL
of	NULL
erythropoietin	NULL
receptor	NULL
function	NULL
:	NULL
Role	NULL
of	NULL
receptor	NULL
dimerization	NULL
.	NULL

Mol	NULL
Cell	NULL
Biol	NULL
14:3535	NULL
,	NULL
1994	NULL
54	NULL
.	NULL

Barber	NULL
DL	NULL
,	NULL
Corless	NULL
CN	NULL
,	NULL
Xia	NULL
K	NULL
,	NULL
Roberts	NULL
TM	NULL
,	NULL
D'Andrea	NULL
AD	NULL
:	NULL
Erythropoietin	NULL
activates	NULL
Rafl	NULL
by	NULL
a	NULL
Shc-independent	NULL
pathway	NULL
in	NULL
CTLL-EPO-R	NULL
cells	NULL
.	NULL

Blood	NULL
89:55	NULL
,	NULL
1997	NULL
55	NULL
.	NULL

Haspel	NULL
R	NULL
,	NULL
Salditt-Georgieff	NULL
M	NULL
,	NULL
Darnell	NULL
J	NULL
:	NULL
The	NULL
rapid	NULL
inactivation	NULL
of	NULL
nuclear	NULL
tyrosine	NULL
phosphorylated	NULL
Statl	NULL
depends	NULL
upon	NULL
a	NULL
protein	NULL
tyrosine	NULL
phosphatase	NULL
.	NULL

EMBO	NULL
J	NULL
15:6262	NULL
,	NULL
1996	NULL
56	NULL
.	NULL

Haque	NULL
S	NULL
,	NULL
Flati	NULL
V	NULL
,	NULL
Deb	NULL
A	NULL
,	NULL
Williams	NULL
B	NULL
:	NULL
Roles	NULL
of	NULL
protein-tyrosine	NULL
phosphatase	NULL
in	NULL
Statl-mediated	NULL
cell	NULL
signaling	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
270:25709	NULL
,	NULL
1995	NULL
57	NULL
.	NULL

David	NULL
M	NULL
,	NULL
Grimley	NULL
P	NULL
,	NULL
Finbloom	NULL
D	NULL
,	NULL
Larner	NULL
A	NULL
:	NULL
A	NULL
nuclear	NULL
tyrosine	NULL
phosphatase	NULL
downregulates	NULL
interferon-induced	NULL
gene	NULL
expression	NULL
.	NULL

Mol	NULL
Cell	NULL
Biol	NULL
13:7515	NULL
,	NULL
1993	NULL
58	NULL
.	NULL

Kirito	NULL
K	NULL
,	NULL
Uchida	NULL
M	NULL
,	NULL
Yamada	NULL
M	NULL
,	NULL
Miura	NULL
Y	NULL
,	NULL
Komatsu	NULL
N	NULL
:	NULL
A	NULL
distinct	NULL
function	NULL
of	NULL
STAT	NULL
proteins	NULL
in	NULL
erythropoietin	NULL
signal	NULL
transduction	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
272:16507	NULL
,	NULL
1997	NULL
59	NULL
.	NULL

Ram	NULL
P	NULL
,	NULL
Waxman	NULL
D	NULL
:	NULL
Interaction	NULL
of	NULL
growth	NULL
hormone-activated	NULL
STATs	NULL
with	NULL
SH2-containing	NULL
phosphotyrosine	NULL
phosphatase	NULL
SHP-1	NULL
and	NULL
nuclear	NULL
JAK2	NULL
tyrosine	NULL
kinase	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
272:17694	NULL
,	NULL
1997	NULL
60	NULL
.	NULL

Jiao	NULL
H	NULL
,	NULL
Berrada	NULL
K	NULL
,	NULL
Yang	NULL
W	NULL
,	NULL
Tabrizi	NULL
M	NULL
,	NULL
Platanias	NULL
L	NULL
,	NULL
Yi	NULL
T	NULL
:	NULL
Direct	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

PKB/Akt	NULL
AND	NULL
STATS	NULL
ACTIVITY	NULL
IN	NULL
ERYTHROID	NULL
CELLS	NULL
association	NULL
with	NULL
and	NULL
dephosphorylation	NULL
of	NULL
Jak2	NULL
kinase	NULL
by	NULL
the	NULL
SH2-domain-containing	NULL
protein	NULL
tyrosine	NULL
phosphatase	NULL
SHP-1	NULL
.	NULL

Mol	NULL
Cell	NULL
Biol	NULL
16:6985	NULL
,	NULL
1996	NULL
61	NULL
.	NULL

Spivak	NULL
J	NULL
,	NULL
Fisher	NULL
J	NULL
,	NULL
Isaacs	NULL
M	NULL
,	NULL
Hankins	NULL
W	NULL
:	NULL
Protein	NULL
kinases	NULL
and	NULL
phosphatase	NULL
are	NULL
involved	NULL
in	NULL
erythropoietin-mediated	NULL
signal	NULL
transduction	NULL
.	NULL

Exp	NULL
Hematol	NULL
20:500	NULL
,	NULL
1992	NULL
62	NULL
.	NULL

Brennan	NULL
P	NULL
,	NULL
Babbage	NULL
JW	NULL
,	NULL
Burgering	NULL
BMT	NULL
,	NULL
Groner	NULL
B	NULL
,	NULL
Reif	NULL
K	NULL
,	NULL
Cantrell	NULL
DA	NULL
:	NULL
Phosphatidylinositol	NULL
3-kinase	NULL
couples	NULL
the	NULL
interleukin-2	NULL
receptor	NULL
to	NULL
the	NULL
cell	NULL
cycle	NULL
regulator	NULL
E2F	NULL
.	NULL

Immunity	NULL
7:679	NULL
,	NULL
1997	NULL
63	NULL
.	NULL

Roche	NULL
S	NULL
,	NULL
Koeg	NULL
!	NULL

M	NULL
,	NULL
Courtneidge	NULL
SA	NULL
:	NULL
The	NULL
phosphatidylinositol	NULL
3-kinase	NULL
a	NULL
is	NULL
required	NULL
for	NULL
DNA	NULL
synthesis	NULL
induced	NULL
by	NULL
some	NULL
,	NULL
but	NULL
not	NULL
all	NULL
,	NULL
growth	NULL
factors	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
91:9185	NULL
,	NULL
1994	NULL
64	NULL
.	NULL

Liu	NULL
Q	NULL
,	NULL
Schacher	NULL
D	NULL
,	NULL
Hurth	NULL
C	NULL
,	NULL
Freund	NULL
GG	NULL
,	NULL
Dantzer	NULL
R	NULL
,	NULL
Kelley	NULL
KW	NULL
:	NULL
Activation	NULL
of	NULL
Phosphatidylinosito	NULL
!	NULL

3'-kinase	NULL
by	NULL
insulin-like	NULL
growth	NULL
factor-1	NULL
rescues	NULL
promyeloid	NULL
cells	NULL
from	NULL
apoptosis	NULL
and	NULL
permits	NULL
their	NULL
differentiation	NULL
into	NULL
granulocytes	NULL
.	NULL

J	NULL
Immunol	NULL
159:829	NULL
,	NULL
1997	NULL
65	NULL
.	NULL

Joneja	NULL
B	NULL
,	NULL
Chen	NULL
H-C	NULL
,	NULL
Seshasayee	NULL
D	NULL
,	NULL
Wrentmore	NULL
AL	NULL
,	NULL
Wojchowshi	NULL
D	NULL
:	NULL
Mechanisms	NULL
of	NULL
stem	NULL
cell	NULL
factor	NULL
and	NULL
erythropoietin	NULL
proliferative	NULL
co-signaling	NULL
in	NULL
Fdc-2	NULL
cells	NULL
.	NULL

Blood	NULL
90:3533	NULL
,	NULL
1997	NULL
66	NULL
.	NULL

Jacobs-Helber	NULL
SM	NULL
,	NULL
Wickrema	NULL
A	NULL
,	NULL
Birrer	NULL
MJ	NULL
,	NULL
Sawyer	NULL
ST	NULL
:	NULL
API	NULL
3773	NULL
regulation	NULL
of	NULL
proliferation	NULL
and	NULL
initiation	NULL
of	NULL
apoptosis	NULL
in	NULL
erythropoictin-dependent	NULL
erythroid	NULL
cells	NULL
.	NULL

Mol	NULL
Cell	NULL
Biol	NULL
18:3699	NULL
,	NULL
1998	NULL
67	NULL
.	NULL

Damen	NULL
JE	NULL
,	NULL
Cutler	NULL
RL	NULL
,	NULL
Jiao	NULL
H	NULL
,	NULL
Yi	NULL
T	NULL
,	NULL
Krystal	NULL
G	NULL
:	NULL
Phosphorylation	NULL
of	NULL
Tyrosine	NULL
503	NULL
in	NULL
the	NULL
erythropoietin	NULL
receptor	NULL
(	NULL
EpoR	NULL
)	NULL
is	NULL
essential	NULL
for	NULL
binding	NULL
the	NULL
p85	NULL
subunit	NULL
of	NULL
phosphatidylinositol	NULL
(	NULL
PT	NULL
)	NULL
3-kinase	NULL
and	NULL
for	NULL
Epor-associated	NULL
PI	NULL
3-kinase	NULL
activity	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
270:23402	NULL
,	NULL
1995	NULL
68	NULL
.	NULL

Miura	NULL
O	NULL
,	NULL
Nakamura	NULL
N	NULL
,	NULL
Thle	NULL
J	NULL
,	NULL
Aoki	NULL
N	NULL
:	NULL
Erythropoietin-dependent	NULL
association	NULL
of	NULL
phosphatidylinositol	NULL
3-kinase	NULL
with	NULL
tyrosine-phosphorylated	NULL
erythropoietin	NULL
receptor	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
269:614	NULL
,	NULL
1994	NULL
69	NULL
.	NULL

Damen	NULL
JE	NULL
,	NULL
Mui	NULL
L-F	NULL
,	NULL
Puil	NULL
L	NULL
,	NULL
Pawson	NULL
T	NULL
,	NULL
Krystal	NULL
G	NULL
:	NULL
Phosphatidy	NULL
]	NULL
-inositol	NULL
3-kinase	NULL
associate	NULL
,	NULL
via	NULL
its	NULL
Src	NULL
homology	NULL
2	NULL
domains	NULL
,	NULL
with	NULL
the	NULL
activated	NULL
erythropoietin	NULL
receptor	NULL
.	NULL

Blood	NULL
81:3204	NULL
,	NULL
1993	NULL
70	NULL
.	NULL

Skorski	NULL
T	NULL
,	NULL
Bellacosa	NULL
A	NULL
,	NULL
Nieborowska-Skorska	NULL
M	NULL
,	NULL
Majewski	NULL
M	NULL
,	NULL
Martinez	NULL
R	NULL
,	NULL
Chooi	NULL
JK	NULL
,	NULL
Trotta	NULL
P	NULL
,	NULL
Perrotti	NULL
D	NULL
,	NULL
Chan	NULL
TO	NULL
:	NULL
Transformation	NULL
of	NULL
hematopoietic	NULL
cells	NULL
by	NULL
BCR/ABL	NULL
requires	NULL
activation	NULL
of	NULL
a	NULL
PI-3k/Akt-dependent	NULL
pathway	NULL
.	NULL

EMBO	NULL
J	NULL
16:6151	NULL
,	NULL
1997	NULL
71	NULL
.	NULL

Klingmiiller	NULL
U	NULL
,	NULL
Wu	NULL
H	NULL
,	NULL
Hsiao	NULL
G	NULL
,	NULL
Toker	NULL
A	NULL
,	NULL
Duckworth	NULL
BC	NULL
,	NULL
Cantley	NULL
LC	NULL
,	NULL
Lodish	NULL
HF	NULL
:	NULL
Identification	NULL
of	NULL
a	NULL
novel	NULL
pathway	NULL
important	NULL
for	NULL
proliferation	NULL
and	NULL
differentiation	NULL
of	NULL
primary	NULL
erythroid	NULL
progenitors	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
94:3016	NULL
,	NULL
1997	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

®	NULL
blO	NULL
0d	NULL
1999	NULL
93	NULL
:	NULL
3757-3773	NULL
Protein	NULL
Kinase	NULL
B	NULL
(	NULL
c-Akt	NULL
)	NULL
,	NULL
Phosphatidylinositol	NULL
3-Kinase	NULL
,	NULL
and	NULL
STATS	NULL
Are	NULL
Activated	NULL
by	NULL
Erythropoietin	NULL
(	NULL
EPO	NULL
)	NULL
in	NULL
HCD57	NULL
Erythroid	NULL
Cells	NULL
But	NULL
Are	NULL
Constitutively	NULL
Active	NULL
in	NULL
an	NULL
EPO-Independent	NULL
,	NULL
Apoptosis-Resistant	NULL
Subclone	NULL
(	NULL
HCD57-SREI	NULL
Cells	NULL
)	NULL
Haifeng	NULL
Bao	NULL
,	NULL
Sarah	NULL
M.	NULL
Jacobs-Helber	NULL
,	NULL
Amy	NULL
E.	NULL
Lawson	NULL
,	NULL
Kalyani	NULL
Penta	NULL
,	NULL
Amittha	NULL
Wickrema	NULL
and	NULL
Stephen	NULL
T.	NULL
Sawyer	NULL
A	NULL
_	NULL
48	NULL
o	NULL
6	NULL
'	NULL
t	NULL
\se	NULL
@	NULL
.	NULL

/	NULL
{	NULL
®	NULL
Updated	NULL
information	NULL
and	NULL
services	NULL
can	NULL
be	NULL
found	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/content/93/11/3757.full.html	NULL
Articles	NULL
on	NULL
similar	NULL
topics	NULL
can	NULL
be	NULL
found	NULL
in	NULL
the	NULL
following	NULL
Blood	NULL
collections	NULL
Hematopoiesis	NULL
and	NULL
Stem	NULL
Cells	NULL
(	NULL
3573	NULL
articles	NULL
)	NULL
Information	NULL
about	NULL
reproducing	NULL
this	NULL
article	NULL
in	NULL
parts	NULL
or	NULL
in	NULL
its	NULL
entirety	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
requests	NULL
Information	NULL
about	NULL
ordering	NULL
reprints	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/site/misc/rights.xhtml	NULL
#	NULL
reprints	NULL
Information	NULL
about	NULL
subscriptions	NULL
and	NULL
ASH	NULL
membership	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/site/subscriptions/index.xhtml	NULL
Blood	NULL
(	NULL
print	NULL
ISSN	NULL
0006-4971	NULL
,	NULL
online	NULL
ISSN	NULL
1528-0020	NULL
)	NULL
,	NULL
is	NULL
published	NULL
weekly	NULL
by	NULL
the	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
,	NULL
2021	NULL
L	NULL
St	NULL
,	NULL
NW	NULL
,	NULL
Suite	NULL
900	NULL
,	NULL
Washington	NULL
DC	NULL
20036	NULL
.	NULL

Copyright	NULL
2011	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
;	NULL
all	NULL
rights	NULL
reserved	NULL
.	NULL

